
<html lang="en"     class="pb-page"  data-request-id="0587036b-2621-4d81-bfc3-e9412ba91b7e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-10;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b01873;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance" /></meta><meta name="dc.Creator" content="Manuel  Lasalle" /></meta><meta name="dc.Creator" content="Vanessa  Hoguet" /></meta><meta name="dc.Creator" content="Nathalie  Hennuyer" /></meta><meta name="dc.Creator" content="Florence  Leroux" /></meta><meta name="dc.Creator" content="Catherine  Piveteau" /></meta><meta name="dc.Creator" content="Loïc  Belloy" /></meta><meta name="dc.Creator" content="Sophie  Lestavel" /></meta><meta name="dc.Creator" content="Emmanuelle  Vallez" /></meta><meta name="dc.Creator" content="Emilie  Dorchies" /></meta><meta name="dc.Creator" content="Isabelle  Duplan" /></meta><meta name="dc.Creator" content="Emmanuel  Sevin" /></meta><meta name="dc.Creator" content="Maxime  Culot" /></meta><meta name="dc.Creator" content="Fabien  Gosselet" /></meta><meta name="dc.Creator" content="Rajaa  Boulahjar" /></meta><meta name="dc.Creator" content="Adrien  Herledan" /></meta><meta name="dc.Creator" content="Bart  Staels" /></meta><meta name="dc.Creator" content="Benoit  Deprez" /></meta><meta name="dc.Creator" content="Anne  Tailleux" /></meta><meta name="dc.Creator" content="Julie  Charton" /></meta><meta name="dc.Description" content="The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising ..." /></meta><meta name="Description" content="The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 5, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01873" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01873" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01873" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01873" /></link>
        
    
    

<title>Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01873" /></meta><meta property="og:title" content="Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0031.jpeg" /></meta><meta property="og:description" content="The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed TGR5 agonists with low intestinal permeability. In this article, we describe their synthesis, characterization, and biological evaluation. Among them, compound 24 is a potent GLP-1 secretagogue, has low effect on gallbladder volume, and improves glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin resistance, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01873"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01873">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01873&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01873&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01873&amp;href=/doi/10.1021/acs.jmedchem.6b01873" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4185-4211</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01818" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00034" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manuel++Lasalle">Manuel Lasalle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vanessa++Hoguet">Vanessa Hoguet</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathalie++Hennuyer">Nathalie Hennuyer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florence++Leroux">Florence Leroux</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Catherine++Piveteau">Catherine Piveteau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lo%C3%AFc++Belloy">Loïc Belloy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sophie++Lestavel">Sophie Lestavel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuelle++Vallez">Emmanuelle Vallez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emilie++Dorchies">Emilie Dorchies</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Isabelle++Duplan">Isabelle Duplan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuel++Sevin">Emmanuel Sevin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maxime++Culot">Maxime Culot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabien++Gosselet">Fabien Gosselet</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rajaa++Boulahjar">Rajaa Boulahjar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adrien++Herledan">Adrien Herledan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bart++Staels">Bart Staels</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benoit++Deprez">Benoit Deprez</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2777-4538" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anne++Tailleux">Anne Tailleux</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∞</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Charton">Julie Charton</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∞</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Univ. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Univ. Artois, EA 2465 - Blood-Brain Barrier Laboratory (LBHE), F-62300 Lens, France</span></div><div class="corresp-info"><strong>*</strong>(B.D.) Phone: +33 0-320 964 924. Fax: +33 0-320 964 709. E-mail: <a href="/cdn-cgi/l/email-protection#e082858e8f8994ce84859092859aa0958e8996cd8c898c8c85d2ce8692"><span class="__cf_email__" data-cfemail="0163646f6e68752f65647173647b41746f68772c6d686d6d64332f6773">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>(J.C.) Phone: +33 0-320 964 928. E-mail: <a href="/cdn-cgi/l/email-protection#711b041d18145f12191003051e1f31041f18075c1d181d1d14435f1703"><span class="__cf_email__" data-cfemail="e58f90898c80cb868d8497918a8ba5908b8c93c8898c898980d7cb8397">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01873&amp;href=/doi/10.1021%2Facs.jmedchem.6b01873" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4185–4211</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 17, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 December 2016</li><li><span class="item_label"><b>Published</b> online</span>5 May 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 May 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01873" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01873</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4185%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DManuel%2BLasalle%252C%2BVanessa%2BHoguet%252C%2BNathalie%2BHennuyer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D10%26contentID%3Dacs.jmedchem.6b01873%26title%3DTopical%2BIntestinal%2BAminoimidazole%2BAgonists%2Bof%2BG-Protein-Coupled%2BBile%2BAcid%2BReceptor%2B1%2BPromote%2BGlucagon%2BLike%2BPeptide-1%2BSecretion%2Band%2BImprove%2BGlucose%2BTolerance%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4211%26publicationDate%3DMay%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01873"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1827</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01873" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Manuel&quot;,&quot;last_name&quot;:&quot;Lasalle&quot;},{&quot;first_name&quot;:&quot;Vanessa&quot;,&quot;last_name&quot;:&quot;Hoguet&quot;},{&quot;first_name&quot;:&quot;Nathalie&quot;,&quot;last_name&quot;:&quot;Hennuyer&quot;},{&quot;first_name&quot;:&quot;Florence&quot;,&quot;last_name&quot;:&quot;Leroux&quot;},{&quot;first_name&quot;:&quot;Catherine&quot;,&quot;last_name&quot;:&quot;Piveteau&quot;},{&quot;first_name&quot;:&quot;Loïc&quot;,&quot;last_name&quot;:&quot;Belloy&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;Lestavel&quot;},{&quot;first_name&quot;:&quot;Emmanuelle&quot;,&quot;last_name&quot;:&quot;Vallez&quot;},{&quot;first_name&quot;:&quot;Emilie&quot;,&quot;last_name&quot;:&quot;Dorchies&quot;},{&quot;first_name&quot;:&quot;Isabelle&quot;,&quot;last_name&quot;:&quot;Duplan&quot;},{&quot;first_name&quot;:&quot;Emmanuel&quot;,&quot;last_name&quot;:&quot;Sevin&quot;},{&quot;first_name&quot;:&quot;Maxime&quot;,&quot;last_name&quot;:&quot;Culot&quot;},{&quot;first_name&quot;:&quot;Fabien&quot;,&quot;last_name&quot;:&quot;Gosselet&quot;},{&quot;first_name&quot;:&quot;Rajaa&quot;,&quot;last_name&quot;:&quot;Boulahjar&quot;},{&quot;first_name&quot;:&quot;Adrien&quot;,&quot;last_name&quot;:&quot;Herledan&quot;},{&quot;first_name&quot;:&quot;Bart&quot;,&quot;last_name&quot;:&quot;Staels&quot;},{&quot;first_name&quot;:&quot;Benoit&quot;,&quot;last_name&quot;:&quot;Deprez&quot;},{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;Tailleux&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Charton&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4185-4211&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01873&quot;},&quot;abstract&quot;:&quot;The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed TGR5 agonists with low intestinal permeability. In this article, we describe their synthesis, characterization, and biological evaluation. Among them, compound 24 is a potent GLP-1 secretagogue, has low effect on gallbladder volume, and improves glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin resistance, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01873&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01873" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01873&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01873" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01873&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01873" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01873&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01873&amp;href=/doi/10.1021/acs.jmedchem.6b01873" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01873" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01873" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01873%26sid%3Dliteratum%253Aachs%26pmid%3D28414465%26genre%3Darticle%26aulast%3DLasalle%26date%3D2017%26atitle%3DTopical%2BIntestinal%2BAminoimidazole%2BAgonists%2Bof%2BG-Protein-Coupled%2BBile%2BAcid%2BReceptor%2B1%2BPromote%2BGlucagon%2BLike%2BPeptide-1%2BSecretion%2Band%2BImprove%2BGlucose%2BTolerance%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D10%26spage%3D4185%26epage%3D4211%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=290925" title="Carbohydrates">Carbohydrates</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/jmcmar.2017.60.issue-10/20170525/jmcmar.2017.60.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed TGR5 agonists with low intestinal permeability. In this article, we describe their synthesis, characterization, and biological evaluation. Among them, compound <b>24</b> is a potent GLP-1 secretagogue, has low effect on gallbladder volume, and improves glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin resistance, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bile acids have been known for over a decade to act not only as lipid solubilizing agents during digestion but also as signaling molecules, through two main receptors:<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> the nuclear receptor FXR<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> (identified in 1999), and the G-protein-coupled bile acid receptor TGR5<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> (aka GP-BAR1, GPR131, M-BAR identified in 2002). TGR5 acts as a sensor of the prandial state of the organism, by detecting bile acids in various tissues, organs, and cells, such as enteroendocrine L-cells, brown adipose tissue, skeletal striated muscles, and also gallbladder, immune cells, and neurons. On the basis of the existing functional and pharmacological data in preclinical models, TGR5 appears as an attractive target to treat metabolic diseases through different pathways.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> First, TGR5 expressed in enteroendocrine L-cells promotes the transcription of the proglucagon gene expression and the secretion of the incretin glucagon-like peptide 1 (GLP-1), which displays numerous beneficial effects on glucose and energy homeostasis (insulin secretion, beta cell preservation, appetite regulation, and gastric emptying).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Second, TGR5 activation in brown adipose tissue (BAT) and muscle increases deiodinase 2 gene expression and consequently the conversion of the inactive T4 hormone into active thyroxin T3 and uncoupling protein-1 (UCP-1) activation leading to energy expenditure. Interestingly, the link between TGR5 activation in BAT and energy expenditure first demonstrated in mouse<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> has been recently shown also in humans.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Nevertheless, recent investigations in preclinical animal models have suggested that systemic TGR5 agonists may trigger unwanted effects such as gallbladder swelling,<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> itching,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> or more recently cardiovascular issues.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> In this context, TGR5 localization on enteroendocrine L-cells in the intestine epithelium offers a new opportunity. Indeed, the development of intestinal-targeted agonists may lead to GLP-1 secretagogue compounds with a systemic bioavailability low enough to get rid of on-target as well as off-target systemic side effects.</div><div class="NLM_p">We aim to obtain compounds with low gastro-intestinal (GI) absorption that can exert their biological activity locally in the GI tract while minimizing systemic exposure.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This strategy seemed particularly suitable for the development of TGR5 agonists because it would enable TGR5 agonists to stimulate GLP-1 release by enteroendocrine L-cells without triggering any other TGR5-related effect.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> To access such compounds, we decided to design our compounds as chimeric molecules associating a “pharmacophore” that would bear the pharmacological activity and a “kinetophore” that would control the kinetic properties of the whole molecule, without modifying significantly its effect on the receptor. The kinetophore concept was introduced in 2006 to describe a highly polar and/or large and hindered chemical moiety that is tethered to a pharmacologically active structure, to drastically modify its pharmacokinetic properties, especially by decreasing its oral absorption.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Our efforts first focused on optimizing the pharmacophore part and developing structure–activity relationships to determine where to link the kinetophore on the molecules. Analysis of an in-house HTS hit family showed similarity to a TGR5 agonist (CpdA) we had synthesized to use as a reference, described in a patent by Exelixis.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> To increase the diversity of this triazole family, a classical C-to-N isosteric replacement strategy to the CpdA led to original compound <b>1</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Surprisingly, although very structurally close to CpdA compound <b>1</b> was completely inactive on TGR5 showing SAR in our aminothiotriazole series contrasting with that of Exelixis. Substitution of the extracyclic nitrogen by a methyl gave compound <b>2</b> that showed promising activity on both human and murine TGR5 receptors. Switch of the central scaffold from a triazole to an imidazole led to compound <b>3</b> with a drastic increase of potency (from 180 nM to 0.8 nM on the murine receptor). Compound <b>3</b> was the starting point for the design of agonists bearing several kinetophore moieties. In this article, we describe SAR around <b>3</b>, followed by the design, synthesis, and characterization of kinetophore bearing analogues in pharmacokinetic and pharmacodynamics models.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Isosteric Replacement Strategy and Scaffold Switching</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> 3-Amino-5-thio-[1,2,4]triazole series</h3><div class="NLM_p">Synthesis of the 3-amino-5-thio-[1,2,4]triazole derivatives was performed in four to five steps with moderate yield (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The first step was the synthesis of the core aminothiotriazole, by a one-pot two-step reaction.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Selective substitution of the sulfur atom was then carried out in classic nucleophilic substitution conditions to afford the 5-benzylsulfanyl-4-phenyl-4<i>H</i>-[1,2,4]triazol-3-ylamine derivative. Access to compound <b>1</b> was enabled via a Chan-Lam coupling, requiring protection and deprotection steps of the exocyclic nitrogen by an acetyl group. Compound <b>2</b> was obtained through the same coupling reaction after methylation of the nitrogen by reductive amination.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route to <b>1</b>–<b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 4-fluorophenylisothiocyanate, DIEA, DMF, 50 °C, 15 h; (ii) NaOH 2 M, 50 °C, 60 h, 87%; (b) 2-bromomethyl-1,3-difluoro-benzene, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 3 h, 98%; (c) (i) MeONa, paraformaldehyde, MeOH, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 30 min, 76%; (d) Chan-Lam coupling, 3,4-dimethoxyphenylboronic acid, pyridine, Cu(OAc)<sub>2</sub>, MS 4 Å, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 24–48 h, 11–50%; (e) Ac<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 30 min, 66%; (f) AcCl, EtOH, reflux, 30 min, 57%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> 5-Amino-2-thio-imidazole series</h3><div class="NLM_p">5-Amino-2-thio-imidazoles derivatives were obtained through a 6 step synthetic route, using simple building blocks such as aniline, amino-acids, or benzyl derivatives to speed up the exemplification in this family. The first step was a monomethylation of the desired aniline by reductive amination. The methylaniline or <i>N</i>-methylbenzylamine was first acetylated by chloroacetyl chloride. Then, a nucleophilic substitution of the chloride by ammonia afforded the primary amine. This synthetic route was later optimized into a more convenient and efficient route: 1-propylphosphonic acid cyclic anhydride acylation with a Boc N-protected glycine followed by an acidic deprotection of the amino group. Use of either a commercial isothiocyanate or an aniline and TCDI led to the thiourea intermediate. The sulfur atom could then be selectively alkylated by a benzyl derivative to give the corresponding isothiourea. Finally, we took advantage of the 1-propylphosphonic acid cyclic anhydride-mediated cyclodehydration method that we have developed previously<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> to obtain the desired 5-amino-2-thioimidazole compounds from the isothiourea intermediates (<a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>).</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route to <b>3</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) paraformaldehyde, MeONa, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 1–3 h, 77%; (b) chloroacetyl chloride, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (c) aq. NH<sub>3</sub>, EtOH, 65 °C, 1 h, 75% (over two steps); (d) 4-fluorophenylisothiocyanate, NEt<sub>3</sub>, EtOH, room temp., 15 min, 76%; (e) R -Cl, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temperature, 16 h, 90–98%; (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150 °C (μW), 10–40 min, or reflux (classical heating), 24 h, 32–61%.</p></p></figure><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route to <b>7</b>–<b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) paraformaldehyde, MeONa, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 1–3 h, 77%; (b) chloroacetyl chloride, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (c) aq. NH<sub>3</sub>, EtOH, 65 °C, 1 h, 75% (over two steps); (b′) Boc-Gly-OH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min–48 h, 100%; (c′) TFA (30%) /DCM, room temp., 30 min, 100%; (d) R-N = C═S, NEt<sub>3</sub>, EtOH, room temp. or 60 °C, 15 min to overnight, 30–53%; (d′) aniline, TCDI, NEt<sub>3</sub>, dioxane, room temp.–60 °C, overnight, 49%; (e) 2-bromomethyl-1,3-difluoro-benzene, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temperature, 16 h, 82–99%; (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAC, 150 °C (μW), 10–40 min, or reflux (classical heating), 24 h, 11–63%.</p></p></figure><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route to <b>13</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) paraformaldehyde, MeONa, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 1–3 h, 51–96%; (a′) allyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 16 h; (b) chloroacetyl chloride, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (c) aq. NH<sub>3</sub>, EtOH, 65 °C, 1 h, 75%; (b′) Boc-Gly-OH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min–48 h, 79–100%; (c′) TFA (30%)/CH<sub>2</sub>Cl<sub>2</sub>, room temp., 30 min; (d) 4-fluorophenylisothiocyanate, NEt<sub>3</sub>, EtOH, room temp., 15–60 min, 90–100%; (e) 2-bromomethyl-1,3-difluoro-benzene, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temperature, overnight, 58–100%; (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150 °C (μW), 10–40 min, or reflux (classical heating), 24 h, 10–59%.</p></p></figure><div class="NLM_p">Compound <b>19</b> was prepared from 4-fluorophenylisothiocyante and 2-aminoacetonitrile. After addition on the isothiocyanate, alkylation using 2-bromomethyl-1,3-difluoro-benzene on the sulfur atom was followed by spontaneous cyclization into the 5-amino-2-thioimidazole <b>19b</b>. The amino group was then acylated using 3,4-dimethoxybenzoic acyl chloride, prepared from the corresponding carboxylic acid to give compound <b>19</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route to <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-aminoacetonitrile hydrochloride, NEt<sub>3</sub>, DMF, room temp. to 0 °C, 30 min, 80%; (b) 2-bromomethyl-1,3-difluorobenzene, DIEA, CH<sub>3</sub>CN, room temp., 10 min; (c) 3,4-dimethoxybenzoic acid, thionyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, THF, pyridine, room temp., 4 h, 31%.</p></p></figure><div class="NLM_p">To prepare compound <b>22</b>, 4-bromo-2,6-difluorobenzyl alcohol was reacted with mesyl chloride in the presence of trimethylamine. (NMR analysis of the product revealed that the product was not the expected mesylate but rather the benzyl chloride.) This benzyl derivative was then used to afford the corresponding imidazole <b>20b</b> in two steps (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). A Sonogashira coupling using <i>N</i>,<i>N</i>-dimethylpropargylamine was then performed on this imidazole to give <b>20</b>. The tertiary amine was finally methylated to give the corresponding quaternary ammonium, which was first obtained as an iodide (<b>21</b>), and then as a formate (<b>22</b>) after purification by preparative HPLC in alkaline buffer (ammonium formate buffer pH 9.2).</div><figure id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0014.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthetic Route to <b>20</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R-Cl, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 16 h, room temp. 95%; (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 24 h, 74%; (c) <i>N</i>,<i>N</i>-dimethylpropargylamine, pyrrolidine, CuI, PdCl<sub>2</sub>(dppf), DMF, 80 °C, 16 h, 47%; (d) MeI, THF/Et<sub>2</sub>O, room temp., 2–6 h, 17–19%.</p></p></figure><div class="NLM_p">The compounds bearing a quaternary ammonium <b>23</b> or a sulfonate <b>24</b> were obtained through a one-step synthesis from the chloropropyl derivative <b>23b</b>. Synthesis of the corresponding benzyl derivative <b>23ii</b> was carried out starting with the 2,6-difluoro-4-hydroxybenzonitrile (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). Alcaline hydrolysis of the cyano group was followed by esterification with methanol in acidic conditions. The corresponding methyl ester was reduced to the benzyl alcohol using DIBAlH to give compound <b>23i</b>. Selective alkylation of the phenolic hydroxyl by 1-bromo-3-chloropropane was then performed, followed by activation of the benzylic carbon using mesyl chloride to give compound <b>23ii</b>.</div><figure id="sch8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0015.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthetic Route to Intermediate <b>23ii</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) NaOH, H<sub>2</sub>O, reflux, 24 h, 94%; (ii) H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux, 18 h, 90%; (iii) DIBAlH, THF, 0 °C, 1.5 h then NaK-tartrate aq (1 M), room temp., 0.5 h, 80%; (b) (i) Cl(CH<sub>2</sub>)<sub>3</sub>Br, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 3 h, 96%; (ii) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp., 16 h, 100%.</p></p></figure><div class="NLM_p">Intermediate <b>23ii</b> was used to obtain the corresponding imidazole <b>23b</b> in two steps (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). The sulfonate derivative <b>24</b> was readily synthesized from <b>23b</b> using sodium sulfite and sodium iodide in a dioxane/water mixture under microwave irradiation.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Quaternary ammonium <b>23</b> was obtained by reaction of <b>23b</b> with 1,4-diazabicylco[2.2.2]octane (DABCO) in acetonitrile under microwave irradiation.</div><figure id="sch9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0016.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthetic Route to Intermediate <b>23</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>23ii</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temp., 16 h, 73%; (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 28 h, 96%; (c) NaI, Na<sub>2</sub>SO<sub>3</sub>, dioxane/H<sub>2</sub>O (1/1), μW, 130 °C, 100 min, 36%; (d) DABCO, CH<sub>3</sub>CN, μW, 100 °C, 30 min, 23%.</p></p></figure><div class="NLM_p">Intermediate <b>25iii</b> was obtained in 3 steps starting from intermediate <b>23i</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). The phenolic oxygen was first alkylated using 1,3-dibromopropane to give intermediate <b>25i</b>. Then, a nucleophilic substitution using <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonylcarbamate was carried out on the bromopropyl derivative to afford intermediate <b>25ii</b>. This benzylic alcohol was then converted into the benzyl chloride derivative <b>25iii</b> using mesyl chloride as described above for intermediate <b>23ii</b>.</div><figure id="sch10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0017.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthetic Route to Intermediate <b>25iii</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1,3-dibromopropane, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 3 h, 76%; (b) <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonylcarbamate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 30 min, 95%; (c) NEt<sub>3</sub>, MsCl, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp., overnight, 87%.</p></p></figure><div class="NLM_p">Intermediate <b>25iii</b> was used to obtain the corresponding imidazole <b>25b</b> in two steps. After deprotection, amine <b>25c</b> was reacted with sodium 2-chloroethanesulfonate in the presence of sodium iodide and DIEA in DMF under microwave irradiation (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).</div><figure id="sch11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0018.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthetic Route to <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>25iii</b>, DIEA, CH<sub>3</sub>CN, room temp., overnight, 35%; (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 48 h, 62%; (c) TFA (10%), CH<sub>2</sub>Cl<sub>2</sub>, room temp., 5 h, 98%; (d) sodium 2-chloroethanesulfonate, NaI, DIEA, DMF, μW, 100 °C, 2 h, 16%.</p></p></figure><div class="NLM_p">Compounds <b>26</b>–<b>30</b> were prepared in a similar way replacing glycine by alanine or correctly protected lysine and glutamic acid (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>).</div><figure id="sch12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0019.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthetic Route to <b>26</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BocHN–CH(R)-COOH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min–1 h, 66–97%; (b) TFA (30%)/ CH<sub>2</sub>Cl<sub>2</sub>, 30 min, 100%; (c) 4-fluorophenylisothiocyanate, TEA, EtOH, 5 min, 70–79%; (d) 2-bromoethyl-1,3-difluoro-benzene, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, room temp., overnight, 84–89%; (e) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux (classical heating), 48 h, 6–32%; (f) NaOH 1N, MeOH, room temp., overnight, 93%; (g) piperidine, EtOAc, room temp., 60%; (h) MeI, DIEA, Et<sub>2</sub>O/THF (1/1), room temp., overnight, 20%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30067" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30067" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All compounds were evaluated <i>in vitro</i> for their TGR5 agonist activity on both human and murine receptors in CRE-driven luciferase reporter assays in TGR5-transfected HEK293 cells. Full agonist activity (efficacy >80% measured relative to lithocholic acid 10 μM) was obtained for all active compounds.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Pharmacophore Optimization</h3><div class="NLM_p">TGR5 agonist activities on both human and murine receptors of compounds <b>1</b> and <b>2</b> are reported in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Surprisingly, compound <b>1</b> was shown to be completely inactive on both receptors. In contrast, compound <b>2</b> showed promising activity on the murine receptor.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Activity of Compounds <b>1</b> and <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0020.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">hTGR5</th><th class="rowsep1 colsep0" colspan="2" align="center">mTGR5</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" colspan="2" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" colspan="2" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4300</td><td class="colsep0 rowsep0" align="left">[3800–4900]</td><td class="colsep0 rowsep0" align="left">180</td><td class="colsep0 rowsep0" align="left">[150–220]</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">EC<sub>50</sub> values are reported with their 95% confidence intervals in parentheses.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">NA: not active (<i>E</i><sub>max</sub> <10% at all concentrations up to 30 μM).</p></div></div></div><div class="NLM_p">Replacing the triazole by an imidazole in <b>3</b> gave an interesting 2 log improvement of potency on both human and murine receptors (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). We then decided to draw structure–activity relationships (SAR) of this series by exploring the role of the substituants on the aromatics rings. SAR on the benzylic ring on the right-hand side of the molecules are described in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. The 2,6-difluoro substitution of this phenyl ring appeared to be important for activity, especially on the murine receptor. Indeed, the hEC<sub>50</sub>/mEC<sub>50</sub> ratio dropped from 44 for compound <b>3</b> to 2 for compound <b>5</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Activity of Compounds <b>2</b>–<b>6</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0021.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0022.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported with their 95% confidence intervals in parentheses.</p></div></div><div></div></div><div class="NLM_p"><a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> describes the SAR on the phenyl ring on the lower part of the molecule. As shown by the drastic decrease in potency for compounds <b>8</b> and <b>9</b>, a more hindered group than fluorine is not tolerated at the para position, whether it is an electrodonor or electroattractor. On the contrary, adding ortho and meta substitution to the para-fluorophenyl moiety showed interesting potency, with even a slight improvement with compound <b>12</b> compared to that with compound <b>3</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> Activity of Compounds <b>3</b> and <b>7</b>–<b>12</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0023.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0024.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported with their 95% confidence intervals in parentheses.</p></div></div><div></div></div><div class="NLM_p">Exploration of the SAR on the phenyl ring of the left-hand side of the molecule is described in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. The 4,5-dimethoxy substitution appeared crucial for the compound’s activity on TGR5, as removal of one or both methoxy groups (compounds <b>14</b> and <b>15</b>) led to a drastic drop of the potency (more than 100-fold on the murine receptor). 4-Chloro-3-methoxy and 3,4-dichloro substitution led to a decrease in potency, especially for the dichloro substitution on compound <b>16</b>. Homologation of the 3,4-dimethoxyphenyl to 3,4-dimethoxybenzyl group led to a less active compound (<b>17</b>). Whereas modification of the phenyl substitution was generally poorly tolerated, modification of the alkyl substitution of the extracyclic nitrogen showed only a moderate decrease of potency (compound <b>18</b>). It is worth noting that we have tried several strategies to obtain the <i>N</i>-desmethyl analogue of compound <b>3</b> but were unable to isolate it because of its high instability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Activity of Compounds <b>3</b> and <b>13</b>–<b>19</b><a class="ref internalNav" href="#t4fn2" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0025.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0026.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported with their 95% confidence intervals in parentheses. <i><sup>b</sup></i>NA: not active (<i>E</i><sub>max</sub> <10% at all concentrations up to 10 μM).</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Kinetophore Positioning and Optimization</h3><div class="NLM_p">Our strategy to obtain intestine-targeted TGR5 agonists was to introduce on our potent agonists a kinetophore group that would limit the intestinal absorption without effect on the TGR5 agonist activity of such compounds. The keystone of this strategy is the identification of a “mute” position where linking such groups would not impact the target interaction. Analysis of the SAR around compound <b>3</b> has demonstrated that the dimethoxy substitution on the left-hand side of the molecule was crucial and that the bottom of the molecule does not tolerate para substitution by bigger groups than fluorine. We then decided to explore para substitution of the benzyl on the right-hand side of the molecule to add our kinetophore groups. The kinetophores were selected among structural groups making the compound large and/or polar.</div><div class="NLM_p">In this article, we will focus on ionic kinetophores, especially permanently ionized quaternary ammonium and sulfonate groups, which cannot be protonated in vivo (p<i>K</i><sub>a</sub> < −1).</div><div class="NLM_p"><a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> describes the TGR5 agonist activity of compound <b>3</b> and its analogues modified by substitution on the para position of the benzyl ring. First, we show here that this position can efficiently tolerate the polar and hindered group, as all of the compounds maintain potency and full efficacy comparable to those of compound <b>3</b>. Both positive and negative charges are well tolerated with better activities for the anionic compounds (<b>24</b> and <b>25</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> Activity of Compounds <b>3</b> and <b>20</b>–<b>25</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0027.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0028.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are reported with their 95% confidence intervals in parentheses.</p></div></div><div></div></div><div class="NLM_p">Finally, we explored the impact of a charged kinetophore moiety on the position 4 of the imidazole ring on potency. As can be seen in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, a drastic loss of potency was observed for all compounds substituted on the position 4 of the imidazole (<b>26</b>-<b>30</b>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. <i>In Vitro</i> Activity of Compounds <b>3</b> and <b>26</b>–<b>30</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0029.gif" alt="" id="fx10" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">hTGR5</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">mTGR5</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" colspan="2" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">EC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">-H</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">[22–54]</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="left">[0.5–1.4]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">337</td><td class="colsep0 rowsep0" align="left">[304–373]</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="left">[6–8]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">-(CH<sub>2</sub>)<sub>4</sub>-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>4500</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">119.0</td><td class="colsep0 rowsep0" align="left">[98–145]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">-(CH<sub>2</sub>)<sub>2</sub>–COOMe</td><td class="colsep0 rowsep0" align="left">1113</td><td class="colsep0 rowsep0" align="left">[992–1249]</td><td class="colsep0 rowsep0" align="char" char=".">82.0</td><td class="colsep0 rowsep0" align="left">[64–104]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">-(CH<sub>2</sub>)<sub>2</sub>–COOH</td><td class="colsep0 rowsep0" align="left">NC<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">1935.0</td><td class="colsep0 rowsep0" align="left">[1483–2526]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">-(CH<sub>2</sub>)<sub>4</sub>-N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub></td><td class="colsep0 rowsep0" align="left">≥10000</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">254.0</td><td class="colsep0 rowsep0" align="left">[195–331]</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">EC<sub>50</sub> values are reported with their 95% confidence intervals in parentheses.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">NC: not calculated (<i>E</i><sub>max</sub> <20% at all concentrations up to 10 μM).</p></div></div></div><div class="NLM_p">The pharmocophore compound <b>3</b> and kinetophore-linked compounds <b>22</b>, <b>23</b>, and <b>24</b> showing interesting <i>in vitro</i> TGR5 activity were then evaluated for physicochemical and <i>in vitro</i> ADME properties.</div><div class="NLM_p">As can be seen in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, the kinetophore part of compounds <b>22</b>–<b>24</b> profoundly impacts physicochemical properties: the aqueous solubility of compounds <b>22</b>–<b>24</b> compared to that of <b>3</b> is largely improved, and their lipophilicity decreased.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In Vitro</i> ADME Evaluation of Kinetophore-Coupled Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0030.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>Table 1</sup><p class="last">Calculated parameters using Pipeline Pilot (Accelrys).</p></div><div class="footnote" id="t7fn2"><sup>Table a</sup><p class="last">Cell membrane permeability assessed on a Caco-2 cell monolayer. “A-B” indicates the transport from the apical side to the basolateral side; “B-A” indicates the transport from the basolateral side to the apical side. Compounds were tested at 10 μM. Permeability is expressed in 10<sup>–6</sup> cm·s<sup>–1</sup> Permeability classification: low, <i>P</i><sub>app</sub> < 2 × 10<sup>–6</sup> cm·s<sup>–1</sup>; high, <i>P</i><sub>app</sub> > 20 × 10<sup>–6</sup> cm·s<sup>–1</sup>.</p></div><div class="footnote" id="t7fn3"><sup>Table b</sup><p class="last">Compound tested at 5 μM.</p></div><div class="footnote" id="t7fn4"><sup>Table c</sup><p class="last">Compound tested as an iodide (i.e., compound <b>21</b>).</p></div></div><div></div></div><div class="NLM_p">As the polar surface area (PSA) has been described as a predictive parameter of the passive molecular transport through membranes and compound absorption in the GI tract, PSA as well as clogD and AlogP were calculated for compounds <b>22</b>–<b>24</b> using Pipeline Pilot (Accelrys).<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23-25)</a></div><div class="NLM_p">In our case, the calculated clogD<sub>7.4</sub> was quite different from the measured logD<sub>7.4</sub> for all of the evaluated compounds (neutral, cationic, and anionic). As can be seen in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, PSA is not impacted by the introduction of our cationic kinetophores (<b>3</b> versus <b>22</b>,<b>23</b>) because the charge is buried in the tetra-substituted ammonium, and neither a lone pair nor a hydrogen atom remains for hydrogen bonding. In contrast, introduction of the sulfonate group, a fully exposed charge leads to a much higher PSA (140 Å<sup>2</sup> described as a threshold value to be usually poorly absorbed).</div><div class="NLM_p">Cellular permeability was performed in the Caco-2 monolayer permeability assay. In this assay, both cationic (<b>22</b> and <b>23</b>) and anionic (<b>24</b>) compounds exhibited a very low permeability, much lower than that of our pharmacophore compound <b>3</b> (<i>P</i><sub>app</sub> A-B ≤ 0.08 × 10<sup>–6</sup> cm·s<sup>–1</sup> and <i>P</i><sub>app</sub> A-B = 5.32 × 10<sup>–6</sup> cm·s<sup>–1</sup> respectively). In this series, cellular permeability is not correlated with PSA. Indeed, compound <b>3</b> and cationic compounds <b>22</b> and <b>23</b> display the same PSA but are highly different in terms of permeability.</div><div class="NLM_p">Incubation with mouse liver microsomes <i>in vitro</i> revealed that our compounds are metabolically unstable (<i>t</i><sub>1/2</sub> = 1.2 min for compound <b>24</b>). This result suggests a high first pass effect for these compounds that will further lower systemic exposure in addition to low intestinal permeability.</div><div class="NLM_p">Compounds <b>22</b> and <b>24</b>, bearing interesting <i>in vitro</i> activity and very low permeability, were chosen for further <i>in vivo</i> pharmacokinetic and pharmacodynamic studies in C57Bl6 mice.</div><div class="NLM_p">The time required by the drug to reach the ileum and colon containing the highest density of target L-cells<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> after oral dosing was unknown. Therefore, compounds <b>22</b> and <b>24</b> were administered orally at three consecutive time-points (T-6h, T-4h, and T-2h; 3 × 20 mg/kg) to ensure the complete exposure of the GI tract. In order to test the ability of compound <b>22</b> to promote GLP-1 secretion, mice were treated with vehicle or compound <b>22</b> as described, prior to an oral glucose (2 g/kg) or water load. Blood samples were collected 15 min later to measure active GLP-1 plasma concentrations. In addition, sitagliptin (25 mg/kg) was given orally 1 h prior to blood sample collection to prevent GLP-1 degradation. As expected, glucose increased GLP-1 concentrations in vehicle treated mice (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, Veh+Water vs Veh+Glc). As expected, compound <b>22</b> further enhanced the glucose-induced GLP-1 secretion compared to that of the vehicle (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, Veh+Glc vs <b>22</b>+Glc). Interestingly, compound <b>22</b> induced a 4-fold increase in active GLP-1 concentrations even in the absence of glucose challenge compared to that in vehicle treated mice (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, Veh+Water vs <b>22</b>+Water). Thus, compound <b>22</b> by itself appears to be a potent GLP-1 secretagogue <i>in vivo</i> even in absence of glucose challenge.</div><figure id="fig1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0001.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound <b>22</b> (gray bars) were administered to mice at 3 consecutive time-points (T-6h, T-4h, and T-2h, 3 × 20 mg/kg) before challenge with a bolus of water or glucose (T0). All groups received sitagliptin (25 mg/kg) 45 min prior to blood sample collection (T+15 min). Mean ± SEM (<i>n</i> = 6/group). * <i>p</i> < 0.05, ** <i>p</i> < 0.01 (ANOVA and Holm-Sidak test). Veh = vehicle (Tween 0.1%). Glc = glucose (2g/kg). <b>22</b> = compound <b>22</b> in Tween 0.1% (3 × 20 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the same experimental setting, <b>24</b> led to a 2.6-fold increase in GLP-1 concentrations compared to that of the vehicle treated group in the absence of glucose challenge (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). To evaluate the impact of the kinetophore in this approach, the effect of naked pharmacophore <b>3</b> was measured <i>in vivo</i> at 15.5 mg/kg, i.e., the same molar quantity as 20 mg/kg of compound <b>24</b>. No difference with vehicle could be detected (data not shown). This contrasts interestingly with what has been observed on kinetophore bearing compounds and illustrates the necessity of controlling the absorption of our TGR5 agonists to reach the distal section of the gut, where most of the L-cells are located.</div><figure id="fig2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0002.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound <b>24</b> (gray bars) were administered to mice at 3 time-points (T-6h, T-4h, and T-2h, 3 × 20 mg/kg) before blood collection (T0) to measure active GLP-1 plasma concentrations. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 8/group). *** <i>p</i> < 0.001 (Student’s <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Then, plasma AUC, as well as liver and gallbladder exposure, was measured in mice dosed orally with compounds <b>22</b> and <b>24</b> at 20 mg/kg. As expected from the low <i>in vitro</i> permeability of compounds <b>22</b> and <b>24</b>, fecal recovery was quantitative (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). Micromolar concentrations were reached after 4 h in the gallbladder, while 100-fold lower <i>C</i><sub>max</sub> was measured in plasma. Of note, the relatively high concentration in gallbladder results from the biliary excretion of only a small fraction (<0.1% for <b>24</b>) of administered compound.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Parameters of Kinetophore-Coupled Compounds <b>22</b> and <b>24</b> in C57Bl6 Mice<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="."><b>22</b></th><th class="colsep0 rowsep0" align="center" char="."><b>24</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[C]<sub>plasma</sub>max (nM)</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[C]<sub>plasma</sub>max (ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max plasma</sub> (min)</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (ng·min/mL)</td><td class="colsep0 rowsep0" align="char" char=".">2909</td><td class="colsep0 rowsep0" align="char" char=".">5774</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">317</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver <i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">nd</td><td class="colsep0 rowsep0" align="char" char=".">385</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gallbladder (tissue and content) <i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">9028</td><td class="colsep0 rowsep0" align="char" char=".">10980</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fecal recovery (%)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last"><i>n</i> = 3 mice/time; male C57Bl6/J mice. Compounds were administered orally (20 mg/kg, formulated in Tween 0.1%).</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Feces collected 24 h after compound dosing (20 mg/kg). Parent compound was extracted with organic solvent and analyzed quantitatively using mass spectrometry.</p></div></div></div><div class="NLM_p">Intestinal exposure was then measured for compound <b>24</b>. Very interestingly, the results of the exposure of the different sections of the GI tract showed that the targeted distal sections (ileum and colon) were maximally exposed by compound <b>24</b> 8 h after oral dosing (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0003.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Time-course of compound <b>24</b> concentrations in the duodenum, jejunum, ileum, and colon of C57Bl6 mice, after a single oral administration (20 mg/kg). Mean ± SEM (<i>n</i> = 3 mice/time).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In light of the results obtained concerning the intestinal exposure by compound <b>24</b>, we next explored the effect of the time elapsed between oral dosing and the GLP-1 secretion assay. As maximal GLP-1 secretion is expected when TGR5 is activated in distal sections of the GI tract, we compared GLP-1 secretion at two time-points after oral load by compound <b>24</b>. Consistent with the pharmacokinetics observed in the intestine, a 3.6-fold and a 10-fold increase in active GLP-1 concentrations were observed, respectively, 4 and 7 h after the administration of <b>24</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0004.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound <b>24</b> (gray bars) were administrated to mice 4 h (<i>t</i> + 4 h) or 7 h (<i>t</i> + 7 h) before blood collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 6/group). ** <i>p</i> < 0.01 (Student’s <i>t</i> test). Vehicle = Tween 0.1%. <b>24</b> = compound <b>24</b> in Tween 0.1% (20 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Then, C57Bl6 mice were orally treated with increasing doses of <b>24</b>, and plasma active GLP-1 concentrations were measured 8 h postdosing. Compound <b>24</b> induced a dose-dependent GLP-1 secretion (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Gallbladder relaxation, described in rodents treated with both bile acid derivatives and nonsteroid small TGR5 agonist molecules,<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> was assessed by gallbladder volume measurement in fasted mice 8 h after a single oral administration of vehicle or <b>24</b> at increasing dose. Interestingly, a high GLP-1 secretion (6-fold increase in active GLP-1 plasma concentrations) was obtained at a dose (5 mg/kg) that did not modify gallbladder volume, suggesting that in these conditions gallbladder exposure is not sufficient to trigger the pharmacological response of the gallbladder (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). Gallbladder motility was then studied by gallbladder volume measurement in fasted and refed conditions at the highest tested dose (20 mg/kg). In this experiment, we showed that gallbladder volume is not significantly increased by <b>24</b> both in fasted and refed conditions. We showed moreover that compound <b>24</b> does not disrupt food stimulated gallbladder emptying and motility (ejection fraction of 30 and 25%, respectively, for vehicle and compound <b>24</b>) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). Thus, the ratio between the lowest active dose (5 mg/kg) and the highest dose that does not modify gallbladder motility (20 mg/kg) defines a therapeutic window of 4.</div><figure id="fig5" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0005.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> dose–response effect of compound <b>24</b> in C57Bl6 mice. (A) GLP-1 secretion after oral administration of the vehicle (white bar) or <b>24</b> (gray bars) 8 h prior to blood sample collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 6/group). **** <i>p</i> < 0.0001 (ANOVA-Dunnet test). (B) Gallbladder volume in fasted mice 8 h after oral administration of compound <b>24</b>. Mean ± SEM (<i>n</i> = 6/group). ** <i>p</i> < 0.01 (ANOVA-Dunnet test). (C) Gallbladder volume in fasted (6 h) and refed (fasted 4 h then refed for 2 h) mice after oral administration of compound <b>24</b> (20 mg/kg) or vehicle. Mean ± SEM (<i>n</i> = 6/group). ANOVA-Tukey test. Veh = vehicle (Tween 0.1%). <b>24</b> = compound <b>24</b> in Tween 0.1%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have shown that compound <b>24</b> is mainly retained in the intestine and triggers GLP-1 secretion in a physiological context, in a dose-dependent manner. Next, the GLP-1 secretagogue effect of compound <b>24</b> was tested in a pathological context, namely, in C57BL6 mice rendered obese and insulin-resistant by feeding a high fat diet (HFD) for 10 weeks. Interestingly, a 20 mg/kg dose of <b>24</b> increased active GLP-1 4-fold in HFD-fed mice (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). This increase in GLP-1 secretion (4-fold) in HFD-fed mice was lower than the one observed in lean mice at the same dose (10-fold, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A).</div><figure id="fig6" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0006.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice fed a HFD. Vehicle (white bars) or compound <b>24</b> (gray bars) were administrated to mice 8 h prior to blood sample collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 10/group). **** <i>p</i> < 0.0001 (Student’s <i>t</i> test). Veh = vehicle (Tween 0.1%). <b>24</b> = compound <b>24</b> in Tween 0.1% (20 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to evaluate the effect of compound <b>24</b> on glucose homeostasis, HFD fed mice treated with a single dose of compound <b>24</b> were submitted to an oral glucose tolerance test 7 h later. Compound <b>24</b> did not modify basal glycemia (T0 in the OGTT test, <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Interestingly, after a glucose challenge, glucose concentrations returned faster to the basal state in <b>24</b>-treated mice compared to that in controls as assessed by the time-course and AUC calculation (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Thus, the GLP-1 secretion induced by compound <b>24</b> translates into improved glucose tolerance in a pathological model.</div><figure id="fig7" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0007.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>24</b> administration on oral glucose tolerance test in HFD fed C57BL6 mice. Obese, insulin-resistant mice were treated with vehicle or <b>24</b>. (Veh = vehicle (Tween 0.1%). <b>24</b> = compound <b>24</b> (20 mg/kg) in Tween 0.1%). Seven hours later, mice were challenged with an oral bolus of glucose (4g/kg) and glucose measured at the indicated time-points. (A) Glycemia excursion curve. (B) Incremental area under the curve (AUC), expressed as arbitrary units (A.U.). Mean ± SEM (<i>n</i> = 8/group). * <i>p</i> < 0.05, ** <i>p</i> < 0.01 (Student’s <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It was recently reported that functional TGR5 appears to be mostly located on the basolateral side of enteroendocrine L-cells, suggesting that crossing the intestinal epithelium is required before bile acids or other TGR5 agonists can elicit a GLP-1 secretory response. Under these conditions, luminally restricted TGR5 agonists would not induce a strong GLP-1 secretion <i>in vivo</i>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Interestingly, despite very low permeability in Caco-2 enterocytes in culture and a concordant poor systemic exposure, compound <b>24</b> was able to trigger a strong <i>in vivo</i> GLP-1 secretion. As can be seen in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, <b>24</b> undergoes a very high active efflux (efflux ratio >600) in the permeability assay on Caco-2 cells, explaining the very low absorption through enterocytes. This also suggests that, in the much less abundant enteroendocrine L-cells which are devoid of efflux mechanisms, a significant fraction of the compound could cross cell membranes and activate TGR5 on the basolateral side without contributing to systemic absorption. A useful consequence of its low intestinal absorption is that <b>24</b> reaches the distal intestine where TGR5 expression is maximal and triggers GLP-1 secretion.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Modification of a potent agonist of TGR5 to decrease intestinal absorption without impacting membrane permeation in target cells was proven to be a valid strategy to activate enteroendocrine L-cells located in the lower intestinal tract, while creating a potency window between the efficacious dose measured on glucose tolerance and the dose triggering gallbladder response. Compound <b>24</b> exhibits high <i>in vitro</i> potency and <i>in vivo</i> GLP-1 secretagogue effect that translates into an improved glucose tolerance in a pathological murine model of obesity/insulin resistance. Thanks to a fine-tuned pharmacokinetic behavior, this TGR5 agonist displays attractive <i>in vivo</i> efficacy and safety.</div><div class="NLM_p last">Further biological evaluations are ongoing to explore in detail the mechanisms underlying the effects of compound <b>24</b> (BDM72881)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and support the therapeutic potential of topical intestinal TGR5 agonists for the treatment of type 2 diabetes.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>In Vitro</i> TGR5 Assay</h3><div class="NLM_p last">TGR5 activation by compounds and subsequent increase in intracellular cAMP were evaluated using a luciferase reporter gene assay. Human embryonic kidney (HEK) 293 cells were transiently cotransfected with pCMV tag4b-TGR5h (to determine hTGR5 activation) or pCMV AC6-TGR5m (to determine mTGR5 activation) expression plasmids and the pCRE TA-Luciferase reporter plasmid using the JET PEI reagent (Polyplus transfection). Transfected cells were seeded in 96-well plates and incubated overnight with the compounds at increasing concentrations in duplicate. Lithocholic acid (LCA) at 10 μM was used as a positive reference compound. The cAMP-dependent luciferase expression was followed using the BrightGlo reagent according to the manufacturer’s (Promega) instructions. Luminescence was measured with a Mithras plate reader (Berthold). Data were expressed as the percentage of the 10 μM LCA value, and EC<sub>50</sub> values were calculated using XL fit 5 software or GraphPad Prism 5. Concentration–response curves were fitted by a nonlinear regression analysis to a 4 parameter logistic equation.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> LC-MS/MS ADME Methods</h3><div class="NLM_p">Chromatography was performed using a UPLC system, Acquity I-Class (Waters). Separation was achieved on a Waters Acquity BEH C18 column (2.1 mm × 50 mm, 1.7 μm). The autosampler and column oven temperatures were 10 and 40 °C, respectively, and the sample injection volume was 1 μL. The mobile phase consisted of 0.1% formic acid (FA) in water as solvent A and 0.1% FA in acetonitrile as solvent B at a flow rate of 600 μL/min. The gradient was as follows: 0–0.2 min (98%A and 2%B), 2–2.5 min (2%A and 98%B), 2.6 min (98%A and 2%B), and 4 min (98%A and 2%B). The gradient step was linear.</div><div class="NLM_p last">Mass spectrometry was performed using a Xevo TQD (Waters Corporation) mass spectrometer. The detection of analytes was achieved by electrospray ionization (ESI) in the positive mode with the appropriate MRM transition. Other mass spectrometer settings were as follows: capillary voltage and cone voltage were optimized for each compound, desolvation temperature of 600 °C at a gas flow of 1200 L/h, and cone gas flow 50 L/h. The LC-MS/MS instrument was controlled by MassLynx software (Waters).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Solubility/LogD Measurements</h3><div class="NLM_p">Ten microliters of a 10 mM solution in DMSO of the compound was diluted either in 490 μL of PBS pH 7.4 or in organic solvent MeOH in a 700 μL-microtube (in triplicate). The tubes were gently shaken 24 h at room temperature, then centrifuged for 5 min at 4000 rpm. The mixtures were filtered over 0.45 μm filters (Millex-LH Millipore). Ten microliters of sample was diluted in 490 μL of MeOH. The solubility is determined by the ratio of mass signal area PBS/organic solvent.</div><div class="NLM_p last">40 μL of a 10 mM solution in DMSO of the compound was diluted in 1.960 mL of a 1/1 octanol/PBS mixture at pH 7.4. The mixture was gently shaken for 2 h at room temperature. Ten microliters of each phase was diluted in 490 μL of MeOH and analyzed by LC-MS/MS. Each compound was tested in triplicate. Log D was determined as the logarithm of the ratio of concentration of product in octanol and PBS, determined by mass signals.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Microsomal Stability</h3><div class="NLM_p last">Male mouse (CD-1) liver microsomes (BD Gentest) were used. All incubations were performed in duplicate in a shaking water bath at 37 °C. The incubation mixtures contained 1 μM compound with 1% methanol used as a vehicle, mouse liver microsomes (0.3 mg of microsomal protein per mL), 5 mM MgCl<sub>2</sub>, 1 mM NADP, 5 mM glucose 6-phosphate, 0.4 U·mL<sup>–1</sup> glucose 6-phosphate dehydrogenase, and 50 mM potassium phosphate buffer (pH 7.4) in a final volume of 0.5 mL. Aliquots were removed at 5, 10, 20, 30, and 40 min after microsome addition, and the reaction was stopped by adding four volumes of ice-cold acetonitrile containing 200 nM of internal standard. The samples were centrifuged for 10 min at 10000 rpm, and the supernatants were transferred in matrix tubes for LC-MS/MS analysis. Each compound was quantified by converting the corresponding analyte/internal standard peak area ratios to the percentage of drug remaining, using the initial ratio values in control incubations as 100%. Propranolol, known as a high hepatic clearance drug in rodents, was used as a quality-control compound for the microsomal incubations. <i>In vitro</i> intrinsic clearance (<i>Cl</i><sub>int</sub> expressed as μL/min/mg) was calculated according to the following formula: <i>Cl</i><sub>int</sub> = dose/AUC<sub>∞</sub>, where dose is the initial amount of drug in the incubation mixture (1 μM), and AUC<sub>∞</sub> is the area under the concentration versus time curve extrapolated to infinity. The slope of the linear regression from log percentage remaining versus incubation time relationships (−<i>k</i>) was used in the conversion to <i>in vitro</i><i>t</i><sub>1/2</sub> values by <i>t</i><sub>1/2</sub> = −ln(2)/<i>k</i>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Caco-2 Permeation Assay<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></h3><div class="NLM_p last">0.4 × 10<sup>5</sup> Caco-2 cells (ATCC No. HTB-37), at passage 28, were seeded on a 25 cm<sup>2</sup> plastic flask and changed every two days with complete medium containing high glucose Dulbecco’s modified Eagle’s medium (DMEM) with <span class="smallcaps smallerCapital">l</span>-glutamine supplemented by 10% of fetal calf/bovine serum and 1% of nonessential amino acids without <span class="smallcaps smallerCapital">l</span>-glutamine. The paracellular barrier characteristics of tje Caco-2 cell monolayer was monitored using measurements of the permeability to the nonpermeant fluorescent molecule, Lucifer yellow (LY). The permeability to Lucifer yellow values (<1 × 10<sup>–6</sup> cm/s) attested to the restriction of the paracellular permeability in Caco-2 cultures in the absence of compound. Caco-2 cells were trypsinized after 3 days of incubation while they cover 80–90% of the flask and seeded at a density of 5 × 10<sup>5</sup> in 75 cm<sup>2</sup> flasks in complete medium supplemented with 73 nM (around 0.04 μg/mL) of the antibacterial puromycin (3′-[α-amino-<i>p</i>-methoxyhydrocinnamamido]-3′-deoxy-<i>N</i>,<i>N</i>-dimethyladenosine dihydrochloride). After 5 to 6 days, Caco2 cells reach high cell density (>0.5 × 10<sup>5</sup> cells/cm<sup>2</sup>) and are then passaged into cell HTS 24-well plates with 0.4 μm polycarbonate membrane inserts. Cells were seeded at 600 000 cells/cm<sup>2</sup> (200 000 cells/insert) and cultivated for 6 days in complete medium with puromycin. Media were replaced every two days. Compound solutions were prepared in HEPES-buffered Ringer’s (RH) solution (NaCl 150 mM, KCl 5.2 mM, CaCl<sub>2</sub> 2.2 mM, MgCl<sub>2</sub> 0.2 mM, NaHCO<sub>3</sub> 6 mM, glucose 2.8 mM, HEPES 5 mM, and water for injection), pH 7.4 at a final concentration of 1 to 10 μM for tested drugs. For the A → B transport experiment, 0.2 mL of the compound solution was placed on the apical side of the cells, and samples were taken from the basolateral compartment. For the B → A transport experiment, 0.8 mL of the solution was placed on the basolateral side of the cells, and samples were taken from apical side. Transport studies were done in Transwell polycarbonate/HTS 24 well plate inserts (surface area, 0.33 cm<sup>2</sup>; 0.4 μm pore size). Cells were equilibrated for 10 min in transport buffer prior to the transport experiment, and then incubations with compounds were performed at 37 °C under agitation. After 1 h, aliquots were taken from each compartment and sampled in 96-well plates with glass inserts. Permeations are calculated using the formulas below:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/jm-2016-018738_m001.gif" alt="" /></img></span><span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/jm-2016-018738_m002.gif" alt="" /></img></span><i>V</i> is the volume of solution on the apical side (A) or basolateral side (B), AUC is the area of the LC-MS/MS signal for the compound measured in the A or B side at initial time (T0) or at the end of the incubation (T), <i>T</i> is the incubation time, and <i>S</i> is the surface area of the inset membrane.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>In Vivo</i> Experiments</h3><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Animals and Diets</h4><div class="NLM_p last">10–12 old week male C57Bl6 mice were purchased from Charles River (France) and fed ad libitum with a standard diet (UAR A04, Villemoison/Orge, France). For high fat diet (HFD) experiments, 10–12 old week male C57Bl6 mice were fed a HFD (D12492; Research Diets; 60% kcal fat) for 8–10 weeks to induce obesity and insulin-resistance. Experiments were performed in mice with a 30% increase in body weight. All animals were maintained in standard animal cages under conventional laboratory conditions (12h/12h light/dark cycle, 22 °C) with ad libitum access to food and water. The animals were maintained in compliance with European standards for the care and use of laboratory animals and experimental protocols approved by the local Animal Ethical Committee (agreement nos. CEEA 07430, 01134.01, and 01134.03).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>In Vivo</i> GLP-1 Secretion</h4><div class="NLM_p last">Mice were fasted from the time of gavage with vehicle or compound as indicated in the figure legends and gavaged with sitagliptin (25 mpk) (MSD) 45 min before blood (250 μL) was sampled by retro-orbital venipuncture under isoflurane anesthesia in EDTA-coated tubes containing DPP-4 inhibitor diprotin A (Sigma-Aldrich). Active GLP-1 plasma concentration was measured by ELISA (Millipore).</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Gallbladder Volume Measurement</h4><div class="NLM_p last">Mice either fasted or fed as indicated in the figure legends were killed by cervical dislocation. Gallbladder volume (length × width × width) was evaluated using a vernier caliper and removed to measure compound content.</div></div><div id="sec5_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Oral Glucose Tolerance Test</h4><div class="NLM_p last">After overnight fasting, mice were gavaged with vehicle or compound and fasted for 7 h. A bolus of glucose (4 g/kg) was administrated by gavage, and glycemia was measured at 0, 15, 30, 60, 90, and 120 min by a glucometer (Roche).</div></div><div id="sec5_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Pharmacokinetics</h4><div class="NLM_p last">Compounds <b>22</b> and <b>24</b> were dissolved in distilled water/0.1% Tween and administered per os at 32 μmol/kg to 10-week old, male, C57Bl6 mice (approximately 25–30 g) (Charles River). Compound <b>22</b> was administered to overnight fasted animals. Three mice per time point were anesthetized with isoflurane and aliquots taken from the retro-orbital sinus using sampling heparinated tubes (4 °C) at 10 min, 20 min, 30 min, 1 h, 2 h, 4 h, and 8h after administration of a single dose of ligands. The blood samples were centrifuged (5000<i>g</i>, 15 min) for plasma separation and stored at −80 °C before compound measurement. Plasma samples were thawed on ice. Aliquots were precipitated with ice cold acetonitrile (1 to 10 ratio) containing compound <b>3</b> (0.2 μM) as internal standard. The samples were vigorously mixed with a vortex and centrifuged for 10 min at 10 000 rpm, 4 °C, and the supernatants were transferred into Matrix tubes for LC-MS/MS analysis. Spiked standard solutions (1, 3, 10, 30, 100, 300, 1000, 3000, 10 000, and 30 000 nM) were prepared the same way. After rodent sacrifice, gallbladders, livers, and intestines were removed. Gallbladders were immediately measured using a vernier caliper. Intestines were cut to isolate the duodenum, jejunum, ileum, and colon. All tissues were frozen in liquid nitrogen and stored at −80 °C. Compounds in tissues and in rehydrated feces (feces collected 24 h after compound dosing of a dedicated group of animals) were extracted with a MeOH/CH<sub>3</sub>CN 50:50 mixture (using a vortex for feces or a Tissue Lyzer II from Qiagen for tissues). After centrifugation (10000 rpm, 10 min, 4 °C) of the homogenate samples, supernatants were diluted (1 to 10) with ice–acetonitrile containing compound <b>3</b> (0.2 μM) as internal standard. After the last centrifugation, the supernatants were transferred into Matrix tubes for LC-MS/MS analysis.</div></div><div id="sec5_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthetic Materiels and Methods</h4><div class="NLM_p last">All commercial reagents and solvents were used without further purification. Microwave-assisted chemical reactions were conducted on a CEM Discover synthesis system or a Biotage Initiator+ microwave synthesizer. Flash column chromatography was performed on prepacked columns (Grace Resolv flash cartridges, Grace). Preparative HPLC were performed using a Varian ProStar system using an Omnisphere 10 C18 column (250 mm × 41.4 mm) Dynamax from Varian, Inc. or a Waters-2 system using a XBridge Prep C18 5 μm OBD (250 mm × 50 mm or 150 × 30 mm). A gradient starting from CH<sub>3</sub>CN-H<sub>2</sub>O and formic acid (20–80–0.1%) and reaching 100%CH<sub>3</sub>CN/0.1% formic acid at a flow rate of 80 mL/mins was used on the Varian ProStar system. Products were detected by UV absorption at 215 nm and/or 254 nm. A gradient mixture of CH<sub>3</sub>CN and water in ammonium formate buffer at pH 9.2 or pH 3.8 and a flow rate at 40 or 80 mL/min were used on a Waters-2 system. Products were detected by UV absorption and/or by MS. NMR spectra were recorded on a Bruker DRX-300 spectrometer. Chemical shifts are in parts per million (ppm). The assignments were made using one-dimensional (1D) <sup>1</sup>H and <sup>13</sup>C spectra and two-dimensional (2D) HSQC, HMBC, and COSY spectra. LCMS analysis was performed on a Waters Alliance Micromass ZQ 2000, using an XBridge C18 column (3.5 μm particle size, dimensions 50 mm × 4.6 mm). A mixture of water and acetonitrile was used as the mobile phase in gradient-elution. The pH of the mobile phase was adjusted with HCOOH and NH<sub>4</sub>OH to form a buffer solution at pH 3.8. The analysis time is 5 min (at a flow rate at 2 mL/min). Purity (%) was determined by reversed phase HPLC, using UV detection (215 nm), and all compounds showed purity greater than 95% unless otherwise stated (<b>17c</b> and <b>26c</b>). HRMS analysis was performed on an LCT Premier XE Micromass, using a C18 X-Bridge 3.5 μm particle size column, dimensions 50 mm × 4.6 mm. A gradient starting from 100% H<sub>2</sub>O–5 mM ammonium formate at pH 3.8 and reaching 100% CH<sub>3</sub>CN–5 mM ammonium formate at pH 3.8 within 2 min at a flow rate of 2 mL/min was used. Purification yields were not optimized. Final compounds were isolated as amorphous solids without collection of melting point data.</div></div><div id="sec5_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> General Procedure A</h4><div class="NLM_p last">The 3-amino-5-thio-[1,2,4]triazolyl-amine derivative (1 equiv) and the phenylboronic acid derivative (1 equiv) were dissolved in dichloromethane (QS 20 mM). Molecular sieve (4 Å), pyridine (2 equiv), and copper(II) acetate (Cu(OAc)<sub>2</sub>) (1.5 equiv) were added to the solution. The reaction mixture was stirred at room temperature for several hours. Pyridine, phenylboronic acid derivative, and Cu(OAc)<sub>2</sub> were added several times until satisfying conversion occurred. The reaction mixture was then filtered on Celite. The filtrate was washed with water and a saturated aqueous solution of NaHCO<sub>3</sub>. The organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was purified by flash chromatography (DCM/MeOH).</div></div><div id="sec5_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Procedure B</h4><div class="NLM_p last">In a round-bottomed flask was added the isothioureido-derivative (1 equiv), K<sub>2</sub>CO<sub>3</sub> (1 equiv), sodium Iodide (0.5 equiv), and acetonitrile (QS 0.2M). The suspension was stirred at room temperature for 10 min, and benzyl halide (1 equiv) was then added. The suspension was stirred at room temperature overnight. The reaction mixture was then evaporated; the residue was dissolved in EtOAc and washed with water and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by flash chromatography (cyclohexane/EtOAc).</div></div><div id="sec5_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Procedure C</h4><div class="NLM_p last">In a microwave tube were introduced the isothioureido-acetamide derivative (1 equiv), EtOAc (QS 0.1M), DIEA (6 equiv), and T3P (3 equiv). The reaction mixture was heated under microwave irradiation at 150 °C for 10 min. The reaction mixture was then diluted with EtOAc and washed with saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by flash chromatography (cyclohexane to cyclohexane/EtOAc).</div></div><div id="sec5_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Procedure D</h4><div class="NLM_p">In a round-bottomed flask were introduced the isothioureido-acetamide derivative (1 equiv), EtOAc (QS 0.1M), DIEA (6 equiv), and T3P (3 equiv). The reaction mixture was heated at reflux for 24 h. After several hours, DIEA, and T3P were added several times, until completion. The reaction mixture was then diluted in EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was purified by flash chromatography (cyclohexane/EtOAc).</div><div id="sec5_6_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 5-Amino-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazole-3-thiol (<b>1a</b>)</h5><div class="NLM_p last">4-Fluorophenylisothiocyanate (1.04 g, 6.54 mmol), aminoguanidinium chloride (1.45 g, 13.1 mmol), and DIEA (3.12 mL, 19.6 mmol) were dissolved in DMF (9.40 mL). The reaction mixture was stirred at 50 °C for 15 h, then evaporated to dryness. Thirteen milliliters of an aqueous solution of 2 M NaOH was then added, and the reaction mixture was stirred at 50 °C for 18 h. The suspension was then filtered, and the filtrate was neutralized by the addition of aqueous 2 M HCl and filtrated. Both precipitates were pulled together, to give an orange powder corresponding to the title product (1.2 g, 87%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 210.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 5.96 (s, 2H), 7.38 (m, 4H), 12.80 (s, 1H).</div></div><div id="sec5_6_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-ylamine (<b>1b</b>)</h5><div class="NLM_p last">5-Amino-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazole-3-thiol (<b>1a</b>) (501 mg, 2.38 mmol), 2-bromomethyl-1,3-difluoro-benzene (492 mg, 2.37 mmol), and DIEA (416 μL, 2.62 mmol) were dissolved in 12 mL of dichloromethane. The reaction mixture was stirred at room temperature for 3 h, then washed with water and brine, and the organic phase was dried over MgSO<sub>4</sub>, and evaporated to dryness to give 787 mg of the expected product as a white powder (98%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 336.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 3.88 (s, 2H), 5.89 (s, 2H), 7.03 (t, <i>J</i> = 8.0 Hz, 2H), 7.26–7.40 (m, 5H).</div></div><div id="sec5_6_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>N</i>-[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-acetamide (<b>1c</b>)</h5><div class="NLM_p last">5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-ylamine (<b>1b</b>) (318 mg, 94.5 μmol) was dissolved in 0.5 mL of dichloromethane, and acetic anhydride (450 μL, 4.73 mmol) was then added. The reaction mixture was stirred at room temperature for 30 min. Five milliliters of an aqueous solution of 2 N NaHCO<sub>3</sub> was then added. Phases were separated, and the organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was recrystallized in isopropanol to give the title product as white crystals (238 mg, 66%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 378.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 1.84 (s, 3H), 4.19 (s, 2H), 7.05 (t, <i>J</i> = 8.0 Hz, 2H), 7.23–7.42 (m, 5H), 10.37 (brs, 1H).</div></div><div id="sec5_6_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>N</i>-[5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-<i>N</i>-(3,4-dimethoxy-phenyl)-acetamide (<b>1d</b>)</h5><div class="NLM_p last">The title compound was obtained as a yellowish oil (420 mg, 50%) following Procedure A, using <i>N</i>-[5-(2,6-difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-acetamide (<b>1c</b>) (570 mg, 1.5 mmol), and 3,4-dimethoxyphenylboronic acid. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 514.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 1.65 (s, 3H), 3.79 (s, 3H), 3.81 (s, 3H), 4.31 (s, 2H), 7.05–7.18 (m, 3H), 7.24–7.54 (m, 7H).</div></div><div id="sec5_6_10_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> [5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-(3,4-dimethoxy-phenyl)-amine (<b>1</b>)</h5><div class="NLM_p last">Acetyl chloride (2.4 mL) and ethanol (5 mL) were gently mixed at 0–5 °C, and the mixture was added to a solution of <i>N</i>-[5-(2,6-difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-<i>N</i>-(3,4-dimethoxy-phenyl)-acetamide (<b>1d</b>) (310 mg, 602 μmol) in 4.6 mL of ethanol. The reaction mixture was then heated at 100 °C for 30 min. The reaction mixture was then evaporated. The residue was dissolved in EtOAc and washed with water and with a saturated aqueous solution of NaHCO<sub>3</sub>. The organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness. The residue was recrystallized in a mixture of isopropanol/methanol to give 163.5 mg of the expected product as a white solid (57%). LC-MS: <i>t</i><sub>R</sub> = 2.60 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 472.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 3.77 (s, 3H, O-<u class="uu">CH</u><sub><u class="uu">3</u></sub>), 3.78 (s, 3H, O-<u class="uu">CH</u><sub><u class="uu">3</u></sub>), 4.22 (s, 2H, S-<u class="uu">CH</u><sub><u class="uu">2</u></sub>), 5.13 (brs, 1H, NH), 7.00 (d, <i>J</i> = 8.8 Hz, 2H, Ar), 7.35–7.55 (m, 8H, Ar). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i>6): δ (ppm) 24.0, 56.0, 56.2, 110.9, 112.0, 112.3, 113.1 (t, <i>J</i> = 18.9 Hz), 117.5 (d, <i>J</i> = 23.2 Hz), 126.6–129.3 (m), 130.9 (t, <i>J</i> = 10.4 Hz), 131.3 (d, <i>J</i> = 8.9 Hz), 132.4–133.0 (m), 142.2, 146.1, 149.2, 151.9, 160.9, 161.1 (dd, <i>J</i> = 248.4, 7.2 Hz), 162.7 (d, <i>J</i> = 247.9 Hz).</div></div><div id="sec5_6_10_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> [5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-methyl-amine (<b>2c</b>)</h5><div class="NLM_p last">A suspension of 5-(2,6-difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-ylamine (<b>1b</b>) (200 mg, 595 μmol) and sodium methanolate (161 mg, 2.98 mmol) in methanol (QS 0.5 M) was added to paraformaldehyde (25 mg, 833 μmol). The reaction mixture was stirred at room temperature for 16 h. NaBH<sub>4</sub> (22.5 mg, 595 μmol) was then added, and the reaction mixture was stirred at reflux for 30 min. After cooling down to room temperature, the reaction mixture was partially evaporated. Aqueous 1 M KOH was then added. This solution was then extracted by EtOAc. The organic phase was dried over MgSO<sub>4</sub>, and evaporated to dryness. The residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH to give the title compound as a yellowish solid (157 mg, 76%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 350.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 2.73 (d, <i>J</i> = 4.8 Hz, 3H), 3.91 (s, 2H), 5.82 (q, <i>J</i> = 4.7 Hz, 1H), 7.04 (t, <i>J</i> = 8.0 Hz, 2H), 7.25–7.43 (m, 5H).</div></div><div id="sec5_6_10_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> [5-(2,6-Difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>2</b>)</h5><div class="NLM_p last">The title compound was obtained as a yellowish solid (42.4 mg, 11%) after purification by preparative HPLC, following Procedure A using [[5-(2,6-difluoro-benzylsulfanyl)-4-(4-fluoro-phenyl)-4<i>H</i>-[1,2,4]triazol-3-yl]-methyl-amine (<b>2c</b>) (281 mg, 800 μmol) and 3,4-dimethoxyphenylboronic acid. LC-MS: <i>t</i><sub>R</sub> = 2.60 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 486.9. HRMS found 487.1394; C<sub>24</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S requires 487.1416. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.69 (s, 3H), 3.92 (s, 3H), 3.95 (s, 3H), 4.26 (s, 2H), 6.84–6.94 (m, 3H), 7.10–7.42 (m, 7H).</div></div><div id="sec5_6_10_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (3,4-Dimethoxy-phenyl)-methyl-amine (<b>3a</b>)</h5><div class="NLM_p last">In a 250 mL flask were added 3 g of 3,4-dimethoxyaniline and 5.29 g of sodium methoxide in 35 mL of methanol (dried over Na<sub>2</sub>SO<sub>4</sub>). Then, 1.18 g of paraformaldehyde and 15 mL of methanol (dried over Na<sub>2</sub>SO<sub>4</sub>) were added. A molecular sieve (4 Å) was then added, and the mixture was stirred overnight at room temperature. 0.74 g of sodium borohydride were then added, and the mixture was heated under reflux for 1 h. The mixture was then evaporated and dissolved in EtOAc and water, and the two phases were separated. The aqueous phase was then basified by the addition of a saturated aqueous solution of NaHCO<sub>3</sub> and extracted by EtOAc. The organic phases were washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness to give the title product as an oily residue (2.67 g, 77%), which was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 168.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 2.62 (d, <i>J</i> = 5.0 Hz, 3H), 3.61 (s, 3H), 3.69 (s, 3H), 5.20 (q, <i>J</i> = 4.9 Hz, 1H), 5.99 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 6.22, (d, <i>J</i> = 2.5 Hz, 1H), 6.71 (d, <i>J</i> = 8.5 Hz, 1H).</div></div><div id="sec5_6_10_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 2-Chloro-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>3b</b>)</h5><div class="NLM_p last">In a 250 mL flask were introduced a solution of 2.67 g of (3,4-dimethoxy-phenyl)-methyl-amine (<b>3a</b>) and 7.9 mL of DIEA in 45 mL of DCM (dried over Na<sub>2</sub>SO<sub>4</sub>). The solution was stirred at 0 °C. Then, a solution of 2.4 mL of chloroacetyl chloride in 30 mL of DCM (dried over Na<sub>2</sub>SO<sub>4</sub>) was added dropwise in the flask. The mixture was then evaporated to dryness to give a brown residue which was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 244.1.</div></div><div id="sec5_6_10_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]ammonium formate (<b>3c</b>)</h5><div class="NLM_p last">The residue corresponding to the 2-chloro-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>3b</b>) obtained was dissolved in 25 mL of ethanol 95°, and added dropwise to a 500 mL flask containing 320 mL of aqueous ammonia at 65 °C. The reaction mixture was then evaporated to dryness. The residue was dissolved in DCM and extracted several times with an aqueous solution of 1 M HCOOH. The aqueous phase was then evaporated to dryness, and the residue was triturated in acetonitrile. The supernatant was evaporated to dryness to give the title product as a brown powder (3.82 g, 75% yield over the 2 steps). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 225.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.17 (s, 3H), 3.76–3.77 (m, 6H), 3.99 (s, 2H), 6.90 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.99–7.03 (m, 2H), 8.00 (brs, 3H), 8.20 (s, 1H).</div></div><div id="sec5_6_10_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>)</h5><div class="NLM_p last">1.5 g of 4-fluorophenylisothiocyanate and 1.59 mL of TEA were added to a 250 mL flask in 15 mL of ethanol. 3.2 g of [2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]ammonium formate (<b>3c</b>) was dissolved in 115 mL of ethanol, 1.33 mL of TEA was added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. The reaction mixture was evaporated to dryness and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc to give the title product as a yellowish powder (2.8 g, 76%). MS [M – H]<sup>−</sup><i>m</i>/<i>z</i> = 244.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d6</i>): δ (ppm) 2.49 (s, 3H), 3.78 (m, 6H), 4.00 (d, <i>J</i> = 4.1 Hz, 2H), 6.92 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.01–7.03 (m, 2H), 7.15 (m, 2H), 7.45 (m, 2H), 7.73 (m, 1H), 9.90 (s, 1H).</div></div><div id="sec5_6_10_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>3e</b>)</h5><div class="NLM_p last">The title product was obtained without purification as an oily residue (1.15 g, 91%), following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>) (940 mg) and 2-bromomethyl-1,3-difluoro-benzene (518 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 504.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i>6): δ (ppm) 3.16 (s, 3H), 3.69–3.76 (m, 8H), 4.19 (s, 2H), 6.61 (m, 2H), 6.79–6.89 (m, 2H), 6.95–7.00 (m, 4H), 7.05–7.13 (m, 3H), 7.38 (m, 1H).</div></div><div id="sec5_6_10_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>3</b>)</h5><div class="NLM_p last">In a 50 mL flask were added 2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>3e</b>) (500 mg), 10 mL EtOAc, NEt<sub>3</sub> (843 μL), and T3P (1.77 mL). The reaction mixture was then stirred at reflux for 28 h. After 8 h, NEt<sub>3</sub> (843 μL) and T3P (1.77 mL) were added. After 25 h, NEt<sub>3</sub> (422 μL) and T3P (885 μL) were added. After dilution with 20 mL of EtOAc, the solution was washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH. The title product was obtained as an oily residue (160 mg, 33%). LC-MS: <i>t</i><sub>R</sub> = 3.13 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 486.3. HRMS found 486.1437; C<sub>25</sub>H<sub>22</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S requires 486.1463. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.92 (s, 3H),3.80 (s, 3H), 3.82 (s, 3H), 4.16 (s, 2H), 6.16 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.30 (d, <i>J</i> = 2.7 Hz, 1H), 6.72 (d, <i>J</i> = 8.7 Hz, 1H), 6.78 (m, 2H), 6.83–6.85 (m, 4H), 6.92 (s, 1H), 7.19 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.9, 40.1, 55.9, 56.4, 99.9, 105.5, 111.2, 112.4, 113.6 (t, <i>J</i> = 19.3 Hz), 115.9 (d, <i>J</i> = 22.9 Hz), 124.4, 129.1, 129.2, 130.8, 138.1, 139.6, 142.7, 143.2, 149.6, 161.1 (dd, <i>J</i> = 250.0, 7.7 Hz), 162.2 (d, <i>J</i> = 249.0 Hz).</div></div><div id="sec5_6_10_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[2-(2-fluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>4e</b>)</h5><div class="NLM_p last">The title product was obtained without purification as an oily residue (254 mg, 96%), following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>) (195 mg) and 1-(bromomethyl)-2-fluoro-benzene (94 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 486.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.16 (s, 3H), 3.39–3.76 (m, 8H), 4.17 (s, 2H), 6.59–6.89 (m, 4H), 6.95–7.00 (m, 4H), 7.11–7.19 (m, 2H), 7.31 (m, 1H), 7.41 (m, 1H).</div></div><div id="sec5_6_10_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (3,4-Dimethoxy-phenyl)-[2-(2-fluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-methyl-amine (<b>4</b>)</h5><div class="NLM_p last">The title product was obtained as an orange powder (130 mg, 61%), following Procedure C, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[2-(2-fluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>4e</b>). LC-MS: <i>t</i><sub>R</sub> = 3.28 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 468.0. HRMS found 468.1544; C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S requires 468.1557. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.77 (s, 3H), 3.81 (s, 3H), 4.27 (s, 2H), 6.11 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.22 (d, <i>J</i> = 2.7 Hz, 1H), 6.69 (d, <i>J</i> = 8.7 Hz, 1H), 6.79–6.84 (m, 2H), 6.90–7.06 (m, 5H), 7.20–7.25 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 31.8, 40.3, 55.9, 56.5, 100.0, 105.8, 112.4, 115.5 (d, <i>J</i> = 21.5 Hz), 116.0 (d, <i>J</i> = 22.8 Hz), 123.8, 124.1, 124.7 (d, <i>J</i> = 14.8 Hz), 129.1, 129.2, 129.4, 130.7, 131.0, 139.1, 139.3, 142.7, 143.1, 149.6, 160.9 (d, <i>J</i> = 248.3 Hz), 162.4 (d, <i>J</i> = 249.8 Hz).</div></div><div id="sec5_6_10_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 2-[2-Benzyl-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>5e</b>)</h5><div class="NLM_p last">The title product was obtained without purification as an oily residue (259 mg, 98%), following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>) (195 mg) and benzyl bromide (85 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 468.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.17 (s, 3H), 3.69–3.76 (m, 8H), 4.14 (s, 2H), 6.61 (m, 3H), 6.88 (m, 1H), 6.95–7.01 (m, 4H), 7.22–7.31 (m, 5H).</div></div><div id="sec5_6_10_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> [2-Benzylsulfanyl-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>5</b>)</h5><div class="NLM_p last">The title product was obtained as an orange powder (68 mg, 32%), following Procedure C, using 2-[2-benzyl-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>5e</b>) (249 mg). LC-MS: <i>t</i><sub>R</sub> = 3.32 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 450.0. HRMS found 450.1659; C<sub>25</sub>H<sub>24</sub>FN<sub>3</sub>O<sub>2</sub>S requires 450.1652. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ (ppm) 2.92 (s, 3H), 3.75 (s, 3H), 3.81 (s, 3H),4.26 (s, 2H), 6.09 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 6.20 (d, <i>J</i> = 2.7 Hz, 1H), 6.68 (d, <i>J</i> = 8.8 Hz, 1H), 6.74–6.78 (m, 2H), 6.89–6.95 (m, 2H), 7.04 (s, 1H), 7.19–7.29 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 38.7, 40.3, 55.9, 56.5, 99.9, 105.8, 112.4, 115.7, 115.9 (d, <i>J</i> = 22.8 Hz), 123.6, 127.4, 128.5, 129.0, 129.3 (d, <i>J</i> = 8.6 Hz), 130.7, 137.4, 139.2, 139.4, 142.7, 143.1, 149.5, 162.4 (d, <i>J</i> = 248.9 Hz).</div></div><div id="sec5_6_10_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[2-(2,6-dimethyl-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>6e</b>)</h5><div class="NLM_p last">The title product was obtained without purification as an oily residue (230 mg, 90%), following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>) (195 mg) and 2-(chloromethyl)-1,3-dimethyl-benzene (77 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 496.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 2.25 (s, 6H), 3.18 (s, 3H), 3.68–3.77 (m, 8H), 4.14 (s, 2H), 6.69–7.05 (m, 11H).</div></div><div id="sec5_6_10_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (3,4-Dimethoxy-phenyl)-[2-(2,6-dimethyl-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-methyl-amine (<b>6</b>)</h5><div class="NLM_p last">The title product was obtained as an orange powder (63 mg, 34%) following Procedure C using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[2-(2,6-dimethyl-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>6e</b>) (200 mg). LC-MS: <i>t</i><sub>R</sub> = 3.45 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 478.0. HRMS found 478.1974; C<sub>27</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>2</sub>S requires 478.1965. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.28 (s, 6H), 2.95 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 4.34 (s, 2H), 6.15 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.25 (d, <i>J</i> = 2.8 Hz, 1H), 6.70 (d, <i>J</i> = 8.7 Hz, 1H), 6.86–7.05 (m, 8H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 19.6, 33.3, 40.4, 56.0, 56.4, 100.1, 106.1, 112.4, 115.9 (d, <i>J</i> = 23.0 Hz), 123.4, 127.5, 128.3, 129.3 (d, <i>J</i> = 8.7 Hz), 130.8, 132.4, 137.6, 139.4, 140.0, 142.8, 143.1, 149.6, 162.3 (d, <i>J</i> = 250.2 Hz).</div></div><div id="sec5_6_10_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-(3,4-Dimethoxy-phenyl)-<i>N</i>-methyl-2-(3-phenyl-isothioureido)-acetamide (<b>7d</b>)</h5><div class="NLM_p last">Phenylisothiocyanate (159.5 μL, 1.33 mmol) and NEt<sub>3</sub> (216 μL, 1.60 mmol) were added to a 100 mL flask in 2 mL of ethanol. The residue from [2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]ammonium formate (<b>3c</b>) (400 mg, 1.33 mmol) was dissolved in 16 mL of ethanol, NEt<sub>3</sub> (180 μL, 1.33 mmol) was added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. The reaction mixture was evaporated to dryness and purified by flash chromatography using as eluent a mixture of DCM/MeOH (99.5/0.5) to give the title product as a yellowish residue (162 mg, 34%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 359.9.</div></div><div id="sec5_6_10_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 2-[2-(2,6-Difluoro-benzyl)-3-phenyl-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>7e</b>)</h5><div class="NLM_p last">The title product was obtained as a yellowish solid (183 mg, 84%), without purification, following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-2-(3-phenyl-isothioureido)-acetamide (<b>7d</b>) (162 mg, 450 μmol) and 2-bromomethyl-1,3-difluoro-benzene (93 mg, 450 μmol). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 486.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.27 (s, 3H), 3.81–3.87 (m, 8H),4.12 (s, 2H), 6.68–7.21 (m, 11H).</div></div><div id="sec5_6_10_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> [2-(2,6-Difluoro-benzylsulfanyl)-3-phenyl-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>7</b>)</h5><div class="NLM_p last">2-[2-(2,6-Difluoro-benzyl)-3-phenyl-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>7e</b>) (183 mg, 0.38 mmol) was dissolved in 3.8 mL of EtOAc. DIEA (395 μL, 2.26 mmol) and T3P in EtOAc (666 μL, 1.13 mmol) were then added. The reaction mixture was heated under microwave irradiation at 150 °C for 10 min. The reaction mixture was then diluted with EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub>, and brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15) and then again by flash chromatography using as eluent a mixture of cyclohexane/DCM (1/1) to DCM/MeOH (99/1) to give the title product as a reddish solid (21 mg, 11%). LC-MS: <i>t</i><sub>R</sub> = 3.10 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 467.9. HRMS found 468.1547; C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub>S requires 468.1557. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.90 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 4.18 (s, 2H), 6.17 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.31 (d, <i>J</i> = 2.8 Hz, 1H), 6.70–6.83 (m, 3H), 6.99–7.04 (m, 3H), 7.18 (m, 1H), 7.25–7.32 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.7, 40.0, 55.9, 56.5, 99.8, 105.3, 111.3 (m), 112.4, 113.6 (t, <i>J</i> = 19.4 Hz), 124.2, 127.3, 128.7, 128.9, 129.1 (t, <i>J</i> = 9.9 Hz), 134.9, 138.3, 139.5, 142.6, 143.3, 149.6, 161.3 (dd, <i>J</i> = 249.8, 7.4 Hz).</div></div><div id="sec5_6_10_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[3-(4-methoxy-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>8d</b>)</h5><div class="NLM_p last">4-Methoxyphenylisothiocyanate (184.0 μL, 1.33 mmol) and NEt<sub>3</sub> (216 μL, 1.60 mmol) were added to a 100 mL flask in 2 mL of ethanol. [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]ammonium formate (<b>3c</b>) (400 mg, 1.33 mmol) was dissolved in 16 mL of ethanol, NEt<sub>3</sub> (180 μL, 1.33 mmol) was added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. The reaction mixture was evaporated to dryness and purified by flash chromatography using as eluent a mixture of DCM/MeOH (99/1), to give the title product as a yellowish powder (157 mg, 30%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 389.9.</div></div><div id="sec5_6_10_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-methoxy-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>8e</b>)</h5><div class="NLM_p last">The title product was obtained as an orange solid (170 mg, 82%) without purification, following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-methoxy-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>8d</b>) (157 mg, 400 μmol) and 2-bromomethyl-1,3-difluoro-benzene (83 mg, 400 μmol). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 516.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.28 (s, 3H), 3.71 (s, 3H), 3.82–3.88 (m, 8H), 4.12 (s, 2H), 6.70–6.85 (m, 9H), 7.17 (m, 1H).</div></div><div id="sec5_6_10_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-methoxy-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>8</b>)</h5><div class="NLM_p last">2-[2-(2,6-Difluoro-benzyl)-3-(4-methoxy-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>8e</b>) (170 mg, 0.33 mmol) was dissolved in 3.3 mL of EtOAc. DIEA (346 μL, 1.98 mmol) and T3P in EtOAc (583 μL, 0.98 mmol) were then added. The mixture was heated under microwave irradiation at 150 °C for 10 min. The reaction mixture was then diluted with EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15) to give the title product a reddish solid (77 mg, 46%). LC-MS: <i>t</i><sub>R</sub> = 3.08 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 498.0. HRMS found 498.1672; C<sub>26</sub>H<sub>25</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S requires 498.1663. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.91 (s, 3H), 3.77 (s, 3H), 3.80–3.81 (m, 6H), 4.17 (s, 2H), 6.16 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.30 (d, <i>J</i> = 2.7 Hz, 1H), 6.70–6.83 (m, 5H), 6.93 (m, 2H), 7.01 (s, 1H), 7.18 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.6, 39.9, 55.4, 55.9, 56.5, 99.6, 105.1, 111.2 (m), 112.4, 113.6 (t, <i>J</i> = 19.6 Hz), 114.1, 124.2, 127.5, 128.5, 129.1 (t, <i>J</i> = 10.4 Hz), 138.6, 139.6, 142.4, 143.4, 149.5, 159.5, 161.2 (dd, <i>J</i> = 250.1, 7.9 Hz).</div></div><div id="sec5_6_10_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> <i>N</i>-(3,4-Dimethoxy-phenyl)-<i>N</i>-methyl-2-[3-(4-trifluoromethyl-phenyl)-isothioureido]-acetamide (<b>9d</b>)</h5><div class="NLM_p last">4-(Trifluomethyl)phenylisothiocyanate (332 mg, 1.63 mmol) and TEA (264 μL, 1.96 mmol) were added to a 100 mL flask in 2 mL of ethanol. [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]ammonium formate (<b>3c</b>) (490 mg, 1.63 mmol) was dissolved in 18 mL of ethanol, NEt<sub>3</sub> (220 μL, 1.63 mmol) was added, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. The reaction mixture was evaporated to dryness, and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (6/4) to give the title product as a yellowish powder (352 mg, 50%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 427.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.18 (s, 3H), 3.78 (s, 3H), 3.79 (s, 3H), 4.02 (d, <i>J</i> = 3.8 Hz, 2H), 6.93 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.01–7.06 (m, 2H), 7.65 (d, <i>J</i> = 8.6 Hz, 2H), 7.80 (d, <i>J</i> = 8.6 Hz, 2H),8.08 (s, 1H), 10.3 (s, 1H).</div></div><div id="sec5_6_10_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-trifluoromethyl-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>9e</b>)</h5><div class="NLM_p last">The title product was obtained as an orange solid (438 mg, 96%) without purification, following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-2-[3-(4-trifluoromethyl-phenyl)-isothioureido]-acetamide (<b>9d</b>) (352 mg) and 2-bromomethyl-1,3-difluoro-benzene (170 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 554.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.16 (s, 3H), 3.68 (s, 3H), 3.76 (m, 5H), 4.21 (s, 2H), 6.77–6.88 (m, 3H), 6.95–6.99 (m, 2H), 7.05–7.11 (m, 3H), 7.39 (m, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H).</div></div><div id="sec5_6_10_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-trifluoromethyl-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>9</b>)</h5><div class="NLM_p last">2-[2-(2,6-Difluoro-benzyl)-3-(4-trifluoromethyl-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>9e</b>) (438 mg, 0.79 mmol) was dissolved in 8 mL of EtOAc. DIEA (829 μL, 4.75 mmol), and T3P in EtOAc (1.40 mL, 2.37 mmol) were then added. The mixture was heated under microwave irradiation at 150 °C for 10 min. The reaction mixture was then diluted with EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15), to give the title compound as an orange solid (166 mg, 39%). LC-MS: <i>t</i><sub>R</sub> = 3.42 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 535.9. HRMS found 536.1433; C<sub>26</sub>H<sub>22</sub>F<sub>5</sub>N<sub>3</sub>O<sub>2</sub>S requires 536.1431. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.92 (s, 3H), 3.80 (s, 3H), 3.83 (s, 3H), 4.16 (s, 2H), 6.19 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.31 (d, <i>J</i> = 2.7 Hz, 1H), 6.72 (d, <i>J</i> = 8.8 Hz, 1H), 6.79 (m, 2H), 7.06 (s, 1H), 7.13 (d, <i>J</i> = 8.3 Hz, 2H), 7.18 (m, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 26.3, 40.3, 56.0, 56.5, 100.2, 106.0, 111.4 (m), 112.5, 113.5 (t, <i>J</i> = 19.3 Hz), 123.7 (q, <i>J</i> = 271.3 Hz), 126.1 (q, <i>J</i> = 10.1 Hz), 130.6 (q, <i>J</i> = 32.6 Hz), 137.9, 138.0, 139.8, 143.0, 149.7, 161.2 (dd, <i>J</i> = 250.0, 7.4 Hz).</div></div><div id="sec5_6_10_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> <i>tert</i>-Butyl <i>N</i>-[2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>10b</b>)</h5><div class="NLM_p last">In a 250 mL flask was added (3,4-dimethoxy-phenyl)-methyl-amine (<b>3a</b>) (903 mg, 5.405 mmol) in 4 mL of EtOAc. Then 2-(<i>tert</i>-butoxycarbonylamino)acetic acid (1136 mg, 6.486 mmol), T3P (4.777 mL, 5159 mmol) and DIEA (2.832 mL, 16.21 mmol) were added. The mixture was stirred at room temperature for 30 min. Then, the reaction mixture was diluted with EtOAc and washed with water, with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness, to give 1.77 g of reddish powder corresponding to the expected product, leading to a 100% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 325.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.42 (s, 9H), 3.27 (s, 3H), 3.68 (s, 2H), 3.89 (m, 6H), 6.68 (d, <i>J</i> = 2.4 Hz, 1H), 6.76 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.86 (d, <i>J</i> = 8.5 Hz, 1H).</div></div><div id="sec5_6_10_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (<b>10c</b>)</h5><div class="NLM_p last">In a 50 mL flask <i>tert</i>-butyl <i>N</i>-[2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>10b</b>) (1770 mg, 5.458 mmol) was dissolved in 13.6 mL of DCM. TFA (5.526 mL, 72.21 mmol) was added, and the reaction mixture was stirred at room temperature for 15 min. The reaction mixture was evaporated to dryness to give a purple oil, corresponding to the expected product. The residue was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 225.1.</div></div><div id="sec5_6_10_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[3-(3-chloro-4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>10d</b>)</h5><div class="NLM_p last">In a 100 mL flask were added 2-chloro-1-fluoro-4-isothiocyanato-benzene (318 mg, 1.697 mmol) and NEt<sub>3</sub> (0.275 mL, 2.036 mmol) in 5 mL of ethanol. A solution of [2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium, 2,2,2-trifluoroacetate (<b>10c</b>) (574 mg, 1.697 mmol), and NEt<sub>3</sub> (0.229 mL, 1.697 mmol) in 20 mL of ethanol was added dropwise at room temperature. The reaction mixture was then evaporated to dryness and purified by flash chromatography using as eluent a mixture of DCM/MeOH (98/2) to give the title product as a pale green powder (367 mg, 53%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 412.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.17 (s, 3H), 3.77 (s, 3H), 3.79 (s, 3H), 4.00 (d, <i>J</i> = 4.2 Hz, 2H), 6.93 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 7.34–7.36 (m, 2H), 7.84–7.95 (m, 2H), 10.05 (s, 1H).</div></div><div id="sec5_6_10_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 2-[2-(2,6-Difluoro-benzyl)-3-(3-chloro-4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>10e</b>)</h5><div class="NLM_p last">The title product was obtained as an orange oil (238 mg, 99%) without purification, following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(3-chloro-4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>10d</b>) (184 mg) and 2-bromomethyl-1,3-difluoro-benzene (92 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 538.1. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.29 (s, 3H), 3.79–3.93 (m, 8H), 4.13 (s, 2H), 6.57–7.00 (m, 9H), 7.15–7.27 (m, 1H).</div></div><div id="sec5_6_10_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(3-chloro-4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>10</b>)</h5><div class="NLM_p last">The title product is obtained as an orange powder (126 mg, 55%), following Procedure C, using 2-[2-(2,6-difluoro-benzyl)-3-(3-chloro-4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>10e</b>) (238 mg). LC-MS: <i>t</i><sub>R</sub> = 3.55 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 520.1. HRMS found 520.1063; C<sub>25</sub>H<sub>21</sub><sup>35</sup>ClF<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S requires 520.1073. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.96 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 4.14 (s, 2H), 6.15 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.71 (d, <i>J</i> = 8.7 Hz, 1H), 6.77–6.89 (m, 3H), 6.91 (dd, <i>J</i> = 6.4, 2.5 Hz, 1H), 7.01 (t, <i>J</i> = 8.5 Hz, 1H), 7.03 (s, 1H), 7.20 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 26.3, 40.6, 56.0, 56.5, 100.6, 106.5, 111.3 (m), 112.3, 113.6 (t, <i>J</i> = 19.4 Hz), 116.6 (d, <i>J</i> = 22.4 Hz), 121.2 (d, <i>J</i> = 19.1 Hz), 124.0, 127.5 (d, <i>J</i> = 7.7 Hz), 129.3 (t, <i>J</i> = 10.2 Hz), 129.7, 131.4 (d, <i>J</i> = 3.9 Hz), 137.9, 139.9, 142.9, 143.2, 149.7, 157.8 (d, <i>J</i> = 251.7 Hz), 161.1 (dd, <i>J</i> = 249.7, 7.6 Hz).</div></div><div id="sec5_6_10_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[3-(2,4-difluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>11d</b>)</h5><div class="NLM_p last">In a 100 mL flask were added 2,4-difluoro-1-isothiocyanato-benzene (290 mg, 1.698 mmol) and NEt<sub>3</sub> (0.275 mL, 2.037 mmol) in 5 mL of ethanol. A solution of [2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium, 2,2,2-trifluoroacetate (<b>10c</b>) (574 mg, 1.698 mmol), and NEt<sub>3</sub> (0.229 mL, 1.698 mmol) in 20 mL of ethanol was added dropwise at room temperature. The reaction mixture was then evaporated to dryness. The residue was then purified by flash chromatography using as eluent a mixture of DCM/methanol (98/2) to give 335 mg of a yellowish powder corresponding to the expected product, leading to a 50% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 396.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.16 (s, 3H), 3.76 (s, 3H), 3.78 (s, 3H), 4.00 (s, 2H), 6.90–7.08 (m, 4H), 7.29 (m, 1H), 7.62 (m, 1H), 7.98 (brs, 1H), 9.59 (brs, 1H).</div></div><div id="sec5_6_10_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 2-[2-(2,6-Difluoro-benzyl)-3-(2,4-difluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>11e</b>)</h5><div class="NLM_p last">The title product was obtained as a yellowish oil (413 mg, 93%) without purification, following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(2,4-difluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>11d</b>) (335 mg) and 2-bromomethyl-1,3-difluoro-benzene (175 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 522.2. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.31 (s, 3H), 3.83–3.99 (m, 8H), 4.18 (s, 2H), 6.65–6.93 (m, 9H), 7.17–7.25 (m, 1H).</div></div><div id="sec5_6_10_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(2,4-difluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>11</b>)</h5><div class="NLM_p last">The title product is obtained as a reddish solid (226 mg, 56%), following Procedure C, using 2-[2-(2,6-difluoro-benzyl)-3-(2,4-difluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>11e</b>) (413 mg). LC-MS: <i>t</i><sub>R</sub> = 3.47 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 504.1. HRMS found 504.1382; C<sub>25</sub>H<sub>21</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>S requires 504.1369. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.02 (s, 3H), 3.77 (s, 3H), 3.80 (s, 3H), 4.17 (m, 2H), 6.14 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.25 (d, <i>J</i> = 2.8 Hz, 1H), 6.64–6.76 (m, 2H), 6.77–6.87 (m, 4H), 7.05 (s, 1H), 7.20 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 26.2, 40.7, 55.8, 56.4, 100.6, 104.9 (dd, <i>J</i> = 26.4, 23.7 Hz), 106.2, 111.1–112.1 (m), 113.7 (t, <i>J</i> = 19.4 Hz), 119.1 (dd, <i>J</i> = 13.0, 4.1 Hz), 123.8, 129.2 (t, <i>J</i> = 10.3 Hz), 130.5 (d, <i>J</i> = 10.2 Hz), 138.7, 140.4, 142.7, 143.0, 149.4, 157.8 (dd, <i>J</i> = 255.1, 12.9 Hz), 161.2 (dd, <i>J</i> = 250.2, 7.5 Hz), 162.9 (dd, <i>J</i> = 252.4, 11.3 Hz).</div></div><div id="sec5_6_10_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> <i>N</i>-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>12d</b>)</h5><div class="NLM_p last">In a 25 mL flask, TCDI (133 mg, 0.749 mmol) was dissolved in 3 mL of dioxane. [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium and 2,2,2-trifluoroacetate (<b>10b</b>) (230 mg, 0.681 mmol) in 3.50 mL of dioxane were then added dropwise. The solution was then stirred at room temperature for 1.5 h. 4-Fluoro-3-methoxy-aniline (106 mg, 0.750 mmol) and NEt<sub>3</sub> (285 μL, 2.04 mmol) were added to the solution. The reaction mixture was stirred at 60 °C overnight. The solvent was then removed. The residue was dissolved in EtOAc and washed with water, with an aqueous 0.1 N HCl solution, and dried over MgSO<sub>4</sub>. After evaporation, the residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (8/2) to give the title product as an orange solid (136 mg, 49%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 408.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.16 (s, 3H), 3.74–3.82 (m, 9H), 4.00 (d, <i>J</i> = 4.2 Hz, 2H); 6.84–6.96 (m, 2H), 6.98–7.06 (m, 2H), 7.15 (dd, <i>J</i> = 11.3, 8.7 Hz, 1H), 7.37 (dd, <i>J</i> = 7.9, 2.2 Hz, 1H), 7.77 (brs, 1H), 9.91 (s, 1H).</div></div><div id="sec5_6_10_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>12e</b>)</h5><div class="NLM_p last">The title product was obtained as a yellowish oil (156 mg, 91%) without purification, following Procedure B, using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>12d</b>) (124 mg) and 2-bromomethyl-1,3-difluoro-benzene (63 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 534.2. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.28 (s, 3H), 3.78–3.84 (m, 11H), 4.11 (brs, 2H), 5.82 (s, 1H), 6.29 (brs, 1H), 6.44 (d, <i>J</i> = 6.3 Hz, 1H), 6.61–6.89 (m 6H), 7.13–7.26 (m, 1H).</div></div><div id="sec5_6_10_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-3-methoxy-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>12</b>)</h5><div class="NLM_p last">The title product is obtained as an orange powder (143 mg, 63%), following Procedure C, using 2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-3-methoxy-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>12e</b>) (156 mg). LC-MS: <i>t</i><sub>R</sub> = 3.42 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 516.2. HRMS found 516.1558; C<sub>26</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S requires 516.1569. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.90 (s, 3H), 3.54 (s, 3H), 3.82 (s, 6H), 4.20 (s, 2H), 6.18 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.33 (d, <i>J</i> = 2.8 Hz, 1H), 6.54 (dd, <i>J</i> = 7.5, 2.4 Hz, 1H), 6.59–6.64 (m, 1H), 6.75 (d, <i>J</i> = 8.7 Hz, 1H), 6.78–6.86 (m, 2H), 6.98 (dd, <i>J</i> = 10.8, 8.6 Hz, 1H), 7.06 (s, 1H), 7.14–7.24 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.7, 39.9, 55.9, 56.0, 56.6, 99.7, 105.2, 111.1–111.4 (m), 112.6, 112.7 (d, <i>J</i> = 2.4 Hz), 113.6 (t, <i>J</i> = 19.4 Hz), 115.9 (d, <i>J</i> = 19.6 Hz), 119.7 (d, <i>J</i> = 7.3 Hz), 124.9, 129.2 (t, <i>J</i> = 10.2 Hz), 130.9 (d, <i>J</i> = 3.6 Hz), 138.6, 139.0, 142.6, 143.5, 147.5 (d, <i>J</i> = 11.6 Hz), 149.8, 152.0 (d, <i>J</i> = 248.9 Hz), 161.2 (dd, <i>J</i> = 249.9, 7.7 Hz).</div></div><div id="sec5_6_10_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (4-Chloro-3-methoxy-phenyl)-methyl-amine (<b>13a</b>)</h5><div class="NLM_p last">In a 50 mL flask were added 4-chloro-3-methoxy-phenylamine (907 mg), sodium methoxide (1.56 g), 10 mL of anhydrous methanol, and paraformaldehyde (690 mg). The reaction mixture was then stirred overnight at room temperature. Then, paraformaldehyde (173 mg) and sodium methoxide (311 mg) were added, and the reaction mixture was heated at reflux for 1 h. Sodium borohydride (436 mg) was then added, and the reaction mixture was stirred at reflux for 4 h. Once back at room temperature, the mixture was partially evaporated, and aqueous KOH 1 M (50 mL) was then added. The obtained suspension was extracted by Et<sub>2</sub>O, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The obtained residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (8/2) to give the title product as a brown powder (650 mg, 66%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 171.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 2.66 (d, <i>J</i> = 4.9 Hz, 3H), 3.77 (s, 3H), 5.80 (q, <i>J</i> = 4.9 Hz, 1H), 6.09 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.25 (d, <i>J</i> = 2.4 Hz, 1H), 7.04 (d, <i>J</i> = 8.7 Hz, 1H).</div></div><div id="sec5_6_10_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 2-Chloro-<i>N</i>-(4-chloro-3-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>13b</b>)</h5><div class="NLM_p last">In a 100 mL flask were introduced a solution of 620 mg of (4-chloro-3-methoxy-phenyl)-methyl-amine (<b>13a</b>) and 1.7 mL of DIEA in 18 mL of DCM (dried over Na<sub>2</sub>SO<sub>4</sub>). The solution was stirred at 0 °C. Then, a solution of 568 μL of chloroacetyl chloride in 14 mL of DCM (dried over Na<sub>2</sub>SO<sub>4</sub>) was added dropwise to the flask. The mixture was then evaporated to dryness to give a brown residue which was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 248.0.</div></div><div id="sec5_6_10_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 2-Amino-<i>N</i>-(4-chloro-3-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>13c</b>)</h5><div class="NLM_p last">The residue corresponding to 2-chloro-<i>N</i>-(4-chloro-3-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>13b</b>) (3.6 mmol) was dissolved in 6 mL of EtOH at 95°. The obtained solution was added dropwise in aqueous ammonia (30% w/w, 75 mL) at 65 °C. After 1 h of stirring at 65 °C, the reaction mixture was evaporated. The residue was dissolved in water, the pH was adjusted to 10, and the solution was extracted several times by DCM. The organic phases were dried over over Na<sub>2</sub>SO<sub>4</sub> and evaporated to give a brown oily residue. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 229.0.</div></div><div id="sec5_6_10_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> <i>N</i>-(4-Chloro-3-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>13d</b>)</h5><div class="NLM_p last">In a 250 mL flask, 4-fluorophenylisothiocyanate (551.4 mg) and NEt<sub>3</sub> (583 μL) were dissolved in 3 mL of ethanol. A solution 2-amino-<i>N</i>-(4-chloro-3-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>13c</b>) in 48 mL of ethanol was added dropwise at room temperature. After 1 h of stirring at room temperature, the mixture was evaporated to dryness, and the residue was purified by flash chromatography using as eluent a mixture of cyclohexane/DCM (1/1) to pure DCM. The title product was obtained as a yellowish powder (546 mg, 39% yield over the 3 steps). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 382.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.21 (s, 3H), 3.88 (s, 3H), 4.06 (brs, 2H), 7.01 (m, 1H), 7.16 (m, 2H), 7.26 (brs, 1H), 7.45 (m, 2H), 7.52 (d, <i>J</i> = 8.3 Hz, 1H), 7.76 (brs, 1H), 9.90 (brs, 1H).</div></div><div id="sec5_6_10_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> <i>N</i>-(4-Chloro-3-methoxy-phenyl)-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>13e</b>)</h5><div class="NLM_p last">The title product was obtained as an oily residue (603 mg, 87%), without purification, following Procedure B, using <i>N</i>-(4-chloro-3-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>13d</b>) (468 mg) and 2-bromomethyl-1,3-difluoro-benzene (254 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 508.2. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.20 (s, 3H), 3.79–3.89 (m, 5H), 4.19 (s, 2H), 6.23 (brs, 2H), 6.95–7.10 (m, 6H), 7.18 (s, 1H), 7.38 (m, 1H), 7.48 (m, 1H).</div></div><div id="sec5_6_10_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (4-Chloro-3-methoxy-phenyl)-[2-(2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-methyl-amine (<b>13</b>)</h5><div class="NLM_p last">In a microwave tube were introduced <i>N</i>-(4-chloro-3-methoxy-phenyl)-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>13e</b>) (145 mg), 3 mL of EtOAc, DIEA (74,8 μL), and T3P (168 μL). The reaction mixture was then heated twice under microwave irradiation at 100 °C for 10 min. T3P (348 μL) and DIEA (206 μL) were then added, and the mixture was heated at 150 °C for 20 min under microwave irradiation. The reaction mixture was washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The obtained residue was purified by flash chromatography using as eluent a mixture of DCM/cyclohexane and then DCM/MeOH to give a yellowish residue corresponding to the title product (83 mg, 59%). LC-MS: <i>t</i><sub>R</sub> = 3.77 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 508.2. HRMS found 490.0953; C<sub>24</sub>H<sub>19</sub><sup>35</sup>ClF<sub>3</sub>N<sub>3</sub>OS requires 490.0968. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 2.96 (s, 3H), 3.75 (s, 3H), 4.08 (s, 2H), 6.09 (dd, <i>J</i> = 8.8, 2.7 Hz, 1H), 6.27 (d, <i>J</i> = 2.6 Hz, 1H), 7.02–7.07 (m, 3H), 7.11–7.15 (m, 3H), 7.21 (m, 2H), 7.37 (m, 1H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 26.0, 26.8, 56.2, 98.2, 106.4, 110.7, 112.1 (d, <i>J</i> = 23.9 Hz), 113.8 (t, <i>J</i> = 19.9 Hz), 116.5 (d, <i>J</i> = 23.2 Hz), 125.2, 130.0, 130.1 (d, <i>J</i> = 9.1 Hz), 130.5 (t, <i>J</i> = 10.9 Hz), 131.2, 137.9, 138.6, 149.0, 155.3, 161.0 (dd, <i>J</i> = 248.8, 7.4 Hz), 162.3 (d, <i>J</i> = 245.9 Hz).</div></div><div id="sec5_6_10_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> <i>tert</i>-Butyl <i>N</i>-[2-(4-methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>14b</b>)</h5><div class="NLM_p last">In a 25 mL flask was added 4-methoxy-<i>N</i>-methyl-aniline (274 mg, 2 mmol) in 4 mL of EtOAc. Then 2-(<i>tert</i>-butoxycarbonylamino)acetic acid (420 mg, 2.4 mmol), T3P (1.768 mL, 3 mmol), and DIEA (1.048 mL, 6 mmol) were added. The mixture was stirred for 30 min at room temperature. Then, the reaction mixture was diluted with EtOAc, washed with water, with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and then evaporated to give the title product as a bronze solid (463 mg, 79%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 295.1.</div></div><div id="sec5_6_10_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> [2-(4-Methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (<b>14c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-[2-(4-Methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>14b</b>) (463.70 mg, 1.575 mmol) was dissolved in 4 mL of DCM. TFA (20.84 mmol, 1.595 mL) was added, and the reaction mixture was stirred at room temperature for 30 min. The solvent was removed to give a viscous reddish oil. 510 mg of residue was obtained corresponding to the expected product and to the rest of 4-methoxy-<i>N</i>-methyl-aniline. The residue was used in the next step without further purification. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 195.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.20 (s, 3H), 3.57 (s, 2H), 3.83 (s, 3H), 6.95 (d, <i>J</i> = 8.9 Hz, 2H), 7.12 (d, <i>J</i> = 9.0 Hz, 2H), 7.80 (s, 3H).</div></div><div id="sec5_6_10_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> <i>N</i>-(4-Methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>14d</b>)</h5><div class="NLM_p last">In a 100 mL flask were added 4-fluorophenylisothiocyanate (1.575 mmol, 241 mg) and NEt<sub>3</sub> (1.890 mmol, 0.255 mL) in 5 mL of ethanol. A solution of [2-(4-methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium, 2,2,2-trifluoroacetate (<b>14c</b>) (1.575 mmol, 485 mg), and NEt<sub>3</sub> (1.575 mmol, 0.213 mL) in 20 mL of ethanol was added dropwise at room temperature. The reaction mixture was evaporated to dryness to give 865 mg of pale green powder, corresponding to the title product. The residue was used without further purification in the next step of the synthesis. MS [M + H] <sup>+</sup><i>m</i>/<i>z</i> = 348.0.</div></div><div id="sec5_6_10_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(4-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>14e</b>)</h5><div class="NLM_p last">The title product was obtained without purification as a yellow oil (727 mg, 97%) following Procedure B, using <i>N</i>-(4-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>14d</b>) (547 mg) and 2-(bromomethyl)-1,3-difluoro-benzene (513 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 475.1.</div></div><div id="sec5_6_10_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(4-methoxy-phenyl)-methyl-amine (<b>14</b>)</h5><div class="NLM_p last">The title product was obtained as an orange powder (120 mg, 17%), following Procedure C, using 2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(4-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>14e</b>) (726 mg). LC-MS: <i>t</i><sub>R</sub> = 3.59 min; MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 456.1. HRMS found 456.1369; C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>OS requires 456.1357. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.92 (s, 3H), 3.76 (s, 3H), 4.18 (brs, 2H), 6.57–6.60 (m, 2H), 6.70–6.77 (m, 2H), 6.80–6.86 (m, 2H), 6.92–6.95 (m, 4H), 7.00 (s, 1H), 7.15–7.23 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.9, 40.2, 55.7, 111.3 (m), 113.6, 114.4, 115.4, 115.9 (d, <i>J</i> = 23.0 Hz), 124.1, 129.0–129.3 (m), 130.9 (d, <i>J</i> = 3.4 Hz), 138.1, 140.0, 142.7, 153.1, 161.3 (dd, <i>J</i> = 250.0, 7.4 Hz), 162.3 (d, <i>J</i> = 249.2 Hz).</div></div><div id="sec5_6_10_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 3-Methoxy-<i>N</i>-methyl-aniline (<b>15a</b>)</h5><div class="NLM_p last">In a 25 mL flask were added 3-methoxyaniline (2.0 mmol, 0.224 mL) and sodium methoxide (10 mmol, 545 mg) in 3.5 mL of anhydrous methanol. Then, paraformaldehyde (4 mmol, 119 mg) was diluted in 1.5 mL of anhydrous methanol, and the solution was added to the mixture. Molecular sieves (4 Å) were then added, and the mixture was stirred overnight at room temperature. The mixture was heated under reflux for 1 h with sodium borohydride (2 mmol, 75.6 mg), then sodium borohydride (3.172 mmol, 120 mg) was added again, and the reaction mixture was stirred under reflux for 3 h. The reaction mixture was filtered on Celite, evaporated, and dissolved in EtOAc and water, and the two phases were separated. The aqueous phase was then basified by the addition of a saturated aqueous solution of NaHCO<sub>3</sub> and extracted with EtOAc. The organic phase was washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub>, evaporated, and dried under reduced pressure to give the title product as a brown oil (266 mg, 96%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 138.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.84 (s, 3H), 3.78 (s, 3H), 6.19 (t, <i>J</i> = 2.3 Hz, 1H), 6.26–6.31 (m, 2H), 7.10 (t, <i>J</i> = 8.1 Hz, 1H).</div></div><div id="sec5_6_10_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> <i>tert</i>-Butyl <i>N</i>-[2-(3-methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>15b</b>)</h5><div class="NLM_p last">In a 25 mL flask was added 3-methoxy-<i>N</i>-methyl-aniline (<b>15a</b>) (1.554 mmol, 213 mg) in 1 mL of EtOAc. Then, 2-(<i>tert</i>-butoxycarbonylamino)acetic acid (1.865 mmol, 326 mg), T3P (2.331 mmol, 1.374 mL), and DIEA (4.662 mmol, 814 μL) were added, and the mixture was stirred for 30 min at room temperature. Then, the reaction mixture was diluted with EtOAc. The solution was washed with water, then with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over MgSO<sub>4</sub> and filtered and then evaporated and dried under reduced pressure to give a light brown solid. This residue was purified by flash chromatography using as eluent a mixture of DCM/cyclohexane (9/1) to pure DCM and then DCM/MeOH (1000/1) to give the expected product as a yellowish powder (444 mg, 97%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 295.2.</div></div><div id="sec5_6_10_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> [2-(3-Methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (<b>15c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-[2-(3-methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>15b</b>) (444.4 mg, 1.510 mmol) was dissolved in 4 mL of DCM. TFA (19.97 mmol, 1.529 mL) was added, and the reaction mixture was stirred at room temperature for 30 min. The solvent was removed to give a viscous reddish oil. 699 mg of residue was obtained corresponding to the expected product and to the rest of 3-methoxy-<i>N</i>-methyl-aniline. The residue was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 195.1.</div></div><div id="sec5_6_10_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> <i>N</i>-(3-Methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>15d</b>)</h5><div class="NLM_p last">In a 100 mL flask were added 1-fluoro-4-isothiocyanato-benzene (1.287 mmol, 446 mg) and NEt<sub>3</sub> (1.544 mmol, 0.208 mL) in 2 mL of ethanol. A solution of [2-(3-methoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium, 2,2,2-trifluoroacetate (<b>15c</b>) (1.287 mmol, 446 mg), and NEt<sub>3</sub> (4.254 mmol, 0.574 mL) in 20 mL of ethanol was added dropwise at room temperature. The reaction mixture was evaporated to dryness to give an oil. This oil was purified by flash chromatography using as eluent a mixture of DCM/MeOH (98/2) to give the title product as a white solid (361 mg, 69%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 386.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.19 (s, 3H), 3.78 (s, 3H), 4.03 (brs, 2H), 6.92–7.04 (m, 3H), 7.09–7.21 (m, 2H), 7.30–7.50 (m, 3H), 7.68–7.79 (m, 1H).</div></div><div id="sec5_6_10_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>15e</b>)</h5><div class="NLM_p last">The title product was obtained as an orange solid (136 mg, 94%) following Procedure B without purification, using <i>N</i>-(3-methoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>15d</b>) (100 mg) and 2-(bromomethyl)-1,3-difluoro-benzene (60 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 474.1. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.32 (s, 3H), 3.81 (s, 3H), 3.90 (brs, 2H), 4.13 (brs, 2H), 6.68–6.96 (m, 9H), 7.16–7.26 (m, 1H), 7.34 (t, <i>J</i> = 8.1 Hz, 1H).</div></div><div id="sec5_6_10_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3H-imidazol-4-yl]-(3-methoxy-phenyl)-methyl-amine (<b>15</b>)</h5><div class="NLM_p last">2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3-methoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>15e</b>) (136 mg, 0.27 mmol) was dissolved in 2.7 mL of EtOAc. DIEA (283 μL, 1.62 mmol) and T3P in EtOAc (477 μL, 0.83 mmol) were then added. The mixture was heated under microwave irradiation at 150 °C for 10 min. DIEA (283 μL, 1.62 mmol) and T3P in EtOAc (477 μL, 0.83 mmol) were added again, and the reaction mixture was heated again under microwave irradiation at 150 °C for 10 min. DIEA (142 μL, 0.81 mmol) and T3P in EtOAc (240 μL, 0.41 mmol) were added again, and the reaction mixture was heated again under microwave irradiation at 150 °C for 10 min. DIEA (142 μL, 0.81 mmol) and T3P in EtOAc (240 μL, 0.41 mmol) were added again, and the reaction mixture was heated again under microwave irradiation at 150 °C for 10 min. The reaction mixture was then diluted with EtOAc and washed with water, with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (85/15), to give the title compound as an orange residue (12.1 mg, 10%). LC-MS: <i>t</i><sub>R</sub> = 3.62 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 456.1. HRMS found 456.1341; C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>OS requires 456.1357. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.91 (s, 3H), 3.77 (s, 3H), 4.19 (s, 2H), 6.22 (t, <i>J</i> = 2.3 Hz, 1H), 6.25 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.37 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.81–6.86 (m, 2H), 6.94–6.99 (m, 4H), 7.05 (s, 1H), 7.10 (t, <i>J</i> = 8.1 Hz, 1H), 7.15–7.25 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.8, 39.4, 55.2, 99.9, 103.5, 106.3, 111.3 (m), 113.5 (t, <i>J</i> = 19.3 Hz), 116.0 (d, <i>J</i> = 22.9 Hz), 125.3, 129.1 (d, <i>J</i> = 8.8 Hz), 129.2 (t, <i>J</i> = 10.3 Hz), 129.8, 130.7 (d, <i>J</i> = 3.1 Hz), 138.5, 138.7, 149.9, 160.6, 161.2 (dd, <i>J</i> = 250.2, 7.6 Hz), 162.3 (d, <i>J</i> = 249.3 Hz).</div></div><div id="sec5_6_10_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 3,4-Dichloro-<i>N</i>-methyl-aniline (<b>16a</b>)</h5><div class="NLM_p last">In a 25 mL flask were added 3,4-dichloroaniline (324 mg, 2.0 mmol) and sodium methoxide (540 mg, 10 mmol) in 3.5 mL of anhydrous methanol. Then, paraformaldehyde (120 mg, 4 mmol) was diluted in 1.5 mL of anhydrous methanol, and the solution was added to the mixture. Molecular sieves (4 Å) were then added, and the mixture was stirred overnight at room temperature. The mixture was then heated under reflux for 1 h with sodium borohydride (151 mg, 4 mmol). The reaction mixture was then filtered on Celite and evaporated, the residue was dissolved in EtOAc and water, and the two phases were separated. The aqueous phase was then basified by the addition of a saturated aqueous solution of NaHCO<sub>3</sub> and extracted by EtOAc. The organic phases were washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub>, evaporated, and dried under vacuum to give yellow oil corresponding to the title product (227 mg, 64%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 179.9. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2,83 (s, 3H), 6,48 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6,70 (d, <i>J</i> = 2.8 Hz, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 1H).</div></div><div id="sec5_6_10_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> <i>tert</i>-Butyl <i>N</i>-[2-(3,4-Dichloro-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>16b</b>)</h5><div class="NLM_p last">To a 10 mL flask was added 3,4-dichloro-<i>N</i>-methyl-aniline (<b>16a</b>) (226 mg, 1.287 mmol) in 2.6 mL of EtOAc. Then, 2-(<i>tert</i>-butoxycarbonylamino)acetic acid (608 mg, 3.474 mmol), T3P (2.27 mL, 3.859 mmol) and DIEA (1.012 mL, 5.791 mmol) were added. The mixture was stirred at 40 °C for 2 days. Then, the reaction mixture was diluted with EtOAc and washed with water, with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness to give a yellowish oil. For the next step of the synthesis, the yield was considered to be 100%. MS [M + H – H<sub>2</sub>C = C(CH<sub>3</sub>)<sub>2</sub>]<sup>+</sup><i>m</i>/<i>z</i> = 277.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.40 (m, 9H), 3.25 (s, 3H), 3.65 (s, 2H), 3.35 (s, 1H), 7.10 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.37 (d, <i>J</i> = 2.3 Hz, 2H), 7.72 (d, <i>J</i> = 8.5 Hz, 1H).</div></div><div id="sec5_6_10_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> [2-(3,4-Dichloro-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium; 2,2,2-trifluoroacetate (<b>16c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-[2-(3,4-dichloro-<i>N</i>-methyl-anilino)-2-oxo-ethyl]carbamate (<b>16b</b>) (428 mg, 1.287 mmol) was dissolved in 4 mL of DCM. TFA (1.30 mL, 17.03 mmol) was added, and the reaction mixture was stirred at room temperature for 30 min. The solvent was removed to give oil. The residue was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 235.1.</div></div><div id="sec5_6_10_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> <i>N</i>-(3,4-Dichloro-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>16d</b>)</h5><div class="NLM_p last">In a 100 mL flask were added 4-fluorophenylisothiocyanate (237 mg, 1.54 mmol) and NEt<sub>3</sub> (0.208 mL, 1.544 mmol) in 2 mL of ethanol. A solution of [2-(3,4-dichloro-<i>N</i>-methyl-anilino)-2-oxo-ethyl] ammonium, 2,2,2-trifluoroacetate (<b>16c</b>) (446 mg 1.287 mmol), and NEt<sub>3</sub> (0.574 mL, 4.25 mmol) in 20 mL of ethanol was added dropwise at room temperature. The reaction mixture was then evaporated to dryness. The residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH (98/2), to give a white solid corresponding to the title product (550 mg, quantitative yield). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 386.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.21 (s, 3H), 4.09 (s, 2H), 7.16 (m, 2H), 7.41–7.47 (m, 3H), 7.74–7.80 (m, 3H), 9.90 (s, 1H).</div></div><div id="sec5_6_10_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dichloro-phenyl)-<i>N</i>-methyl-acetamide (<b>16e</b>)</h5><div class="NLM_p last">The title product was obtained as a yellowish oil (334 mg, 90%), without purification, following Procedure B, using <i>N</i>-(3,4-dichloro-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>16d</b>) (280 mg) and 2-bromomethyl-1,3-difluoro-benzene (150 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 512.1. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.31 (s, 3H), 3.92 (s, 2H), 4.12 (s, 2H), 6.75–6.98 (m, 6H), 7.13 (m, 1H), 7.23 (m, 1H), 7.38 (m, 1H), 7.53 (d, <i>J</i> = 8.5 Hz, 1H).</div></div><div id="sec5_6_10_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dichloro-phenyl)-methyl-amine (<b>16</b>)</h5><div class="NLM_p last">The title product was obtained as an orange powder (143 mg, 44%), following Procedure C, using 2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dichloro-phenyl)-<i>N</i>-methyl-acetamide (<b>16e</b>) (334 mg). LC-MS: <i>t</i><sub>R</sub> = 3.97 min; MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 496.0. HRMS found 494.0457; C<sub>23</sub>H<sub>16</sub><sup>35</sup>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub>S requires 494.0472. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ (ppm) 2,92 (s, 3H), 4,19 (s, 2H), 6,45 (dd, <i>J</i> = 8.9, 3.1 Hz, 1H), 6,72 (d, <i>J</i> = 3.0 Hz, 1H), 6,87 (t, <i>J</i> = 7.7 Hz, 1H), 6,82–6,95 (m, 6H), 7,05 (s, 1H), 7,2 (d, <i>J</i> = 2.6 Hz, 1H), 7,22 (d, <i>J</i> = 2.6 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.8, 39.6, 111.4 (m), 112.5, 113.5 (t, <i>J</i> = 19.4 Hz), 114.5, 116.3 (d, <i>J</i> = 23.1 Hz), 121.7, 125.6, 129.0 (d, <i>J</i> = 8.8 Hz), 129.3 (t, <i>J</i> = 10.3 Hz), 130.4, 132.9, 137.4, 139.5, 148.0, 161.2 (dd, <i>J</i> = 250.0, 7.3 Hz), 162.5 (d, <i>J</i> = 249.9 Hz).</div></div><div id="sec5_6_10_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> 2-Chloro-<i>N</i>-[(3,4-dimethoxyphenyl)methyl]-<i>N</i>-methylacetamide (<b>17b</b>)</h5><div class="NLM_p last">In a 100 mL flask was introduced commercial [(3,4-dimethoxyphenyl)methyl](methyl)amine (<b>17a</b>) (1.05 mL, 5.3 mmol) and DIEA (2.74 mL, 15.89 mmol) in 13 mL of DCM (dried over Na<sub>2</sub>SO<sub>4</sub>). The solution was stirred at 0 °C. Then, chloroacetyl chloride (0.84 mL, 10.59 mmol) in 13 mL of DCM (dried over Na<sub>2</sub>SO<sub>4</sub>) was added dropwise to the flask. The mixture was then evaporated to dryness to give a brown residue. Conversion was considered to be 100% for the next reaction. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 257.9.</div></div><div id="sec5_6_10_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> [(3,4-Dimethoxy-benzyl)-methyl-carbamoyl]-methylammonium formate (<b>17c</b>)</h5><div class="NLM_p last">2-Chloro-<i>N</i>-[(3,4-dimethoxyphenyl)methyl]-<i>N</i>-methylacetamide (<b>17b</b>) was dissolved in 9 mL of ethanol at 95 °C and added dropwise in a 250 mL flask containing 100 mL of aqueous ammonia at 65 °C. After the addition, heating was stopped. The mixture was evaporated to dryness. The residue was then dissolved in DCM and extracted several times by an aqueous solution of 1 M HCOOH. During this extraction, a precipitate appeared and was filtered. The filtrate was then evaporated to dryness, and the residue was triturated in acetonitrile. The supernatant was evaporated to dryness to give the title product as a pale brown oily residue (90% UV<sub>215 nm</sub> purity) (1.51 g, 90%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 239.0.</div></div><div id="sec5_6_10_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> <i>N</i>-(3,4-Dimethoxy-benzyl)-2-[3-(4-fluoro-phenyl)-thioureido]-<i>N</i>-methyl-acetamide (<b>17d</b>)</h5><div class="NLM_p last">732 mg of 4-fluorophenylisothiocyanate and 774 μL of NEt<sub>3</sub> were added to a 250 mL flask in 4 mL of ethanol. [(3,4-Dimethoxy-benzyl)-methyl-carbamoyl]-methylammonium formate (<b>17c</b>) (1.51 g, 4.78 mmol) was dissolved in 60 mL of ethanol, and 645 μL of NEt<sub>3</sub> was then added. This solution was added dropwise at room temperature. After the addition, the reaction was over. The reaction mixture was evaporated to dryness and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (6/4) to give the title product as a yellowish solid (880 mg, 47% yield). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 391.9. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>): δ (ppm) 2.91–2.99 (m, 3H), 3.81–3.84 (m, 6H), 4.47–4.58 (m, 4H), 6.81–6.98 (m, 3H), 7.08–7.15 (m, 2H), 7.39–7.45 (m, 2H).</div></div><div id="sec5_6_10_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-benzyl)-<i>N</i>-methyl-acetamide (<b>17e</b>)</h5><div class="NLM_p last">The title product was obtained as an oily residue (207 mg, 58%), following Procedure B, using <i>N</i>-(3,4-dimethoxy-benzyl)-2-[3-(4-fluoro-phenyl)-thioureido]-<i>N</i>-methyl-acetamide (<b>17d</b>) (0,300 g) and 2-bromomethyl-1,3-difluoro-benzene (77 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 518.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 2.85 (m, 3H), 3.65 (m, 3H), 3.70 (s, 3H), 4.15 (m, 2H), 4.23 (m, 2H), 4.47 (m, 2H), 6.64 (m, 2H), 6.77–6.89 (m, 4H), 6.99 (m, 2H), 7.09 (m, 2H), 7.39 (m, 1H).</div></div><div id="sec5_6_10_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-benzyl)-methyl-amine (<b>17</b>)</h5><div class="NLM_p last">The title product was obtained as a yellowish powder (91 mg, 47%) following Procedure C using 2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-benzyl)-<i>N</i>-methyl-acetamide (<b>17e</b>) (200 mg). LC-MS: <i>t</i><sub>R</sub> = 3.33 min. MS: [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 499.9. HRMS found 500.1622; C<sub>26</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S requires 500.1620. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.48 (s, 3H), 3.68 (s, 2H), 3.77 (s, 3H), 3.86 (s, 3H), 4.10 (s, 2H), 6.37 (d, <i>J</i> = 1.9 Hz, 1H), 6.56 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 6.74 (d, <i>J</i> = 8.1 Hz, 1H), 6.77–6.85 (m, 3H), 7.10–7.22 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 26.0, 40.4, 55.8, 55.9, 60.6, 110.6, 111.1, 111.3, 113.5 (t, <i>J</i> = 19.0 Hz), 116.0 (d, <i>J</i> = 22.1 Hz), 117.6, 121.0, 129.1 (t, <i>J</i> = 10.1 Hz), 129.7, 129.9 (d, <i>J</i> = 8.5 Hz), 131.6 (d, <i>J</i> = 2.3 Hz), 136.4, 145.8, 148.3, 148.8, 161.2 (dd, <i>J</i> = 250.0, 7.7 Hz), 162.3 (d, <i>J</i> = 248.9 Hz).</div></div><div id="sec5_6_10_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> <i>N</i>-Allyl-3,4-dimethoxy-aniline (<b>18a</b>)</h5><div class="NLM_p last">Allyl bromide (0.519 mL, 6.0 mmol) was added dropwise to a solution of 3,4-dimethoxyaniline (919 mg, 6.0 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.99 g, 14.4 mmol) in DMF (15 mL). The solution was heated to 80 °C and stirred at this temperature overnight. The reaction mixture was then filtered, washed with H<sub>2</sub>O, and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness. The residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (8/2) to give the title product as a pale yellowish oil (587 mg, 51%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 194.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.74 (Dt, <i>J</i> = 5.5, 1.5 Hz, 2H), 3.81 (s, 3H), 3.84 (s, 3H), 5.17 (Dq, <i>J</i> = 10.3, 1.5 Hz, 1H), 5.29 (Dq, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.98 (Ddt, <i>J</i> = 17.2, 10.6, 5.3 Hz, 1H), 6.18 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.29 (d, <i>J</i> = 2.6 Hz, 1H), 6.75 (d, <i>J</i> = 8.5 Hz, 1H).</div></div><div id="sec5_6_10_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> <i>tert</i>-Butyl <i>N</i>-[2-(<i>N</i>-Allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]carbamate (<b>18b</b>)</h5><div class="NLM_p last">In a 100 mL flask were added <i>N</i>-allyl-3,4-dimethoxy-aniline (<b>18a</b>) (587.0 mg, 3.04 mmol), 6 mL of EtOAc, Boc-Gly-OH (638.6 mg, 3.65 mmol), T3P (2.69 mL, 4.56 mmol), and DIEA (1.59 mL, 9.11 mmol). The reaction mixture was then stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and brine, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to give the title product as a yellowish viscous oil (1.07 g, 100%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 351.1. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.41 (s, 9H), 3.66 (d, <i>J</i> = 4.2 Hz, 2H), 3.85 (s, 3H), 3.88 (s, 3H), 4.26 (d, <i>J</i> = 6.4 Hz, 2H), 5.04–5.19 (m, 2H), 5.39 (brs, 1H), 5.85 (Ddt, <i>J</i> = 16.8, 10.3, 6.5 Hz, 1H), 6.64 (d, <i>J</i> = 2.2 Hz, 1H), 6.72 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.83 (d, <i>J</i> = 8.4 Hz, 1H).</div></div><div id="sec5_6_10_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> [2-(<i>N</i>-Allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]ammonium-2,2,2-trifluoroacetate (<b>18c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-[2-(<i>N</i>-Allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]carbamate (<b>18b</b>) (1.07 g, 3.05 mmol) was dissolved in 7 mL of DCM. Three milliliters of TFA was then gently added, and the reaction mixture was then stirred at room temperature for 30 min. The reaction mixture was then evaporated to dryness, to give a pale orange oil, corresponding to the title product. This oil will enter into the next step without further purification. Yield was considered to be 100%. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 251.1.</div></div><div id="sec5_6_10_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> <i>N</i>-Allyl-<i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-acetamide (<b>18d</b>)</h5><div class="NLM_p last">4-Fluorophenylisothiocyanate (468 mg, 3.05 mmol) and NEt<sub>3</sub> (494 μL, 3.66 mmol) were added to a 250 mL flask in 9 mL of ethanol. [2-(<i>N</i>-Allyl-3,4-dimethoxy-anilino)-2-oxo-ethyl]ammonium-2,2,2-trifluoroacetate (<b>18c</b>) (3.05 mmol) was dissolved in 31 mL of ethanol, NEt<sub>3</sub> was added until pH was over 8, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. After 1 h of stirring a room temperature, a precipitate appeared. It was then filtered, to give a white powder corresponding to the title product (1.09 g, 88%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 404.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.75 (s, 3H), 3.78 (s, 3H), 4.01 (d, <i>J</i> = 4.4 Hz, 2H), 4.23 (d, <i>J</i> = 5.8 Hz, 2H), 5.01–5.20 (m, 2H), 5.80 (Ddt, <i>J</i> = 16.0, 11.5, 5.7 Hz, 1H), 6.87 (dd, <i>J</i> = 7.3, 1.1 Hz, 1H), 6.93–7.05 (m, 2H), 7.09–7.21 (m, 2H), 7.38–7.51 (m, 2H), 7.74 (brs, 1H), 9.89 (s, 1H).</div></div><div id="sec5_6_10_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> <i>N</i>-Allyl-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-acetamide (<b>18e</b>)</h5><div class="NLM_p last">In a 25 mL flask were added <i>N</i>-allyl-<i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-acetamide (<b>18d</b>) (400 mg, 0.99 mmol), K<sub>2</sub>CO<sub>3</sub> (137 mg, 0.99 mmol), sodium iodide (74 mg, 0.50 mmol), and 5 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, and 2-(bromomethyl)-1,3-difluoro-benzene (205 mg, 0.99 mmol) was then added. The suspension was stirred at room temperature overnight. The medium was then evaporated, the residue was dissolved in EtOAc and washed with water and brine, the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness to give 543 mg of an orange solid corresponding to the title product (100%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 530.2. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.81–3.92 (m, 8H), 4.13 (brs, 2H), 4.29 (d, <i>J</i> = 6.3 Hz, 2H), 5.07–5.21 (m, 2H), 5.78–5.96 (m, 1H), 6.63–6.95 (m, 10H), 7.21 (m, 1H).</div></div><div id="sec5_6_10_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> Allyl-[2-(2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-amine (<b>18</b>)</h5><div class="NLM_p last">In a microwave tube were introduced <i>N</i>-allyl-2-[2-(2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-acetamide (<b>18e</b>) (373 mg, 0.7 mmol), 7 mL of EtOAc, DIEA (738 μL, 4.2 mol), and T3P (1245 μL, 2.1 mmol). The mixture was heated under microwave irradiation at 150 °C for 10 min. The reaction mixture was then diluted with EtOAc and washed with water, with a saturated aqueous solution of NaHCO<sub>3</sub>, and with brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was then purified by flash chromatography using as eluent a mixture of CHCl<sub>3</sub>/MeOH (99/1) to give an orange solid corresponding to the title product (192 mg, 53%). LC-MS: <i>t</i><sub>R</sub> = 3.27 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 512.1. HRMS found 512.1617; C<sub>27</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S requires 512.1620. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.75–3.86 (m, 8H), 4.15 (s, 2H), 5.2–5.14 (m, 2H), 5.67 (Ddt, <i>J</i> = 17.4, 10.0, 5.5 Hz, 1H), 6.17 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.30 (d, <i>J</i> = 2.8 Hz, 1H), 6.69 (d, <i>J</i> = 8.8 Hz, 1H), 6.74–6.86 (m, 2H), 6.88–6.98 (m, 4H), 7.04 (s, 1H), 7.18 (tt, <i>J</i> = 8.4, 6.5 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.9, 55.3, 55.9, 56.4, 100.7, 106.6, 111.0–111.5 (m), 112.2, 113.6 (t, <i>J</i> = 19.3 Hz), 115.8 (d, <i>J</i> = 22.9 Hz), 117.3, 125.5, 129.2 (t, <i>J</i> = 10.8 Hz), 129.4 (d, <i>J</i> = 8.9 Hz), 130.8 (d, <i>J</i> = 3.2 Hz), 133.6, 138.4, 142.4, 142.7, 149.5, 161.2 (dd, <i>J</i> = 250.0, 7.6 Hz), 162.3 (d, <i>J</i> = 249.2 Hz).</div></div><div id="sec5_6_10_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> 1-Cyanomethyl-3-(4-fluoro-phenyl)-isothiourea (<b>19a</b>)</h5><div class="NLM_p last">2-Aminoacetonitrile hydrochloride (725 mg, 7.83 mmol) and NEt<sub>3</sub> (1090 μL, 7.83 mmol) were added to 12 mL of DMF. Then, a solution of 4-fluoro-phenylisothiocyanate (1.00 g, 6.53 mmol) in 2 mL of DMF was added, and the reaction mixture was stirred at room temperature for 5 min, then cooled down to 0 °C. After the addition of roughly 60 mL of water, a precipitate was obtained. The mixture was stirred at 0 °C for 30 min and filtrated. The purple crystals obtained correspond to the title product (1.09 g, 80%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 209.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 4.49 (d, <i>J</i> = 5.5 Hz, 2H), 7.20 (t, <i>J</i> = 8.7 Hz, 2H), 7.38 (Dd, <i>J</i> = 8.6, 5.0 Hz, 2H), 8.03 (brs, 1H), 10.02 (s, 1H).</div></div><div id="sec5_6_10_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> 2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-ylamine (<b>19b</b>)</h5><div class="NLM_p last">In a 50 mL flask were added 1-cyanomethyl-3-(4-fluoro-phenyl)-isothiourea (<b>19a</b>) (1.09 g, 5.21 mmol), 10 mL of dry acetonitrile, sodium iodide (390 mg, 2.60 mmol), 2-bromomethyl-1,3-difluoro-benzene (1.08 g), and DIEA (891 μL, 5.21 mmol). The reaction mixture was stirred at room temperature for 10 min. The reaction mixture was then diluted with EtOAc, washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. All attempts to purify that compound were unsuccessful due to its instability. The next step of the synthesis was performed on the crude residue. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 335.9.</div></div><div id="sec5_6_10_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> <i>N</i>-[2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-3,4-dimethoxy-benzamide (<b>19</b>)</h5><div class="NLM_p last">3,4-Dimethoxybenzoic acid (130 mg, 0.72 mmol) was dissolved in 752 μL of a mixture of thionyl chloride and DCM (2/8, v/v). After 1 h of stirring at room temperature, it was evaporated. Then, 2-(2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-ylamine (<b>19b</b>) (200 mg, 0.36 mmol) in 1.8 mL of dry THF and pyridine (57.9 μL, 0.72 mmol) were added over the residue, and the mixture was stirred at room temperature for 4 h. The reaction mixture was then evaporated, dissolved in EtOAc, and washed with water, with a saturated aqueous solution of NaHCO<sub>3</sub> and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (7/3) and then DCM/MeOH (98/2) to give a reddish solid corresponding to the pure title product (56 mg, 31%). LC-MS: <i>t</i><sub>R</sub> = 2.80 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 499.8. HRMS found 500.1256; C<sub>25</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>S requires 500.1256. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 3.87 (s, 3H), 3.89 (s, 3H), 4.13 (s, 2H), 6.75–6.87 (m, 3H), 7.05–7.26 (m, 7H), 7.37 (d, <i>J</i> = 2.0 Hz, 1H), 8.15 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 26.0, 56.1, 110.4, 110.9, 111.2–111.6 (m), 113.2 (t, <i>J</i> = 19.2 Hz), 116.6 (d, <i>J</i> = 23.0 Hz), 120.1, 123.4, 125.5, 129.3, 129.5 (t, <i>J</i> = 10.2 Hz), 129.7 (d, <i>J</i> = 8.8 Hz), 130.1 (d, <i>J</i> = 3.3 Hz), 138.7, 149.2, 152.6, 161.3 (dd, <i>J</i> = 254.5, 3.7 Hz), 162.9 (d, <i>J</i> = 250.5 Hz), 165.9.</div></div><div id="sec5_6_10_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> 2-[2-(4-Bromo-2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>20a</b>)</h5><div class="NLM_p last">(4-Bromo-2,6-difluoro-phenyl)-methanol (892 mg) and NEt<sub>3</sub> (594 μL) were dissolved in dry DCM at 0 °C. Mesyl chloride (310 μL) was then added dropwise, and the mixture was stirred at room temperature overnight. Water was then added to quench the reaction. The organic phase was washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to give an orange oil corresponding to 5-bromo-2-(chloromethyl)-1,3-difluoro-benzene. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 4.62 (s, 2H), 7.14 (d, <i>J</i> = 6.7 Hz; 2H)). The title product was then obtained as a yellowish powder (1.07 g, 95%) following Procedure B using <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>) (750 mg) and 5-bromo-2-(chloromethyl)-1,3-difluoro-benzene (461 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 583.8. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d6</i>): δ (ppm) 3.15 (s, 3H), 3.73 (m, 8H), 4.14 (s, 2H), 6.60 (m, 2H), 6.79 (brs, 1H), 6.86 (m, 1H), 6.97 (m, 4H), 7.46 (m, 2H).</div></div><div id="sec5_6_10_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> [2-(4-Bromo-2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>20b</b>)</h5><div class="NLM_p last">The title product was obtained as an orange oil (867 mg, 74%) following Procedure D using 2-[2-(4-bromo-2,6-difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>20a</b>) (1.07 g). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 565.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 2.91 (s, 3H), 3.64–3.65 (m, 6H), 3.97 (s, 2H), 6.04 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.20 (d, <i>J</i> = 2.8 Hz, 1H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.96 (s, 1H), 7.11 (dd, <i>J</i> = 9.0, 5.1 Hz, 2H), 7.19 (m, 2H), 7.41 (m, 2H).</div></div><div id="sec5_6_10_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> (3,4-Dimethoxy-phenyl)-[2-[4-(3-dimethylamino-prop-1-ynyl)-2,6-difluoro-benzylsulfanyl]-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-methyl-amine (<b>20</b>)</h5><div class="NLM_p last">In a 25 mL flask, [2-(4-bromo-2,6-difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>20b</b>) (600 mg, 1.06 mmol), dimethylpropargylamine (172 μL, 1.60 mmol), and pyrrolidine (133 μL, 1.60 mmol) were added to 5 mL of dry and degassed DMF. Then, PdCl<sub>2</sub>(dppf) (68 mg, 53 μmol) and CuI (20 mg, 106 μmol) were added. The reaction mixture was heated under argon at 80 °C for 6 h. The reaction mixture was cooled down to room temperature, diluted with EtOAc, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The crude product was purified by flash chromatography using as eluent a mixture of DCM/cyclohexane and then DCM/MeOH to give 281 mg of a white powder (47%). LC-MS: <i>t</i><sub>R</sub> = 2.82 min. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 566.9. HRMS found 567.2054; C<sub>30</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S requires 567.2042. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.35 (s, 6H), 2.91 (s, 3H), 3.45 (s, 2H), 3.79 (s, 3H), 3.82 (s, 3H), 4.08 (s, 2H), 6.15 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.28 (d, <i>J</i> = 2.7 Hz, 1H), 6.72 (d, <i>J</i> = 8.7 Hz, 1H), 6.87 (d, <i>J</i> = 8.0 Hz, 2H), 6.97 (m, 4H), 7.02 (s, 1H).</div></div><div id="sec5_6_10_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> (3-{4-[5-[(3,4-Dimethoxy-phenyl)-methylamino]-1-(4-fluoro-phenyl)-1<i>H</i>-imidazol-2-ylsulfanylmethyl]-3,5-difluoro-phenyl}-prop-2-ynyl)-trimethylammonium iodide (<b>21</b>)</h5><div class="NLM_p last">In a 25 mL flask were added (3,4-dimethoxy-phenyl)-[2-[4-(3-dimethylamino-prop-1-ynyl)-2,6-difluoro-benzylsulfanyl]-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-methyl-amine (<b>20</b>) (254 mg, 448 μmol) and 5 mL of a mixture dry Et<sub>2</sub>O/dry THF (1:1). Iodomethane (27.7 μL, 1.345 mmol) was then added, and the reaction mixture was stirred at room temperature. After 1 h 30 min and 4 h, iodomethane (27.7 μL, 1.345 mmol) was added again. The reaction mixture was then evaporated to dryness. The residue was triturated in Et<sub>2</sub>O and filtrated, and the residue was purified by preparative HPLC (ammonium formate buffer, pH 3.8) to give the title product as a brown residue (55 mg, 17%). LC-MS: <i>t</i><sub>R</sub> = 2.83 min. MS [M]<sup>+</sup><i>m</i>/<i>z</i> = 581.1. HRMS found 581.2212; C<sub>31</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S requires 581.2198. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 2.92 (s, 3H), 3.21 (s, 9H), 3.64 (s, 3H), 3.65 (s, 3H), 4.01 (s, 2H), 4.68 (s, 2H), 6.06 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 6.21 (d, <i>J</i> = 2.7 Hz, 1H), 6.75 (d, <i>J</i> = 8.8 Hz, 1H), 6.95 (s, 1H), 7.13–7.25 (m, 4H), 7.40 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 26.2, 52.7, 52.9, 55.9, 56.7, 80.7, 88.1, 100.1, 105.6; 113.8, 115.6, 116.3, 116.5, 122.0, 124.4, 130.2, 131.5, 136.5, 140.4, 142.6, 143.4, 149.8, 160.6, 162.2.</div></div><div id="sec5_6_10_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> (3-{4-[5-[(3,4-Dimethoxy-phenyl)-methylamino]-1-(4-fluoro-phenyl)-1<i>H</i>-imidazol-2-ylsulfanylmethyl]-3,5-difluoro-phenyl}-prop-2-ynyl)-trimethylammonium formate (<b>22</b>)</h5><div class="NLM_p last">(3,4-Dimethoxy-phenyl)-[2-[4-(3-dimethylamino-prop-1-ynyl)-2,6-difluoro-benzylsulfanyl]-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-methyl-amine (<b>20</b>) (365 mg, 644 μmol) was dissolved in 6.4 mL of a mixture of dry Et<sub>2</sub>O/THF (1/1), under argon, and iodomethane (80 μL, 1.29 mmol) was then added. The reaction mixture was stirred at room temperature. After 1 h 30 min, iodomethane (80 μL, 1.29 mmol) was added again. After 30 min, the reaction mixture was evaporated to dryness. The residue was then purified twice by preparative HPLC (HCOOH 0.1% first, then ammonium formate buffer, pH 9.2) to give the title product as a yellowish powder (75 mg, 19%). LC-MS: <i>t</i><sub>R</sub> = 2.83 min. MS [M]<sup>+</sup><i>m</i>/<i>z</i> = 581.1. HRMS found 581.2213; C<sub>31</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S requires 581.2198. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.94 (s, 3H), 3.45 (s, 9H), 3.78–3.80 (m, 6H), 4.01 (s, 2H), 4.87 (s, 2H), 6.16 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.27 (d, <i>J</i> = 2.7 Hz, 1H), 6.71 (d, <i>J</i> = 8.7 Hz, 1H), 6.96–7.07 (m, 7H), 8.58 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.9, 40.5, 53.4, 56.0, 56.6, 57.1, 89.6, 100.4, 106.0, 112.6, 115.5 (d, <i>J</i> = 26.8 Hz), 116.2 (d, <i>J</i> = 23.0 Hz), 116.8 (t, <i>J</i> = 19.2 Hz), 121.4 (t, <i>J</i> = 12.5 Hz), 124.3, 129.4 (d, <i>J</i> = 8.7 Hz), 131.0 (d, <i>J</i> = 3.2 Hz), 137.3, 140.4, 143.0, 143.2, 149.7, 160.9 (dd, <i>J</i> = 251.9, 9.1 Hz), 162.5 (d, <i>J</i> = 250.3 Hz), 167.5.</div></div><div id="sec5_6_10_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 2,6-Difluoro-4-hydroxy-benzoic Acid</h5><div class="NLM_p last">2,6-Difluoro-4-hydroxy-benzonitrile (1.5 g) was dissolved in 7 mL of distilled water, and a solution of 1,35 g of NaOH in 4 mL water was then added. The reaction mixture was then heated at reflux for 4 days. Heating was then stopped, and the reaction mixture was acidified by adding concentrated HCl and extracted with Et<sub>2</sub>O. The organic phase was then extracted by a saturated aqueous solution of NaHCO<sub>3</sub>. This aqueous solution was then acidified by adding concentrated HCl and then extracted with Et<sub>2</sub>O. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to give the title product as a white solid (1.58 g, 94%). MS [M – H]<sup>−</sup><i>m</i>/<i>z</i> = 172.9. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 6.49 (m, 2H), 10.96 (brs, 1H), 13.20 (brs, 1H).</div></div><div id="sec5_6_10_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 2,6-Difluoro-4-hydroxy-benzoic acid methyl ester</h5><div class="NLM_p last">2,6-Difluoro-4-hydroxy-benzoic acid (1.58 g) was dissolved in 18 mL of methanol, concentrated sulfuric acid (257 μL) was then added, and the reaction mixture was heated at reflux overnight. The reaction mixture was then evaporated, and the residue was dissolved in EtOAc, washed twice with water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to give the title product as a white powder (1.48 g, 90%). MS [M – H]<sup>−</sup><i>m</i>/<i>z</i> = 187.1. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 3.80 (s, 3H), 6.54 (m, 2H), 11.12 (s, 1H).</div></div><div id="sec5_6_10_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 3,5-Difluoro-4-hydroxymethyl-phenol (<b>23i</b>)</h5><div class="NLM_p last">In a 100 mL flask were added 2,6-difluoro-4-hydroxy-benzoic acid methyl ester (1.48 g), 26 mL of anhydrous THF, and 34 mL of a 1 M solution of diisobutylaluminum hydride (DIBAl-H) in cyclohexane at 0–5 °C. The reaction mixture was then stirred at this temperature for 1.5 h and then poured into a 250 mL flask containing 27 mL of cold (0–5 °C) 1 M aqueous potassium sodium <span class="smallcaps smallerCapital">l</span>-tartrate solution. The reaction mixture was stirred at room temperature for 30 min. The aqueous phase was extracted by EtOAc, and combined organic phases were then washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The aqueous phase was acidified to pH 5 and extracted by EtOAc. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The title product was obtained as a yellowish powder (1g, 80%). MS [M – H]<sup>−</sup><i>m</i>/<i>z</i> = 159.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) 4.36 (d, <i>J</i> = 5.2 Hz, 2H), 5.00 (t, <i>J</i> = 5.5 Hz, 1H), 6.41 (m, 2H), 10.28 (s, 1H).</div></div><div id="sec5_6_10_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> [4-(3-Chloropropoxy)-2,6-difluoro-phenyl]methanol</h5><div class="NLM_p last">1-Bromo-3-chloro-propane (1.30 mL, 13.2 mmol), 3,5-difluoro-4-hydroxymethyl-phenol (<b>23i</b>) (2.64 mmol, 423 mg), and K<sub>2</sub>CO<sub>3</sub> (365 mg, 2.64 mmol) were added to acetonitrile (9 mL), and the reaction mixture was stirred at reflux for 3 h. The solvent was removed under reduced pressure. The crude was dissolved in EtOAc and washed with water. The aqueous phase was extracted by EtOAc, washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under reduced pressure to give the title product as a colorless oil (602 mg, 96%). MS [M + H – H<sub>2</sub>O]<sup>+</sup><i>m</i>/<i>z</i> = 218.9. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.24 (quin, <i>J</i> = 6.1 Hz, 2H), 3.73 (t, <i>J</i> = 6.3 Hz, 2H), 4.10 (t, <i>J</i> = 5.8 Hz, 2H), 4.71 (s, 2H), 6.41–6.52 (m, 2H).</div></div><div id="sec5_6_10_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> 2-Chloromethyl-5-(3-chloro-propoxy)-1,3-difluoro-benzene (<b>23ii</b>)</h5><div class="NLM_p last">[4-(3-Chloropropoxy)-2,6-difluoro-phenyl]methanol (602 mg, 2.54 mmol) and NEt<sub>3</sub> (428 μL, 3.17 mmol) were dissolved in 5 mL of dry DCM at 0 °C. Mesyl chloride (197 μL, 2.54 mmol) was then added dropwise, and the mixture was stirred at room temperature overnight. The reaction mixture was then evaporated to dryness. Water was added to quench the reaction. The organic phase was then washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then evaporated. The obtained residue corresponding to the title product would enter into the next step of the synthesis without further purification.</div></div><div id="sec5_6_10_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> 2-[2-[2,6-Difluoro-4-(3-chloropropoxy)-benzyl]-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>23a</b>)</h5><div class="NLM_p last">The title product was obtained as a yellowish solid (915 mg, 73%), following Procedure B, using <i>N</i>-(3,4-dimethoxy-benzyl)-2-[3-(4-fluoro-phenyl)-thioureido]-<i>N</i>-methyl-acetamide (<b>3d</b>) (800 mg) and 2-chloromethyl-5-(3-chloro-propoxy)-1,3-difluoro-benzene (<b>23ii</b>). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 595.9. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.15 (quin, <i>J</i> = 5.9 Hz, 2H), 3.27 (s, 3H), 3.66 (t, <i>J</i> = 6.2 Hz, 2H), 3.76–3.93 (m, 8H), 3.95–4.14 (m, 4H), 6.32–6.46 (m, 2H), 6.60–6.94 (m, 7H).</div></div><div id="sec5_6_10_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> [2-(2,6-Difluoro-4-(3-chloropropoxy)-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>23b</b>)</h5><div class="NLM_p last">The title product was obtained as a brown solid (895 mg, 96%), following Procedure D (without flash chromatography purification), using 2-[2-[2,6-difluoro-4-(3-chloropropoxy)-benzyl]-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-acetamide (<b>23a</b>) (915 mg). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 577.9. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.21 (quin, <i>J</i> = 6.0 Hz, 2H), 2.91 (s, 3H), 3.72 (t, <i>J</i> = 6.2 Hz, 2H), 3.77–3.86 (m, 6H), 4.00–4.14 (m, 4H), 6.16 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.30 (d, <i>J</i> = 2.7 Hz, 1H), 6.32–6.42 (m, 2H), 6.72 (d, <i>J</i> = 8.7 Hz, 1H), 6.91–7.05 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.8, 31.8, 40.1, 41.1, 55.9, 56.4, 64.8, 98.0–98.6 (m), 100.0, 105.5, 105.6 (t, <i>J</i> = 20.2 Hz), 112.4, 115.9 (d, <i>J</i> = 22.9 Hz), 124.3, 129.2 (d, <i>J</i> = 8.7 Hz), 130.9 (d, <i>J</i> = 3.1 Hz), 138.5, 139.5, 142.7, 143.2, 149.6, 159.5 (t, <i>J</i> = 14.1 Hz), 161.7 (dd, <i>J</i> = 248.1, 11.0 Hz), 162.3 (d, <i>J</i> = 249.2 Hz).</div></div><div id="sec5_6_10_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> 2-[[4-[3-(1-Aza-4-azoniabicyclo[2.2.2]octan-4-yl)propoxy]-2,6-difluoro-phenyl]methylsulfanyl]-<i>N</i>-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-<i>N</i>-methyl-imidazol-4-amine-formate (<b>23</b>)</h5><div class="NLM_p last">[2-(2,6-Difluoro-4-(3-chloropropoxy)-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>23b</b>) (225 mg, 370 μmol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) (112 mg, 1.0 mmol) were dissolved in dry acetonitrile (3.7 mL). The reaction mixture was then heated under microwave irradiation at 100 °C for 30 min. It was then evaporated to dryness and purified by preparative HPLC (ammonium formate buffer, pH 9.2) to give the title compound as a pale orange powder (60 mg, 23%). LC-MS: <i>t</i><sub>R</sub> = 2.47 min; MS [M]<sup>+</sup><i>m</i>/<i>z</i> = 654.2. HRMS found 654.2733; C<sub>34</sub>H<sub>39</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S requires 654.2726. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.31 (brs, 2H), 2.94 (s, 3H), 3.32 (brs, 6H), 3.48–3.82 (m, 14H), 3.94 (s, 2H), 4.06 (brs, 2H), 6.16 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.27 (d, <i>J</i> = 2.7 Hz, 1H), 6.35–6.47 (m, 2H), 6.71 (d, <i>J</i> = 8.8 Hz, 1H), 6.93–7.11 (m, 5H), 8.60 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 22.1, 25.7, 40.3, 45.3, 52.6, 55.9, 56.5, 61.8, 65.2, 98.2–98.8 (m), 100.1, 105.9, 106.0 (t, <i>J</i> = 20.1 Hz), 112.5, 116.0 (d, <i>J</i> = 22.9 Hz), 123.9, 129.3 (d, <i>J</i> = 8.8 Hz), 130.9 (d, <i>J</i> = 3.2 Hz), 137.8, 140.1, 142.8, 143.1, 149.6, 159.0 (t, <i>J</i> = 14.1 Hz), 161.6 (dd, <i>J</i> = 248.2, 11.0 Hz), 162.3 (d, <i>J</i> = 249.3 Hz).</div></div><div id="sec5_6_10_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> 3-[4-[[5-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propane-1-sulfonate-ammonium (<b>24</b>)</h5><div class="NLM_p last">In a 2–5 mL microwave tube, [2-(2,6-difluoro-4-(3-chloropropoxy)-benzylsulfanyl)-3-(4-fluoro-phenyl)-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>23b</b>) (540 mg, 0.89 mmol) was dissolved in 6 mL of a mixture of dioxane and water (1/1, V/V). Sodium sulfite (559 mg, 4.44 mmol) and sodium iodide (133 mg, 0.89 mmol) were then added. The reaction mixture was heated under microwave irradiation at 130 °C for 30 min and then at 130 °C for 40 min. Then sodium sulfite (223 mg, 1.8 mmol) and sodium iodide (53 mg, 0.36 mmol) were added again, before heating under microwave irradiation at 130 °C for 30 min. The reaction mixture was evaporated to dryness and purified by preparative HPLC (ammonium formate buffer at pH 3.8) to give the title product as a yellowish powder (207 mg, 36%). LC-MS: <i>t</i><sub>R</sub> = 2.40 min. MS [M]<sup>−</sup><i>m</i>/<i>z</i> = 622.1. HRMS found 624.1453; C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>3</sub>O<sub>6</sub>S<sub>2</sub> requires 624.1450. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d</i><sub>4</sub>): δ (ppm) 2.18–2.30 (m, 2H), 2.92–3.02 (m, 5H), 3.73 (s, 3H), 3.75 (s, 3H), 3.93 (s, 2H), 4.11 (t, <i>J</i> = 6.3 Hz, 2H), 6.16 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.30 (d, <i>J</i> = 2.7 Hz, 1H), 6.48–6.58 (m, 2H), 6.78 (d, <i>J</i> = 8.7 Hz, 1H), 6.89–6.98 (m, 2H), 6.99–7.11 (m, 3H). <sup>13</sup>C NMR (75 MHz, MeOD-<i>d</i><sub>4</sub>): δ (ppm) 24.6, 26.6, 39.8, 47.7, 55.2, 55.8, 67.2, 98.0–98.3 (m), 101.7, 105.3 (t, <i>J</i> = 20.0 Hz), 107.6, 113.1, 115.3, (d, <i>J</i> = 23.4 Hz), 121.4, 129.7 (d, <i>J</i> = 9.0 Hz), 130.6 (d, <i>J</i> = 3.1 Hz), 137.3, 141.1, 142.9, 143.5, 149.8, 160.2 (t, <i>J</i> = 14.3 Hz), 161.5 (dd, <i>J</i> = 246.6, 11.2 Hz), 162.6 (d, <i>J</i> = 248.3 Hz).</div></div><div id="sec5_6_10_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> [4-(3-Bromopropoxy)-2,6-difluoro-phenyl]methanol (<b>25i</b>)</h5><div class="NLM_p last">1,3-Dibromopropane (950.87 μL, 9.37 mmol), 3,5-difluoro-4-(hydroxymethyl)phenol (300 mg, 1.87 mmol), and K<sub>2</sub>CO<sub>3</sub> (258.95 mg, 1.87 mmol) were added to acetonitrile (6 mL), and the reaction mixture was stirred at reflux for 3 h. The solvent was removed under reduced pressure. The crude was dissolved in EtOAc and washed with water. The aqueous phase was extracted with EtOAc, washed with brine, and dried under Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under reduced pressure, and the crude was purified by flash chromatography using as eluent a mixture of Cy/EA (80/20) to give 400 mg of [4-(3-bromopropoxy)-2,6-difluoro-phenyl]methanol as a colorless oil, leading to a 76% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 264.</div></div><div id="sec5_6_10_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> <i>tert</i>-Butyl <i>N</i>-<i>tert</i>-Butoxycarbonyl-<i>N</i>-[3-[3,5-difluoro-4-(hydroxymethyl)-phenoxy]propyl]-carbamate (<b>25ii</b>)</h5><div class="NLM_p last">[4-(3-Bromopropoxy)-2,6-difluoro-phenyl]methanol <b>25i</b> (320 mg, 1.14 mmol) was dissolved in 11 mL of dry dimethylformamide. <i>tert</i>-Butyl <i>N</i>-<i>tert</i>-butoxycarbonylcarbamate (247.33 mg, 1.14 mmol) and cesium carbonate (370.91 mg, 1.14 mmol) were added, and the reaction mixture was stirred at 70 °C for 30 min. The solvent was removed. The crude was dissolved in EtOAc, washed with water, and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed. The crude was purified by flash chromatography using as eluent a mixture of Cy/EA (90/10) to give 500 mg of <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[3,5-difluoro-4-(hydroxymethyl)phenoxy]propyl]carbamate as a colorless oil, leading to a 95% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 344. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d6</i>): δ (ppm) 1.41 (s, 18H), 1.87–1.96 (q, <i>J</i> = 12.6, 6.1 Hz, 2H), 3.64 (t, <i>J</i> = 6.9 Hz, 2H), 3.99 (t, <i>J</i> = 5.7 Hz, 2H), 4.39 (d, <i>J</i> = 5.7 Hz, 2H), 5.08 (t, <i>J</i> = 5.4 Hz, 2H), 6.59–6.68 (m, 2H).</div></div><div id="sec5_6_10_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> <i>tert</i>-Butyl <i>N</i>-<i>tert</i>-Butoxycarbonyl-<i>N</i>-[3-[4-(chloromethyl)-3,5-difluoro-phenoxy]propyl]carbamate (<b>25iii</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[3,5-difluoro-4-(hydroxymethyl)phenoxy]propyl]-carbamate <b>25ii</b> (520 mg, 1.25 mmol) and NEt<sub>3</sub> (420.17 μL, 3.11 mmol) were dissolved in dry dichloromehtane at 0 °C. Mesyl chloride (144.91 μL, 1.87 mmol) was then added dropwise, and the mixture was stirred at room temperature overnight. Water was then added to quench the reaction. The organic phase was then washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then evaporated to give 475 mg of the titled compound as a colorless oil, leading to a 87% yield. It will be used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 453.0.</div></div><div id="sec5_6_10_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> <i>tert</i>-Butyl <i>N</i>-<i>tert</i>-Butoxycarbonyl-<i>N</i>-[3-[4-[[(<i>Z</i>)-<i>N</i>-[2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]-<i>N</i>′-(4-fluorophenyl)carbamimidoyl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (<b>25a</b>)</h5><div class="NLM_p last">In a 50 mL flask were added <i>N</i>-(3,4-dimethoxyphenyl)-2-[[(<i>Z</i>)-<i>N</i>-(4-fluorophenyl)-<i>C</i>-sulfanyl-carbonimidoyl]amino]-<i>N</i>-methyl-acetamide (411.3 mg, 1.09 mmol), DIEA (206.57 μL, 1.2 mmol), and 2.5 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, and the residue from <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[4-(chloromethyl)-3,5-difluoro-phenoxy]propyl]carbamate (<b>25iii</b>) (475 mg, 1.09 mmol) in 3 mL of acetonitrile was then added. The suspension was stirred at room temperature overnight. The solvent was then evaporated, the residue was dissolved in EtOAc and washed with water and brine, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (6/4) to give 300 mg (35%) of <b>25a</b> as a yellowish oil. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 777. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d6</i>): δ (ppm) 1.37 (s, 18H), 1.89 (t, <i>J</i> = 6.4 Hz, 2H), 3.16 (s, 3H), 3.61 (t, <i>J</i> = 7.0 Hz, 2H), 3.68 (s, 3H), 3.71–3.74 (m, 2H), 3.76 (s, 3H), 3.98 (t, <i>J</i> = 5.4 Hz, 2H), 4.10 (s, 2H), 6.58–6.63 (m, 2H), 6.66 (d, <i>J</i> = 9.6 Hz, 2H), 6.88 (d, <i>J</i> = 8.3 Hz, 2H), 6.90–7.01 (m, 4H).</div></div><div id="sec5_6_10_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> <i>tert</i>-Butyl <i>N</i>-<i>tert</i>-Butoxycarbonyl-<i>N</i>-[3-[4-[[5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (<b>25b</b>)</h5><div class="NLM_p last">In a 100 mL flask were introduced <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[4-[[(<i>Z</i>)-<i>N</i>-[2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-2-oxo-ethyl]-<i>N</i>′-(4-fluorophenyl)carbamimidoyl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (300 mg, 0,39 mmol), 4 mL of EtOAc, DIEA (0.4 mL, 2.32 mmol), and T3P (0.68 mL, 1.16 mmol). The mixture was heated at reflux for 7 h. After 7 h, DIEA (0.4 mL, 2.32 mmol) and T3P (0.68 mL, 1.16 mmol) were added again. After 24 h, DIEA (0.4 mL, 2.32 mmol) and T3P (0.68 mL, 1.16 mmol) were added again. After 48 h, the reaction was over, and the reaction mixture was diluted in EtOAc. The solution was then washed with a saturated aqueous solution of NaHCO<sub>3</sub> and with brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH (99/1) to give 183 mg of the title compound as an orange oil, leading to a 62% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 759. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d6</i>): δ (ppm) 1.40 (s, 18H), 1.91 (t, <i>J</i> = 6.3 Hz, 2H), 2.92 (s, 3H), 3.63 (s, 3H), 3.64 (s, 3H), 3.63 (t, <i>J</i> = 6.3 Hz, 2H), 3.98 (t, <i>J</i> = 5.5 Hz, 2H), 3.98 (s, 2H), 6.03–6.07 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.20 (d, <i>J</i> = 2.8 Hz, 1H), 6.63 (d, <i>J</i> = 9.8 Hz, 2H), 6.73 (d, <i>J</i> = 8.7 Hz, 1H), 6.95 (s, 1H), 7.10–7.23 (m, 4H).</div></div><div id="sec5_6_10_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> 2-[[4-(3-Aminopropoxy)-2,6-difluoro-phenyl]methylsulfanyl]-<i>N</i>-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-<i>N</i>-methyl-imidazol-4-amine (<b>25c</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-[3-[4-[[5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl]carbamate (180 mg, 0.24 mmol) was diluted in 4 mL of dry DCM, and 400 μL of TFA was added. The reaction mixture was stirred at 0 °C during 30 min and at room temperature during 5 h. The crude was diluted in DCM, washed with a saturated aqueous solution of NaHCO<sub>3</sub>, and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed to give 130 mg of the titled compound as a yellow oil, leading to a 98% yield. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 559. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d6</i>): δ (ppm) 1.74–1.79 (m, 2H), 2.68 (t, <i>J</i> = 6.6 Hz, 2H), 2.92 (s, 3H), 3.32 (s, 2H), 3.63 (s, 3H), 3.64 (s, 3H), 3.98 (s, 2H), 4.03 (t, <i>J</i> = 6.6 Hz, 2H), 6.03–6.07 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 6.20 (d, <i>J</i> = 2.8 Hz, 1H), 6.67 (d, <i>J</i> = 9.8 Hz, 2H), 6.73 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (s, 1H), 7.09–7.23 (m, 4H).</div></div><div id="sec5_6_10_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> 2-[3-[4-[[5-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-2-yl]sulfanylmethyl]-3,5-difluoro-phenoxy]propyl-(2-sulfonatoethyl)amino]ethanesulfonate-diammonium (<b>25</b>)</h5><div class="NLM_p last">In a microwave tube were added 2-[[4-(3-aminopropoxy)-2,6-difluoro-phenyl]methylsulfanyl]-<i>N</i>-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-<i>N</i>-methyl-imidazol-4-amine (92 mg, 0.16 mmol), sodium 2-chloroethanesulfonate (219.44 mg, 1.32 mmol), sodium iodide (24.69 mg, 0.16 mmol), and DIEA (114.75 μL, 0.66 mmol) in 700 μL of DMF. The reaction mixture was heated under microwave irradiation at 100 °C for 2 h. The reaction mixture was evaporated to dryness and was purified by preparative HPLC (ammonium formate buffer at pH 3.8) to give 22 mg of the title compound as a colorless oil, leading to a 16% yield. LC-MS: <i>t</i><sub>R</sub> = 2.65 min. MS [M+2H]<sup>2+</sup><i>m</i>/<i>z</i> = 775. HRMS found 775.1745; C<sub>32</sub>H<sub>35</sub>F<sub>3</sub>N<sub>4</sub>O<sub>9</sub>S<sub>3</sub> requires 775.1753. <sup>1</sup>H NMR (300 MHz, MeOD-<i>d4</i>): δ (ppm) 2.26–2.32 (m, 2H), 2.98 (s, 3H), 3.26 (t, <i>J</i> = 6.7 Hz, 4H), 3.48 (t, <i>J</i> = 7.2 Hz, 2H), 3.65 (t, <i>J</i> = 6.7 Hz, 4H), 3.74 (s, 3H), 3.75 (s, 3H), 3.91 (s, 2H), 4.11 (t, <i>J</i> = 5.6 Hz, 1H), 6.14–6.18 (dd, <i>J</i> = 8.6, 2.8 Hz, 1H), 6.29 (d, <i>J</i> = 2.8 Hz, 1H), 6.58 (d, <i>J</i> = 9.5 Hz, 2H), 6.78 (d, <i>J</i> = 8.6 Hz, 1H), 6.92–7.07 (m, 5H). <sup>13</sup>C NMR (75 MHz, MeOD-<i>d4</i>): δ (ppm) 23.7, 26.5, 39.6, 44.8, 50.3, 51.4, 55.2, 56.0, 65.7, 98.0–98.6 (m), 101.0, 106.0 (t, <i>J</i> = 20.1 Hz), 106.8, 113.3, 115.3 (d, <i>J</i> = 23.4 Hz), 122.8, 129.6, 129.7, 130.8, 137.4, 140.7, 143.1, 143.2, 149.8, 159.6 (t, <i>J</i> = 14.0 Hz), 161.5 (dd, <i>J</i> = 246.7, 10.9 Hz), 162.5 (d, <i>J</i> = 247.9 Hz).</div></div><div id="sec5_6_10_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> <i>tert</i>-Butyl <i>N</i>-[2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-1-methyl-2-oxo-ethyl]carbamate (<b>26a</b>)</h5><div class="NLM_p last">In a 10 mL flask were added (3,4-dimethoxy-phenyl)-methyl-amine (<b>3a</b>) (275 mg, 1.55 mmol), EtOAc (3 mL), Boc-Ala-OH (351 mg, 1.86 mmol), T3P (1366 μL, 2.319 mmol), and DIEA (810 μL, 4.64 mmol). The reaction mixture was then stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc and washed with water, saturated aqueous solution of NaHCO<sub>3</sub>, and brine, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to give 523 mg of <i>tert</i>-butyl <i>N</i>-[2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-methyl-2-oxo-ethyl]carbamate as a yellow powder, leading to a 66% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 339.2.</div></div><div id="sec5_6_10_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-1-methyl-2-oxo-ethyl]ammonium-2,2,2-trifluoroacetate (<b>26b</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl <i>N</i>-[2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-methyl-2-oxo-ethyl]carbamate (<b>26a</b>) (345 mg, 1.0 mmol) was dissolved in 2.3 mL of dichloromethane. One milliliter of TFA was then gently added, and the reaction mixture was then stirred at room temperature for 30 min. The reaction mixture was then evaporated to dryness, to give [2-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-methyl-2-oxo-ethyl]ammonium-2,2,2-trifluoroacetate as a purple oil. This oil will enter the next step without further purification. Yield was considered to be 100%. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 239.1.</div></div><div id="sec5_6_10_100" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> N-(3,4-Dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-propionamide (<b>26c</b>)</h5><div class="NLM_p last">4-Fluorophenylisothiocyanate (150 mg, 0.982 mmol) and NEt<sub>3</sub> (159 μL, 1.18 mmol) were added to a 50 mL flask in 3 mL of ethanol. [2-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-1-methyl-2-oxo-ethyl]ammonium-2,2,2-trifluoroacetate (<b>26b</b>) (346 mg, 0.982 mmol) was dissolved in 10 mL of ethanol, NEt<sub>3</sub> was added until pH was over 8, and the mixture was added dropwise at room temperature. After the addition, the reaction was over. The reaction mixture was evaporated to dryness and purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (7/3) to give 295 mg of the title compound as a white powder (94% purity), leading to a 72% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 392.1. <sup>1</sup>H NMR (DMSO-<i>d6</i>): δ (ppm) 1.10 (d, <i>J</i> = 6.9 Hz, 3H), 3.15 (s, 3H), 3.75–3.80 (m, 6H), 4.99 (m, 1H), 6.96 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.10 (d, <i>J</i> = 8.5 Hz, 1H), 7.06–7.19 (m, 3H), 7.41–7.51 (m, 2H), 7.83 (d, <i>J</i> = 7.7 Hz, 1H).</div></div><div id="sec5_6_10_101" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> 2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-propionamide (<b>26d</b>)</h5><div class="NLM_p last">In a 5 mL flask were added <i>N</i>-(3,4-dimethoxy-phenyl)-2-[3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-methyl-propionamide (<b>26c</b>) (75 mg, 180 μmol), K<sub>2</sub>CO<sub>3</sub> (26 mg, 188 μmol), sodium iodide (14 mg, 93 μmol), and 1 mL of acetonitrile (QS 0.2 M). The suspension was stirred at room temperature for 10 min, and 2-(bromomethyl)-1,3-difluoro-benzene (40 mg, 193 μmol) was then added. The suspension was stirred at room temperature for 16 h. The medium was then evaporated, the residue was dissolved in EtOAc and washed with water and brine, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was purified by flash chromatography using as eluent a mixture of DCM/MeOH (97/3) to give 78 mg of the title compound as a white solid, leading to a 84% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 518.2. <sup>1</sup>H NMR (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ (ppm) 1.22 (d, <i>J</i> = 6.4 Hz, 3H), 3.25 (s, 3H), 3.63 (s, 3H), 3.85 (s, 3H), 4.11 (s, 2H), 4.58 (brs, 1H), 6.65–7.02 (m, 10H), 7.28 (m, 1H).</div></div><div id="sec5_6_10_102" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> [2-(2,6-Difluoro-benzylsulfanyl)-3-(4-fluoro-phenyl)-5-methyl-3<i>H</i>-imidazol-4-yl]-(3,4-dimethoxy-phenyl)-methyl-amine (<b>26</b>)</h5><div class="NLM_p last">2-[2-(2,6-Difluoro-benzyl)-3-(4-fluoro-phenyl)-isothioureido]-<i>N</i>-(3,4-dimethoxy-phenyl)-<i>N</i>-methyl-propionamide (<b>26d</b>) (78 mg, 0.15 mmol) was dissolved in 1.5 mL of dry EtOAc. DIEA (157.9 μL, 0.90 mmol) and T3P in EtOAc (266 μL, 0.45 mmol) were then added. Half of the mixture was heated in a microwave at 150 °C for 10 min. The expected product was observed, and the starting material disappeared, but unfortunately, the reaction mixture was dirty. The other half of the reaction mixture was heated at reflux for 45 h. T3P (3 equiv) and DIEA (6 equiv) were added after 4, 19, and 24 h. T3P (1.5 equiv) and DIEA (3 equiv) were added after 42 h. The reaction mixture was then diluted with EtOAc, washed with water, a saturated aqueous solution of NaHCO<sub>3</sub>, and brine. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was then purified by preparative HPLC (ammonium formate buffer pH 3.8) to give 4.5 mg of the title compound as a yellowish solid, leading to a 6% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 500.1. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.11 (s, 3H, CH<sub>3</sub>),2.87 (s, 3H, N-<u class="uu">CH</u><sub><u class="uu">3</u></sub>), 3.84 (s, 3H, O-<u class="uu">CH</u><sub><u class="uu">3</u></sub>), 3.86 (s, 3H, O-<u class="uu">CH</u><sub><u class="uu">3</u></sub>), 4.13 (s, 2H, S-<u class="uu">CH</u><sub><u class="uu">2</u></sub>), 6.10 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H, Ar), 6.23 (d, <i>J</i> = 2.8 Hz, 1H, Ar), 6.76–6.83 (m, 3H, Ar), 6.93–6.97 (m, 4H, Ar), 7.19 (m, 1H, Ar). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 12.4, 26.3, 38.6, 55.9, 56.5, 98.1, 103.5, 111.1–111.3 (m), 112.7, 113.8 (t, <i>J</i> = 19.6 Hz), 115.9 (d, <i>J</i> = 22.9 Hz), 128.9 (d, <i>J</i> = 8.6 Hz), 129.1 (t, <i>J</i> = 10.0 Hz), 131.2, 133.6, 134.4, 136.6, 142.0, 142.9, 149.8, 161.2 (dd, <i>J</i> = 249.9, 7.7 Hz), 162.1 (d, <i>J</i> = 248.8 Hz).</div></div><div id="sec5_6_10_103" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> 9<i>H</i>-Fluoren-9-ylmethyl <i>N</i>-[(5S)-5-(<i>tert</i>-Butoxycarbonylamino)-6-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-6-oxo-hexyl]carbamate (<b>27a</b>)</h5><div class="NLM_p last">In a 50 mL flask were added 3,4-dimethoxy-<i>N</i>-methyl-aniline (<b>3a</b>) (500 mg, 2.99 mmol), 6 mL of EtOAc, (2<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-6-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)hexanoic acid (1681.33 mg, 3.59 mmol), DIEA (1.57 mL, 8.97 mmol), and T3P (2.64 mL, 4.49 mmol). The reaction mixture was then stirred at 50 °C for 1 h. The reaction mixture was diluted in EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and with brine, and the organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness to give 1.85 g of the title compound as a dark red oil, leading to a quantitative yield. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 618.</div></div><div id="sec5_6_10_104" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> [(1<i>S</i>)-1-[(3,4-Dimethoxyphenyl)-methyl-carbamoyl]-5-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)pentyl]ammonium-2,2,2-trifluoroacetate (<b>27b</b>)</h5><div class="NLM_p last">9<i>H</i>-Fluoren-9-ylmethyl <i>N</i>-[(5<i>S</i>)-5-(<i>tert</i>-Butoxycarbonylamino)-6-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-6-oxo-hexyl]carbamate (<b>27a</b>) (1.85 g, 2.99 mmol) and TFA (2.56 mL, 33.42 mmol) were dissolved in 5 mL of DCM. The reaction mixture was stirred at room temperature for 1 h. One milliliter of TFA was added again at the reaction mixture, and it was stirred at room temperature for 30 min. The reaction mixture was evaporated to dryness to give 1.58 g of the title compound as a purple oil, leading to a quantitative yield. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 518.</div></div><div id="sec5_6_10_105" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> 9<i>H</i>-Fluoren-9-ylmethyl <i>N</i>-[(5<i>S</i>)-6-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-5-[[(<i>Z</i>)-<i>N</i>-(4-fluorophenyl)-<i>C</i>-sulfanyl-carbonimidoyl]amino]-6-oxo-hexyl]carbamate (<b>27c</b>)</h5><div class="NLM_p last">1-Fluoro-4-isothiocyanato-benzene (0.46 g, 2.99 mmol) and NEt<sub>3</sub> (0.4 mL, 2.99 mmol) were added to a 500 mL flask in 20 mL of ethanol. [(1<i>S</i>)-1-[(3,4-Dimethoxyphenyl)-methyl-carbamoyl]-5-(9<i>H</i>-fluoren-9-ylmethoxycarbonylamino)pentyl]ammonium-2,2,2-trifluoroacetate (<b>27b</b>) (1.89 g, 2.99 mmol) was dissolved in 20 mL of ethanol, NEt<sub>3</sub> (0.47 mL, 3.47 mmol) was added, and the mixture was added dropwise at room temperature. Then, 1 mL of NEt<sub>3</sub> was added to reach pH 10. The reaction mixture was evaporated to dryness. Purification of the crude by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (50/50) gave 1.58 g of the title compound as a yellowish oil, leading to a 79% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 671. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.09–1.36 (m, 4H), 1.46–1.70 (m, 2H), 3.00 (s, 2H), 3.20 (s, 3H), 3.87 (s, 3H), 3.93 (s, 3H), 4.18 (d, <i>J</i> = 7.3 Hz, 1H), 4.36 (d, <i>J</i> = 7.1 Hz, 2H), 4.91 (t, <i>J</i> = 5.6 Hz, 1H), 6.88 (s, 2H), 6.99 (t, <i>J</i> = 8.5 Hz, 2H), 7.12 (s, 1H), 7.20–7.42 (m, 6H), 7.57 (d, <i>J</i> = 7.4 Hz, 2H), 7.67 (s, 1H), 7.74 (d, <i>J</i> = 7.4 Hz, 2H), 8.51 (s, 1H).</div></div><div id="sec5_6_10_106" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151"> 9<i>H</i>-Fluoren-9-ylmethyl <i>N</i>-[(5<i>S</i>)-5-[[(<i>Z</i>)-<i>C</i>-[(2,6-Difluorophenyl)methylsulfanyl]-<i>N</i>-(4-fluorophenyl)carbonimidoyl]amino]-6-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-6-oxo-hexyl]carbamate (<b>27d</b>)</h5><div class="NLM_p last">In a 25 mL flask were added 2-(bromomethyl)-1,3-difluoro-benzene (486.14 mg, 2.348 mmol), K<sub>2</sub>CO<sub>3</sub> (357.02 mg, 2.583 mmol), and 11.7 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, and 9<i>H</i>-fluoren-9-ylmethyl <i>N</i>-[(5<i>S</i>)-6-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-5-[[(4-fluoroanilino)-sulfanyl-methyl]amino]-6-oxo-hexyl]carbamate (<b>27c</b>) (1.58 g, 2.35 mmol) was then added. The suspension was stirred at room temperature overnight. The reaction mixture was then evaporated, the residue was dissolved in EtOAc, washed with water and brine, and the organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness to give 1.87 g of the desired product as a dark oil, leading to an 89% yield. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 799. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.30 (brs, 4H), 1.62 (brs, 3H), 3.08 (brs, 2H), 3.27 (brs, 3H), 3.62 (s, 3H), 3.84 (s, 3H), 4.08 (brs, 2H), 4.19 (m, 1H), 4.39 (d, <i>J</i> = 6.9 Hz, 2H), 4.70 (brs, 1H), 5.24 (brs, 1H), 6.74 (brs, 1H), 6.75–6.95 (m, 8H), 7.15–7.23 (m, 1H), 7.30 (t, <i>J</i> = 7.4 Hz, 2H), 7.39 (t, <i>J</i> = 7.4 Hz, 2H), 7.57 (d, <i>J</i> = 7.2 Hz, 2H), 7.76 (d, <i>J</i> = 7.2 Hz, 2H).</div></div><div id="sec5_6_10_107" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> 9<i>H</i>-Fluoren-9-ylmethyl <i>N</i>-[4-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butyl]carbamate (<b>27e</b>)</h5><div class="NLM_p last">In a 50 mL flask were added 9<i>H</i>-fluoren-9-ylmethyl <i>N</i>-[(5<i>S</i>)-5-[[(<i>Z</i>)-<i>C</i>-[(2,6-difluorophenyl)methylsulfanyl]-<i>N</i>-(4-fluorophenyl)carbonimidoyl]amino]-6-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-6-oxo-hexyl]carbamate (<b>27d</b>) (1.625 mg, 2.039 mmol), T3P (3.605 mL, 6.117 mmol), DIEA (2.137 mL, 12.23 mmol), and 20.39 mL of EtOAc. The suspension was stirred 24 h at 80 °C. The same quantities of T3P and DIEA were added twice at 24 and 48 h. The medium was then evaporated, the residue was dissolved in EtOAc and washed with water and brine, and the organic phase was dried over MgSO<sub>4</sub> and evaporated. Purification of the crude by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (7/3) gave 507 mg of the title compound as a yellow solid, leading to a 32% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 779. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.42–1.56 (m, 2H), 1.61–1.74 (m, 2H), 2.43 (t, <i>J</i> = 7.4 Hz, 2H), 2.83 (s, 3H), 3.15–3.22 (m, 2H), 3.80 (s, 3H), 3.81 (s, 3H), 4.07 (s, 2H), 4.21 (t, <i>J</i> = 6.8 Hz, 2H), 4.38 (d, <i>J</i> = 7.0 Hz, 2H), 5.03 (brs, 1H), 6.04 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.18 (d, <i>J</i> = 2.8 Hz, 1H), 6.70–6.81 (m, 3H), 6.88–6.94 (m, 4H), 7.09–7.20 (m, 1H), 7.30(t, <i>J</i> = 7.4 Hz, 2H), 7.38 (d, <i>J</i> = 7.4 Hz, 2H), 7.60 (d, <i>J</i> = 7.2 Hz, 2H), 7.75 (d, <i>J</i> = 7.2 Hz, 2H).</div></div><div id="sec5_6_10_108" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> 4-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butylammonium-formate (<b>27</b>)</h5><div class="NLM_p last">To a solution of 9<i>H</i>-fluoren-9-ylmethyl <i>N</i>-[4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butyl]carbamate (<b>27e</b>) (0.24 g, 0.31 mmol) in EtOAc (1.45 mL) was added piperidine (0.06 mL, 0.62 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then evaporated under reduced pressure. Purification of the crude by preparative HPLC (ammonium formate buffer pH 3.8) gave 100 mg of the desired product as a yellowish oil, leading to a 60% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 557. HRMS found 585.2126; C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S requires 585.2147. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.60–1.80 (m, 4H), 2.32–2.50 (m, 2H), 2.82 (s, 3H), 2.90–3.00 (m, 2H), 3.80 (s, 3H), 3.81 (s, 3H), 3.94 (s, 2H), 6.03 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 6.17 (d, <i>J</i> = 2.4 Hz, 1H), 5.50–6.50 (m, 3H), 6.70–6.82 (m, 3H), 6.83–6.95 (m, 4H), 7.10–7.21 (m, 1H), 8.46 (brs, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 25.8, 25.9, 26.9, 27.6, 39.0, 56.0, 56.6, 70.6, 98.2, 103.8, 111.3 (m), 112.9, 114.0 (t, <i>J</i> = 19.3 Hz), 115.9 (d, <i>J</i> = 22.8 Hz), 129.2 (d, <i>J</i> = 9.0 Hz), 129.3 (t, <i>J</i> = 9.2 Hz), 131.1 (d, <i>J</i> = 3.1 Hz), 134.7, 136.4, 137.2, 142.2, 142.9, 149.9, 161.1 (dd, <i>J</i> = 249.7, 7.8 Hz), 162.3 (d, <i>J</i> = 249.1 Hz), 168.6.</div></div><div id="sec5_6_10_109" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> Methyl (4<i>S</i>)-4-(<i>tert</i>-Butoxycarbonylamino)-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-5-oxo-pentanoate (<b>28a</b>)</h5><div class="NLM_p last">In a 50 mL flask were added 3,4-dimethoxy-<i>N</i>-methyl-aniline (intermediate <b>1a</b>) (500 mg, 2.99 mmol), 6 mL of EtOAc, (2<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-5-methoxy-5-oxo-pentanoic acid (937.55 mg, 3.59 mmol), T3P (2.64 mL, 4.49 mmol), and DIEA (1.57 mL, 8.97 mmol). The reaction mixture was then stirred at 50 °C for 1 h. The reaction mixture was diluted in EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and with brine, and the organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness to give 1.187 g of the desired product as a brown oil, leading to a 97% yield. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 411.</div></div><div id="sec5_6_10_110" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> (1<i>S</i>)-1-[(3,4-Dimethoxyphenyl)-methyl-carbamoyl]-4-methoxy-4-oxo-butyl]ammonium;2,2,2-trifluoroacetate (<b>28b</b>)</h5><div class="NLM_p last">Methyl (4<i>S</i>)-4-(<i>tert</i>-butoxycarbonylamino)-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-5-oxo-pentanoate (<b>28a</b>) (1.19 g, 2.89 mmol) and 1.5 mL of TFA were dissolved in 5 mL of DCM, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness to give 1.23 g of the title compound as purple oil. The product will be used in the next step of the synthesis without further purification (the yield was considered to be 100%). MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 311.</div></div><div id="sec5_6_10_111" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> Methyl (4<i>S</i>)-5-(3,4-Dimethoxy-<i>N</i>-methyl-anilino)-4-[[(<i>Z</i>)-<i>N</i>-(4-fluorophenyl)-<i>C</i>-sulfanyl-carbonimidoyl]amino]-5-oxo-pentanoate (<b>28c</b>)</h5><div class="NLM_p last">4-Fluorophenylisothiocyanate (0.44 g, 2.89 mmol) and NEt<sub>3</sub> (0.39 mL, 2.89 mmol) were added to a 500 mL flask in 20 mL of ethanol. (1<i>S</i>)-1-[(3,4-Dimethoxyphenyl)-methyl-carbamoyl]-4-methoxy-4-oxo-butyl]ammonium-2,2,2-trifluoroacetate (<b>28b</b>) (1.23 g, 2.89 mmol) was dissolved in 20 mL of ethanol, NEt<sub>3</sub> (0.47 mL, 3.47 mmol) was added, and the mixture was added dropwise at room temperature Then, 1 mL of NEt<sub>3</sub> was added to reach pH 10. After 30 min of reaction, the conversion was complete. The reaction mixture was evaporated to dryness. Purification of the crude by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (50/50) gave 940 mg of the title compound as a yellowish oil, leading to a 70% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 464. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.73–1.89 (m, 1H) ; 1.89–2.03 (m, 2H), 2.10–2.37 (m, 2H), 3.22 (s, 3H), 3.57 (s, 3H), 3.92 (s, 3H), 3.94 (s, 3H), 6.91 (s, 2H), 7.00–7.12 (m, 3H), 7.27 (s, 2H), 7.28 (m, 1H), 8.26 (s, 1H).</div></div><div id="sec5_6_10_112" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> Methyl (4<i>S</i>)-4-[[(<i>Z</i>)-<i>C</i>-[(2,6-Difluorophenyl)methylsulfanyl]-<i>N</i>-(4-fluorophenyl)carbonimidoyl]amino]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-5-oxo-pentanoate (<b>28d</b>)</h5><div class="NLM_p last">In a 50 mL flask were added methyl 2-(bromomethyl)-1,3-difluoro-benzene (419.82 mg, 2.03 mmol), K<sub>2</sub>CO<sub>3</sub> (308.3 mg, 2.23 mmol), and 10.2 mL of acetonitrile. The suspension was stirred at room temperature for 10 min, methyl (4<i>S</i>)-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-4-[(4-fluorophenyl)carbamothioylamino]-5-oxo-pentanoate (<b>28c</b>) (940 mg, 2.03 mmol) was then added to the reaction mixture, and it was stirred at room temperature overnight. The medium was then evaporated, the residue was dissolved in EtOAc, washed with water and brine, and dried over MgSO<sub>4</sub>. The crude was evaporated to dryness to give 1.05 g of the desired product as a dark oil, leading to a 87% yield. It was used without further purification in the next step of the synthesis. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 590. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.93 (brs, 2H), 2.29 (brs, 2H), 3.27 (s, 3H), 3.60 (s, 3H), 3.66 (s, 3H), 3.88 (s, 4H), 4.10 (brs, 2H), 4.70 (brs, 1H), 5.40 (brs, 1H), 6.72 (brs, 2H), 6.83–6.94 (m, 8H).</div></div><div id="sec5_6_10_113" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> Methyl 3-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]propanoate (<b>28</b>)</h5><div class="NLM_p last">In a 100 mL flask were added methyl (4<i>S</i>)-4-[[(<i>Z</i>)-<i>C</i>-[(2,6-difluorophenyl)methylsulfanyl]-<i>N</i>-(4-fluorophenyl)carbonimidoyl]amino]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-5-oxo-pentanoate (<b>28d</b>) (1 g, 1.7 mmol), T3P (3.01 mL, 5.1 mmol), DIEA (1.88 mL, 10.21 mmol), and 17 mL of EtOAc. The medium was stirred at 80 °C for 24 h. The reaction mixture was diluted in EtOAc and washed with water and brine, and dried over MgSO<sub>4</sub> and evaporated to dryness. The conversion was not complete. The residue was dissolved in 17 mL of EtOAc. T3P (3.01 mL, 5.1 mmol) and DIEA (1.88 mL, 10.21 mmol) were added to the reaction mixture, and it was stirred at 80 °C for 24 h. The reaction mixture was diluted in EtOAc and washed with water and brine. The organic phase was dried over MgSO<sub>4</sub> and evaporated. The crude was purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (70/30) to give 265 mg of the desired product with the starting material. The crude was again dissolved in EtOAc and T3P (0.6 mL, 1.018 mmol), DIEA (0.376 mL, 2.035 mmol) was added, and the reaction mixture was stirred at 80 °C for 24 h. The reaction mixture was diluted in EtOAc and washed with water and brine. The organic phase was dried over MgSO<sub>4</sub> and evaporated. The crude was then purified by flash chromatography using as eluent a mixture of cyclohexane/EtOAc (70/30) to give 104 mg of the desired product as a yellowish oil, leading to an 11% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 572.2. HRMS found 572.1814; C<sub>29</sub>H<sub>28</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S requires 572.1831. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.67–2.72 (m, 4H), 2.85 (s, 3H), 3.62 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 4.07 (s, 2H), 6.04 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.17 (d, <i>J</i> = 2.8 Hz, 1H), 6.72 (d, <i>J</i> = 8.7 Hz, 1H), 6.77 (t, <i>J</i> = 7.7 Hz, 2H), 6.87–6.92 (m, 4H), 7.01–7.21 (m, 1H).</div></div><div id="sec5_6_10_114" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> 3-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]propanoic Acid (<b>29</b>)</h5><div class="NLM_p last">Methyl 3-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]propanoate (<b>28</b>) (104.6 mg, 0.18 mmol) was dissolved in MeOH (1.83 mL), and 1 N NaOH (640 μL, 0.64 mmol) was added. The mixture was stirred overnight at room temperature and evaporated to dryness. The residue was dissolved in DCM and washed with aqueous 1 N HCl, water, and brine. The organic phase was dried over MgSO<sub>4</sub> and evaporated to dryness to give 95 mg of the title compound as a yellowish oil, leading to a 93% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 558.3. HRMS found 558.1650; C<sub>28</sub>H<sub>26</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>S requires 558.1674. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 2.73 (s, 4H), 2.84 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 4.09 (s, 2H), 6.03 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.16 (d, <i>J</i> = 2.6 Hz, 1H), 6.73 (d, <i>J</i> = 8.7 Hz, 1H), 6.78 (t, <i>J</i> = 7.9 Hz, 2H), 6.85–6.98 (m, 4H), 7.11–7.23 (m, 1H), 8.75 (brs, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 21.1, 26.7, 33.5, 38.9, 56.1, 56.5, 98.4, 104.1, 111.4 (m), 112.9, 113.4 (t, <i>J</i> = 19.2 Hz), 116.2 (d, <i>J</i> = 23.0 Hz), 129.1 (d, <i>J</i> = 8.9 Hz), 129.6 (t, <i>J</i> = 10.2 Hz), 130.4 (d, <i>J</i> = 3.2 Hz), 134.6, 135.2, 137.1, 142.5, 150.0, 161.1 (dd, <i>J</i> = 250.0, 7.6 Hz), 162.5 (d, <i>J</i> = 250.0 Hz), 175.8.</div></div><div id="sec5_6_10_115" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> 4-[2-[(2,6-Difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butyl-trimethylammonium-formate (<b>30</b>)</h5><div class="NLM_p last">In a 5 mL flask was diluted 4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butylammonium-formate (<b>27</b>) (45 mg, 0.07 mmol) in 400 μL of a mixture of Et<sub>2</sub>O/THF (1/1). Iodomethane (18.59 μL, 0.3 mmol) and DIEA (13.01 μL, 0.07 mmol) were added to the reaction mixture, and it was stirred at room temperature overnight. The reaction mixture was evaporated to dryness. In a 5 mL flask was diluted 4-[2-[(2,6-difluorophenyl)methylsulfanyl]-5-(3,4-dimethoxy-<i>N</i>-methyl-anilino)-1-(4-fluorophenyl)imidazol-4-yl]butylammonium-formate (30 mg, 0.05 mmol) in 250 μL of a mixture of Et<sub>2</sub>O/THF (1/1). Iodomethane (12.4 μL, 0.2 mmol) and DIEA (8.67 μL, 0.05 mmol) were added to the reaction mixture, and it was stirred at room temperature overnight. The reaction mixture was evaporated to dryness. The crude was diluted in EtOAc and washed with water and brine, dried over MgSO<sub>4</sub>, and evaporated to dryness. Purification of the crude by preparative chromatography (ammonium formate buffer at pH 3.8) gave 7.3 mg of the desired product as a yellowish oil, leading to a 20% yield. MS [M + H]<sup>+</sup><i>m</i>/<i>z</i> = 599. HRMS found 599.2665; C<sub>32</sub>H<sub>38</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S requires 599.2668. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ (ppm) 1.69 (brs, 2H), 1.82 (brs, 2H), 2.45 (t, <i>J</i> = 6.6 Hz, 2H), 2.87 (s, 3H), 3.31 (brs, 9H), 3.45 (brs, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 4.03 (s, 2H), 6.06 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.18 (d, <i>J</i> = 2.7 Hz, 1H), 6.76 (d, <i>J</i> = 8.6 Hz, 1H), 6.81 (t, <i>J</i> = 7.8 Hz, 2H), 6.90–6.98 (m, 4H), 7.15–7.25 (m, 1H), 8.61 (s, 1H), <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ (ppm) 22.6, 25.3, 25.6, 26.6, 29.8, 34.1, 39.2, 53.5, 56.2, 56.7, 66.9, 98.5, 104.1, 111.5 (m), 113.0, 114.1 (t, <i>J</i> = 19.2 Hz), 116.1 (d, <i>J</i> = 22.9 Hz), 129.1 (d, <i>J</i> = 8.4 Hz), 129.4 (t, <i>J</i> = 10.2 Hz), 131.1 (d, <i>J</i> = 3.1 Hz), 134.9, 136.3, 136.9, 142.3, 143.0, 149.9, 161.2 (dd, <i>J</i> = 249.3, 7.8 Hz), 162.4 (d, <i>J</i> = 249.3 Hz).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d140e9848-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i161"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01873">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01873" class="ext-link">10.1021/acs.jmedchem.6b01873</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01873/suppl_file/jm6b01873_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01873/suppl_file/jm6b01873_si_001.csv">jm6b01873_si_001.csv (1.87 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01873" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benoit Deprez</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2777-4538" title="Orcid link">http://orcid.org/0000-0002-2777-4538</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#294b4c4746405d074d4c595b4c53695c47405f04454045454c1b074f5b"><span class="__cf_email__" data-cfemail="1577707b7a7c613b71706567706f55607b7c6338797c797970273b7367">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Charton</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#caa0bfa6a3afe4a9a2abb8bea5a48abfa4a3bce7a6a3a6a6aff8e4acb8"><span class="__cf_email__" data-cfemail="5a302f36333f7439323b282e35341a2f34332c77363336363f68743c28">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manuel Lasalle</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vanessa Hoguet</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathalie Hennuyer</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florence Leroux</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Catherine Piveteau</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loïc Belloy</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie Lestavel</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuelle Vallez</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emilie Dorchies</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Isabelle Duplan</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuel Sevin</span> - <span class="hlFld-Affiliation affiliation">Univ.
Artois, EA 2465 - Blood-Brain
Barrier Laboratory (LBHE), F-62300 Lens, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maxime Culot</span> - <span class="hlFld-Affiliation affiliation">Univ.
Artois, EA 2465 - Blood-Brain
Barrier Laboratory (LBHE), F-62300 Lens, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabien Gosselet</span> - <span class="hlFld-Affiliation affiliation">Univ.
Artois, EA 2465 - Blood-Brain
Barrier Laboratory (LBHE), F-62300 Lens, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajaa Boulahjar</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrien Herledan</span> - <span class="hlFld-Affiliation affiliation">Univ.
Lille, Inserm,
Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living
Systems, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bart Staels</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne Tailleux</span> - <span class="hlFld-Affiliation affiliation">Univ. Lille, Inserm,
CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.L. and V.H. contributed equally to this work.</p><span class="author-information-subsection-header">Author Contributions</span><p>A.T. and J.C. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d140e9835-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i164">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to the institutions that support our laboratory: INSERM, Université de Lille, Institut Pasteur de Lille. This project was supported by Conseil Régional Nord-Pas de Calais, ERDF (convention no. 11003609), Etat DRRT, European Genomic Institute for Diabetes (EGID, ANR-10-LABX-46), the European Research Council (ERC Grant Immunobile, contract 694717), European Commission, INSERM, Université Lille 2 (Appel à projets ≪orientations stratégiques ≫ : convention no. A007), and SATT Nord (M0075/SATTNORD). M.L. and V.H. are recipients of a doctoral fellowship of the French Ministère de la Recherche. NMR acquisitions were done at the Laboratoire d’Application de Résonance Magnétique Nucléaire (LARMN), Lille, France. B.S. is a member of the Institut Universitaire de France.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i165" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i165"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i166" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i166"> Abbreviations Used</h2><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">CH<sub>3</sub>CN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">1,2-dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DIO</td><td class="NLM_def"><p class="first last">diet-induced obesity</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">equiv</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastro-intestinal</p></td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide-1</p></td></tr><tr><td class="NLM_term">GP-BAR1</td><td class="NLM_def"><p class="first last">G-protein coupled bile acid receptor 1</p></td></tr><tr><td class="NLM_term">HFD</td><td class="NLM_def"><p class="first last">high fat diet</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TCDI</td><td class="NLM_def"><p class="first last">1,1′-thiocarbonyldiimidazole</p></td></tr><tr><td class="NLM_term">TGR5</td><td class="NLM_def"><p class="first last">Takeda G-protein-coupled receptor 5</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">1-propylphosphonic acid cyclic anhydride</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i167">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lefebvre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cariou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staels, B.</span><span> </span><span class="NLM_article-title">Role of bile acids and bile acid receptors in metabolic regulation</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1152/physrev.00010.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1152%2Fphysrev.00010.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=19126757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Cqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=147-191&author=P.+Lefebvreauthor=B.+Cariouauthor=F.+Lienauthor=F.+Kuipersauthor=B.+Staels&title=Role+of+bile+acids+and+bile+acid+receptors+in+metabolic+regulation&doi=10.1152%2Fphysrev.00010.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Role of bile acids and bile acid receptors in metabolic regulation</span></div><div class="casAuthors">Lefebvre, Philippe; Cariou, Bertrand; Lien, Fleur; Kuipers, Folkert; Staels, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-191</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The incidence of the metabolic syndrome has taken epidemic proportions in the past decades, contributing to an increased risk of cardiovascular disease and diabetes.  The metabolic syndrome can be defined as a cluster of cardiovascular disease risk factors including visceral obesity, insulin resistance, dyslipidemia, increased blood pressure, and hypercoagulability.  The farnesoid X receptor (FXR) belongs to the superfamily of ligand-activated nuclear receptor transcription factors.  FXR is activated by bile acids, and FXR-deficient (FXR-/-) mice display elevated serum levels of triglycerides and high-d. lipoprotein cholesterol, demonstrating a crit. role of FXR in lipid metab.  In an opposite manner, activation of FXR by bile acids (BAs) or nonsteroidal synthetic FXR agonists lowers plasma triglycerides by a mechanism that may involve the repression of hepatic SREBP-1c expression and/or the modulation of glucose-induced lipogenic genes.  A cross-talk between BA and glucose metab. was recently identified, implicating both FXR-dependent and FXR-independent pathways.  The first indication for a potential role of FXR in diabetes came from the observation that hepatic FXR expression is reduced in animal models of diabetes.  While FXR-/- mice display both impaired glucose tolerance and decreased insulin sensitivity, activation of FXR improves hyperglycemia and dyslipidemia in vivo in diabetic mice.  Finally, a recent report also indicates that BA may regulate energy expenditure in a FXR-independent manner in mice, via activation of the G protein-coupled receptor TGR5.  Taken together, these findings suggest that modulation of FXR activity and BA metab. may open new attractive pharmacol. approaches for the treatment of the metabolic syndrome and type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc0VIzJznf17Vg90H21EOLACvtfcHk0ljKze4BzEAR3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Cqtro%253D&md5=b540fb270c957511e5511730f31f6181</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00010.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00010.2008%26sid%3Dliteratum%253Aachs%26aulast%3DLefebvre%26aufirst%3DP.%26aulast%3DCariou%26aufirst%3DB.%26aulast%3DLien%26aufirst%3DF.%26aulast%3DKuipers%26aufirst%3DF.%26aulast%3DStaels%26aufirst%3DB.%26atitle%3DRole%2520of%2520bile%2520acids%2520and%2520bile%2520acid%2520receptors%2520in%2520metabolic%2520regulation%26jtitle%3DPhysiol.%2520Rev.%26date%3D2009%26volume%3D89%26spage%3D147%26epage%3D191%26doi%3D10.1152%2Fphysrev.00010.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollister, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, B. M.</span><span> </span><span class="NLM_article-title">Endogenous bile acids are ligands for the nuclear receptor FXR/BAR</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1016/S1097-2765(00)80348-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2FS1097-2765%2800%2980348-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10360171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=543-553&author=H.+Wangauthor=J.+Chenauthor=K.+Hollisterauthor=L.+C.+Sowersauthor=B.+M.+Forman&title=Endogenous+bile+acids+are+ligands+for+the+nuclear+receptor+FXR%2FBAR&doi=10.1016%2FS1097-2765%2800%2980348-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous bile acids are ligands for the nuclear receptor FXR/BAR</span></div><div class="casAuthors">Wang, Haibo; Chen, Jasmine; Hollister, Kevin; Sowers, Lawrence C.; Forman, Barry M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-553</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The major metabolic pathway for elimination of cholesterol is via conversion to bile acids.  In addn. to this metabolic function, bile acids also act as signaling mols. that neg. regulate their own biosynthesis.  However, the precise nature of this signaling pathway has been elusive.  We have isolated an endogenous biliary component (chenodeoxycholic acid) that selectively activates the orphan nuclear receptor, FXR.  Structure-activity anal. defined a subset of related bile acid ligands that activate FXR and promote coactivator recruitment.  Finally, we show that ligand-occupied FXR inhibits transactivation from the oxysterol receptor LXRα, a pos. regulator of cholesterol degrdn.  We suggest that FXR (BAR) is the endogenous bile acid sensor and thus an important regulator of cholesterol homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoauTFRc0isNLVg90H21EOLACvtfcHk0lgXQHX7PDoLVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqurg%253D&md5=3665b97ff39dd986916101f5834e5ae5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980348-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980348-2%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHollister%26aufirst%3DK.%26aulast%3DSowers%26aufirst%3DL.%2BC.%26aulast%3DForman%26aufirst%3DB.%2BM.%26atitle%3DEndogenous%2520bile%2520acids%2520are%2520ligands%2520for%2520the%2520nuclear%2520receptor%2520FXR%252FBAR%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D543%26epage%3D553%26doi%3D10.1016%2FS1097-2765%2800%2980348-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itadani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span> </span><span class="NLM_article-title">Identification of membrane-type receptor for bile acids (M-BAR)</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span><span class="refDoi"> DOI: 10.1016/S0006-291X(02)02550-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2FS0006-291X%2802%2902550-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=12419312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=714-719&author=T.+Maruyamaauthor=Y.+Miyamotoauthor=T.+Nakamuraauthor=Y.+Tamaiauthor=H.+Okadaauthor=E.+Sugiyamaauthor=T.+Nakamuraauthor=H.+Itadaniauthor=K.+Tanaka&title=Identification+of+membrane-type+receptor+for+bile+acids+%28M-BAR%29&doi=10.1016%2FS0006-291X%2802%2902550-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of membrane-type receptor for bile acids (M-BAR)</span></div><div class="casAuthors">Maruyama, Takaharu; Miyamoto, Yasuhisa; Nakamura, Takao; Tamai, Yoshitaka; Okada, Hiromasa; Sugiyama, Eiji; Nakamura, Tatsuji; Itadani, Hiraku; Tanaka, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">714-719</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Bile acids play an essential role in the solubilization and absorption of dietary fat and lipid-sol. vitamins.  Bile acids also modulate the transcription of various genes for enzymes and transport proteins for their own and cholesterol homeostasis through binding to nuclear receptors.  Here we report a novel category of bile acid receptor, a membrane-type G protein-coupled receptor (GPCR), BG37.  Bile acids induced rapid and dose-dependent elevation of intracellular cAMP levels in BG37-expressing cells, but not in mock-transfected cells, independently of nuclear receptor expression.  The rank order of potency of various bile acids for BG37-expressing cells was different from that for the nuclear receptor-mediated response.  These observations demonstrate the presence of two independent signaling pathways for bile acids; membrane-type GPCR for rapid signaling and nuclear receptors for delayed signaling.  Expression of BG37 was detected in various specific tissues, suggesting its physiol. role, although it remains to be further characterized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFW81vc2oQfLVg90H21EOLACvtfcHk0lgXQHX7PDoLVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12kt78%253D&md5=6d3133ccf80e6222d7beb52ae31f3324</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2802%2902550-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252802%252902550-0%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DTamai%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DE.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DItadani%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520membrane-type%2520receptor%2520for%2520bile%2520acids%2520%2528M-BAR%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2002%26volume%3D298%26spage%3D714%26epage%3D719%26doi%3D10.1016%2FS0006-291X%2802%2902550-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kawamata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukusumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shintani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">A G protein-coupled receptor responsive to bile acids</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">9435</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span><span class="refDoi"> DOI: 10.1074/jbc.M209706200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1074%2Fjbc.M209706200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=12524422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvV2isrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=9435-9440&author=Y.+Kawamataauthor=R.+Fujiiauthor=M.+Hosoyaauthor=M.+Haradaauthor=H.+Yoshidaauthor=M.+Miwaauthor=S.+Fukusumiauthor=Y.+Habataauthor=T.+Itohauthor=Y.+Shintaniauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=A+G+protein-coupled+receptor+responsive+to+bile+acids&doi=10.1074%2Fjbc.M209706200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A G Protein-coupled Receptor Responsive to Bile Acids</span></div><div class="casAuthors">Kawamata, Yuji; Fujii, Ryo; Hosoya, Masaki; Harada, Masataka; Yoshida, Hiromi; Miwa, Masanori; Fukusumi, Shoji; Habata, Yugo; Itoh, Takashi; Shintani, Yasushi; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9435-9440</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We have identified a G protein-coupled receptor, TGR5, that is responsive to bile acids as a cell-surface receptor.  Bile acids specifically induced receptor internalization, the activation of extracellular signal-regulated kinase mitogen-activated protein kinase, the increase of guanosine 5'-O-3-thio-triphosphate binding in membrane fractions, and intracellular cAMP prodn. in Chinese hamster ovary cells expressing TGR5.  Our quant. analyses for TGR5 mRNA showed that it was abundantly expressed in monocytes/macrophages in human and rabbit.  Treatment with bile acids was found to suppress the functions of rabbit alveolar macrophages including phagocytosis and lipopolysaccharide-stimulated cytokine productions.  We prepd. a monocytic cell line expressing TGR5 by transfecting a TGR5 cDNA into THP-1 cells that did not express TGR5 originally.  Treatment with bile acids suppressed the cytokine productions in the THP-1 cells expressing TGR5, whereas it did not influence those in the original THP-1 cells, suggesting that TGR5 is implicated in the suppression of macrophage functions by bile acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb5GfTzFYNbrVg90H21EOLACvtfcHk0ljOMRuDI0DxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvV2isrY%253D&md5=1add10cd2720795a8c1c2fa3a40e6638</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M209706200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M209706200%26sid%3Dliteratum%253Aachs%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DMiwa%26aufirst%3DM.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DHabata%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DShintani%26aufirst%3DY.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DA%2520G%2520protein-coupled%2520receptor%2520responsive%2520to%2520bile%2520acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D9435%26epage%3D9440%26doi%3D10.1074%2Fjbc.M209706200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Porez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prawitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staels, B.</span><span> </span><span class="NLM_article-title">Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1723</span><span class="NLM_x">–</span> <span class="NLM_lpage">1737</span><span class="refDoi"> DOI: 10.1194/jlr.R024794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1194%2Fjlr.R024794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=22550135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ghs7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=1723-1737&author=G.+Porezauthor=J.+Prawittauthor=B.+Grossauthor=B.+Staels&title=Bile+acid+receptors+as+targets+for+the+treatment+of+dyslipidemia+and+cardiovascular+disease&doi=10.1194%2Fjlr.R024794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease</span></div><div class="casAuthors">Porez, Geoffrey; Prawitt, Janne; Gross, Barbara; Staels, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1723-1737</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis.  When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD.  Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge.  Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis.  The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metab., rendering them potential pharmacol. targets for MS therapy.  This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAdJV6_suFibVg90H21EOLACvtfcHk0ljOMRuDI0DxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ghs7bM&md5=6ead79e9c31616180658f7660ce0a5e3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R024794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R024794%26sid%3Dliteratum%253Aachs%26aulast%3DPorez%26aufirst%3DG.%26aulast%3DPrawitt%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DB.%26aulast%3DStaels%26aufirst%3DB.%26atitle%3DBile%2520acid%2520receptors%2520as%2520targets%2520for%2520the%2520treatment%2520of%2520dyslipidemia%2520and%2520cardiovascular%2520disease%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2012%26volume%3D53%26spage%3D1723%26epage%3D1737%26doi%3D10.1194%2Fjlr.R024794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Campbell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Pharmacology, physiology, and mechanisms of incretin hormone action</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span><span class="refDoi"> DOI: 10.1016/j.cmet.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.cmet.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=23684623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=819-837&author=J.+E.+Campbellauthor=D.+J.+Drucker&title=Pharmacology%2C+physiology%2C+and+mechanisms+of+incretin+hormone+action&doi=10.1016%2Fj.cmet.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action</span></div><div class="casAuthors">Campbell, Jonathan E.; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">819-837</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concns., lipid metab., gut motility, appetite and body wt., and immune function, providing a scientific basis for utilizing incretin-based therapies in the treatment of type 2 diabetes.  Activation of GLP-1 and GIP receptors also leads to nonglycemic effects in multiple tissues, through direct actions on tissues expressing incretin receptors and indirect mechanisms mediated through neuronal and endocrine pathways.  Here we contrast the pharmacol. and physiol. of incretin hormones and review recent advances in mechanisms coupling incretin receptor signaling to pleiotropic metabolic actions in preclin. studies.  We discuss whether mechanisms identified in preclin. studies have potential translational relevance for the treatment of human disease and highlight controversies and uncertainties in incretin biol. that require resoln. in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRNiGuKdmu97Vg90H21EOLACvtfcHk0ljOMRuDI0DxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGktbs%253D&md5=8a82721ed5d7542784f27ca95c62a694</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DPharmacology%252C%2520physiology%252C%2520and%2520mechanisms%2520of%2520incretin%2520hormone%2520action%26jtitle%3DCell%2520Metab.%26date%3D2013%26volume%3D17%26spage%3D819%26epage%3D837%26doi%3D10.1016%2Fj.cmet.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houten, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mataki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoffolete, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messaddeq, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harney, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auwerx, J.</span><span> </span><span class="NLM_article-title">Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">484</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.1038/nature04330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1038%2Fnature04330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=16400329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFWmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=484-489&author=M.+Watanabeauthor=S.+M.+Houtenauthor=C.+Matakiauthor=M.+A.+Christoffoleteauthor=B.+W.+Kimauthor=H.+Satoauthor=N.+Messaddeqauthor=J.+W.+Harneyauthor=O.+Ezakiauthor=T.+Kodamaauthor=K.+Schoonjansauthor=A.+C.+Biancoauthor=J.+Auwerx&title=Bile+acids+induce+energy+expenditure+by+promoting+intracellular+thyroid+hormone+activation&doi=10.1038%2Fnature04330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation</span></div><div class="casAuthors">Watanabe, Mitsuhiro; Houten, Sander M.; Mataki, Chikage; Christoffolete, Marcelo A.; Kim, Brian W.; Sato, Hiroyuki; Messaddeq, Nadia; Harney, John W.; Ezaki, Osamu; Kodama, Tatsuhiko; Schoonjans, Kristina; Bianco, Antonio C.; Auwerx, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7075</span>),
    <span class="NLM_cas:pages">484-489</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">While bile acids (BAs) have long been known to be essential in dietary lipid absorption and cholesterol catabolism, in recent years an important role for BAs as signaling mols. has emerged.  BAs activate mitogen-activated protein kinase pathways, are ligands for the G-protein-coupled receptor (GPCR) TGR5 and activate nuclear hormone receptors such as farnesoid X receptor α (FXR-α; NR1H4).  FXR-α regulates the enterohepatic recycling and biosynthesis of BAs by controlling the expression of genes such as the short heterodimer partner (SHP; NR0B2) that inhibits the activity of other nuclear receptors.  The FXR-α-mediated SHP induction also underlies the downregulation of the hepatic fatty acid and triglyceride biosynthesis and very-low-d. lipoprotein prodn. mediated by sterol-regulatory-element-binding protein 1c.  This indicates that BAs might be able to function beyond the control of BA homeostasis as general metabolic integrators.  The administration of BAs to mice increases energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin.  This novel metabolic effect of BAs is critically dependent on induction of the cyclic-AMP-dependent thyroid hormone activating enzyme type 2 iodothyronine deiodinase (D2) because it is lost in D2-/- mice.  Treatment of brown adipocytes and human skeletal myocytes with BA increases D2 activity and oxygen consumption.  These effects are independent of FXR-α, and instead are mediated by increased cAMP prodn. that stems from the binding of BAs with the G-protein-coupled receptor TGR5.  In both rodents and humans, the most thermogenically important tissues are specifically targeted by this mechanism because they coexpress D2 and TGR5.  The BA-TGR5-cAMP-D2 signaling pathway is therefore a crucial mechanism for fine-tuning energy homeostasis that can be targeted to improve metabolic control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvq784CAfKkrVg90H21EOLACvtfcHk0liyRueaGiadEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFWmuw%253D%253D&md5=13c8bfe241fac294ba3fb1de99577d67</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature04330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04330%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DHouten%26aufirst%3DS.%2BM.%26aulast%3DMataki%26aufirst%3DC.%26aulast%3DChristoffolete%26aufirst%3DM.%2BA.%26aulast%3DKim%26aufirst%3DB.%2BW.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMessaddeq%26aufirst%3DN.%26aulast%3DHarney%26aufirst%3DJ.%2BW.%26aulast%3DEzaki%26aufirst%3DO.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DBianco%26aufirst%3DA.%2BC.%26aulast%3DAuwerx%26aufirst%3DJ.%26atitle%3DBile%2520acids%2520induce%2520energy%2520expenditure%2520by%2520promoting%2520intracellular%2520thyroid%2520hormone%2520activation%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D484%26epage%3D489%26doi%3D10.1038%2Fnature04330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Broeders, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nascimento, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havekes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roumans, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tailleux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvy, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottaghy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Marken Lichtenbelt, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrauwen, P.</span><span> </span><span class="NLM_article-title">The bile acid chenodeoxycholic acid increases human brown adipose tissue activity</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">418</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1016/j.cmet.2015.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.cmet.2015.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=26235421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=418-426&author=E.+P.+Broedersauthor=E.+B.+Nascimentoauthor=B.+Havekesauthor=B.+Bransauthor=K.+H.+Roumansauthor=A.+Tailleuxauthor=G.+Schaartauthor=M.+Kouachauthor=J.+Chartonauthor=B.+Deprezauthor=N.+D.+Bouvyauthor=F.+Mottaghyauthor=B.+Staelsauthor=W.+D.+van+Marken+Lichtenbeltauthor=P.+Schrauwen&title=The+bile+acid+chenodeoxycholic+acid+increases+human+brown+adipose+tissue+activity&doi=10.1016%2Fj.cmet.2015.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity</span></div><div class="casAuthors">Broeders, Evie P. M.; Nascimento, Emmani B. M.; Havekes, Bas; Brans, Boudewijn; Roumans, Kay H. M.; Tailleux, Anne; Schaart, Gert; Kouach, Mostafa; Charton, Julie; Deprez, Benoit; Bouvy, Nicole D.; Mottaghy, Felix; Staels, Bart; van Marken Lichtenbelt, Wouter D.; Schrauwen, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">418-426</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.  In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.  Here we examd. the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.  Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.  Whole-body energy expenditure was also increased upon CDCA treatment.  In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.  These findings identify bile acids as a target to activate BAT in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIqcIdgYe7ArVg90H21EOLACvtfcHk0liyRueaGiadEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbfM&md5=29e30c2fae177db869be0fe7fde441f6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DBroeders%26aufirst%3DE.%2BP.%26aulast%3DNascimento%26aufirst%3DE.%2BB.%26aulast%3DHavekes%26aufirst%3DB.%26aulast%3DBrans%26aufirst%3DB.%26aulast%3DRoumans%26aufirst%3DK.%2BH.%26aulast%3DTailleux%26aufirst%3DA.%26aulast%3DSchaart%26aufirst%3DG.%26aulast%3DKouach%26aufirst%3DM.%26aulast%3DCharton%26aufirst%3DJ.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DBouvy%26aufirst%3DN.%2BD.%26aulast%3DMottaghy%26aufirst%3DF.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3Dvan%2BMarken%2BLichtenbelt%26aufirst%3DW.%2BD.%26aulast%3DSchrauwen%26aufirst%3DP.%26atitle%3DThe%2520bile%2520acid%2520chenodeoxycholic%2520acid%2520increases%2520human%2520brown%2520adipose%2520tissue%2520activity%26jtitle%3DCell%2520Metab.%26date%3D2015%26volume%3D22%26spage%3D418%26epage%3D426%26doi%3D10.1016%2Fj.cmet.2015.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lavoie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balemba, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassileva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mawe, G. M.</span><span> </span><span class="NLM_article-title">Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels</span> <span class="citation_source-journal">J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">588</span><span class="NLM_x">, </span> <span class="NLM_fpage">3295</span><span class="NLM_x">–</span> <span class="NLM_lpage">3305</span><span class="refDoi"> DOI: 10.1113/jphysiol.2010.192146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1113%2Fjphysiol.2010.192146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=20624794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2rur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=588&publication_year=2010&pages=3295-3305&author=B.+Lavoieauthor=O.+B.+Balembaauthor=C.+Godfreyauthor=C.+A.+Watsonauthor=G.+Vassilevaauthor=C.+U.+Corveraauthor=M.+T.+Nelsonauthor=G.+M.+Mawe&title=Hydrophobic+bile+salts+inhibit+gallbladder+smooth+muscle+function+via+stimulation+of+GPBAR1+receptors+and+activation+of+KATP+channels&doi=10.1113%2Fjphysiol.2010.192146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels</span></div><div class="casAuthors">Lavoie, Brigitte; Balemba, Onesmo B.; Godfrey, Cody; Watson, Conall A.; Vassileva, Galya; Corvera, Carlos U.; Nelson, Mark T.; Mawe, Gary M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">588</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3295-3305</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Hydrophobic bile salts are thought to contribute to the disruption of gallbladder smooth muscle (GBSM) function that occurs in gallstone disease, but their mechanism of action is unknown.  The current study was undertaken to det. how hydrophobic bile salts interact with GBSM, and how they reduce GBSM activity.  The effect of hydrophobic bile salts on the activity of GBSM was measured by intracellular recording and calcium imaging using wholemount prepns. from guinea pig and mouse gallbladder.  RT-PCR and immunohistochem. were used to evaluate expression of the G protein-coupled bile acid receptor, GPBAR1.  Application of tauro-chenodeoxycholate (CDC, 50-100 μM) to in situ GBSM rapidly reduced spontaneous Ca2+ flashes and action potentials, and caused a membrane hyperpolarization.  Immunoreactivity and transcript for GPBAR1 were detected in gallbladder muscularis.  The GPBAR1 agonist, tauro-lithocholic acid (LCA, 10 μM) mimicked the effect of CDC on GBSM.  The actions of LCA were blocked by the protein kinase A (PKA) inhibitor, KT5720 (0.5-1.0 μM) and the KATP channel blocker, glibenclamide (10 μM).  Furthermore, LCA failed to disrupt GBSM activity in Gpbar1-/- mice.  The findings of this study indicate that hydrophobic bile salts activate GPBAR1 on GBSM, and this leads to activation of the cAMP-PKA pathway, and ultimately the opening of KATP channels, thus hyperpolarizing the membrane and decreasing GBSM activity.  This inhibitory effect of hydrophobic bile salt activation of GPBAR1 could be a contributing factor in the manifestation of gallstone disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFGGa0RZVV67Vg90H21EOLACvtfcHk0ljXM9E_rh5aSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2rur%252FP&md5=d9f817f60f8ba9f97b20958af25c875e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2010.192146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2010.192146%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DB.%26aulast%3DBalemba%26aufirst%3DO.%2BB.%26aulast%3DGodfrey%26aufirst%3DC.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DVassileva%26aufirst%3DG.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26aulast%3DNelson%26aufirst%3DM.%2BT.%26aulast%3DMawe%26aufirst%3DG.%2BM.%26atitle%3DHydrophobic%2520bile%2520salts%2520inhibit%2520gallbladder%2520smooth%2520muscle%2520function%2520via%2520stimulation%2520of%2520GPBAR1%2520receptors%2520and%2520activation%2520of%2520KATP%2520channels%26jtitle%3DJ.%2520Physiol.%26date%3D2010%26volume%3D588%26spage%3D3295%26epage%3D3305%26doi%3D10.1113%2Fjphysiol.2010.192146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Keitel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cupisti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoefel, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Häussinger, D.</span><span> </span><span class="NLM_article-title">The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">870</span><span class="refDoi"> DOI: 10.1002/hep.23032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1002%2Fhep.23032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=861-870&author=V.+Keitelauthor=K.+Cupistiauthor=C.+Ullmerauthor=W.+T.+Knoefelauthor=R.+Kubitzauthor=D.+H%C3%A4ussinger&title=The+membrane-bound+bile+acid+receptor+TGR5+is+localized+in+the+epithelium+of+human+gallbladders&doi=10.1002%2Fhep.23032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.23032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23032%26sid%3Dliteratum%253Aachs%26aulast%3DKeitel%26aufirst%3DV.%26aulast%3DCupisti%26aufirst%3DK.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DKnoefel%26aufirst%3DW.%2BT.%26aulast%3DKubitz%26aufirst%3DR.%26aulast%3DH%25C3%25A4ussinger%26aufirst%3DD.%26atitle%3DThe%2520membrane-bound%2520bile%2520acid%2520receptor%2520TGR5%2520is%2520localized%2520in%2520the%2520epithelium%2520of%2520human%2520gallbladders%26jtitle%3DHepatology%26date%3D2009%26volume%3D50%26spage%3D861%26epage%3D870%26doi%3D10.1002%2Fhep.23032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Alemi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattaruzza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cevikbas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero-Alba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez-Morales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnett, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span> </span><span class="NLM_article-title">The TGR5 receptor mediates bile acid-induced itch and analgesia</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1172/JCI64551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1172%2FJCI64551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=23524965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVKhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=1513-1530&author=F.+Alemiauthor=E.+Kwonauthor=D.+P.+Pooleauthor=T.+Lieuauthor=V.+Lyoauthor=F.+Cattaruzzaauthor=F.+Cevikbasauthor=M.+Steinhoffauthor=R.+Nassiniauthor=S.+Materazziauthor=R.+Guerrero-Albaauthor=E.+Valdez-Moralesauthor=G.+S.+Cottrellauthor=K.+Schoonjansauthor=P.+Geppettiauthor=S.+J.+Vannerauthor=N.+W.+Bunnettauthor=C.+U.+Corvera&title=The+TGR5+receptor+mediates+bile+acid-induced+itch+and+analgesia&doi=10.1172%2FJCI64551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The TGR5 receptor mediates bile acid-induced itch and analgesia</span></div><div class="casAuthors">Alemi, Farzad; Kwon, Edwin; Poole, Daniel P.; Lieu, TinaMarie; Lyo, Victoria; Cattaruzza, Fiore; Cevikbas, Ferda; Steinhoff, Martin; Nassini, Romina; Materazzi, Serena; Guerrero-Alba, Raquel; Valdez-Morales, Eduardo; Cottrell, Graeme S.; Schoonjans, Kristina; Geppetti, Pierangelo; Vanner, Stephen J.; Bunnett, Nigel W.; Corvera, Carlos U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1513-1530</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Patients with cholestatic disease exhibit pruritus and analgesia, but the mechanisms underlying these symptoms are unknown.  We report that bile acids, which are elevated in the circulation and tissues during cholestasis, cause itch and analgesia by activating the GPCR TGR5.  TGR5 was detected in peptidergic neurons of mouse dorsal root ganglia and spinal cord that transmit itch and pain, and in dermal macrophages that contain opioids.  Bile acids and a TGR5-selective agonist induced hyperexcitability of dorsal root ganglia neurons and stimulated the release of the itch and analgesia transmitters gastrin-releasing peptide and leucine-enkephalin.  Intradermal injection of bile acids and a TGR5-selective agonist stimulated scratching behavior by gastrin-releasing peptide- and opioid-dependent mechanisms in mice.  Scratching was attenuated in Tgr5-KO mice but exacerbated in Tgr5-Tg mice (overexpressing mouse TGR5), which exhibited spontaneous pruritus.  Intraplantar and intrathecal injection of bile acids caused analgesia to mech. stimulation of the paw by an opioid-dependent mechanism.  Both peripheral and central mechanisms of analgesia were absent from Tgr5-KO mice.  Thus, bile acids activate TGR5 on sensory nerves, stimulating the release of neuropeptides in the spinal cord that transmit itch and analgesia.  These mechanisms could contribute to pruritus and painless jaundice that occur during cholestatic liver diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo96EIvqKSC4rVg90H21EOLACvtfcHk0ljXM9E_rh5aSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVKhsL8%253D&md5=cd059ff96952743f065d002d7eb2d1cd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1172%2FJCI64551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64551%26sid%3Dliteratum%253Aachs%26aulast%3DAlemi%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DE.%26aulast%3DPoole%26aufirst%3DD.%2BP.%26aulast%3DLieu%26aufirst%3DT.%26aulast%3DLyo%26aufirst%3DV.%26aulast%3DCattaruzza%26aufirst%3DF.%26aulast%3DCevikbas%26aufirst%3DF.%26aulast%3DSteinhoff%26aufirst%3DM.%26aulast%3DNassini%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DS.%26aulast%3DGuerrero-Alba%26aufirst%3DR.%26aulast%3DValdez-Morales%26aufirst%3DE.%26aulast%3DCottrell%26aufirst%3DG.%2BS.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DVanner%26aufirst%3DS.%2BJ.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26atitle%3DThe%2520TGR5%2520receptor%2520mediates%2520bile%2520acid-induced%2520itch%2520and%2520analgesia%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D1513%26epage%3D1530%26doi%3D10.1172%2FJCI64551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Futatsugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahnck, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman-Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinchey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowski, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roush, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolford, A. C.</span><span> </span><span class="NLM_article-title">Optimization of triazole-based TGR5 agonists towards orally available agents</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1039/C2MD20174G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1039%2FC2MD20174G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=205-210&author=K.+Futatsugiauthor=K.+B.+Bahnckauthor=M.+B.+Brennerauthor=J.+Buxtonauthor=J.+E.+Chinauthor=S.+B.+Coffeyauthor=J.+Dubinsauthor=D.+Flynnauthor=D.+Gautreauauthor=A.+Guzman-Perezauthor=J.+R.+Hadcockauthor=D.+Hepworthauthor=M.+Herrauthor=T.+Hincheyauthor=A.+M.+Janssenauthor=S.+M.+Jenningsauthor=W.+Jiaoauthor=S.+Y.+Lavergneauthor=B.+Liauthor=M.+Liauthor=M.+J.+Munchhofauthor=S.+T.+M.+Orrauthor=D.+W.+Piotrowskiauthor=N.+S.+Roushauthor=M.+Sammonsauthor=B.+D.+Stevensauthor=G.+Storerauthor=J.+Wangauthor=J.+S.+Warmusauthor=L.+Weiauthor=A.+C.+Wolford&title=Optimization+of+triazole-based+TGR5+agonists+towards+orally+available+agents&doi=10.1039%2FC2MD20174G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1039%2FC2MD20174G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20174G%26sid%3Dliteratum%253Aachs%26aulast%3DFutatsugi%26aufirst%3DK.%26aulast%3DBahnck%26aufirst%3DK.%2BB.%26aulast%3DBrenner%26aufirst%3DM.%2BB.%26aulast%3DBuxton%26aufirst%3DJ.%26aulast%3DChin%26aufirst%3DJ.%2BE.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DDubins%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DGautreau%26aufirst%3DD.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHerr%26aufirst%3DM.%26aulast%3DHinchey%26aufirst%3DT.%26aulast%3DJanssen%26aufirst%3DA.%2BM.%26aulast%3DJennings%26aufirst%3DS.%2BM.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DLavergne%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DRoush%26aufirst%3DN.%2BS.%26aulast%3DSammons%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DStorer%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWolford%26aufirst%3DA.%2BC.%26atitle%3DOptimization%2520of%2520triazole-based%2520TGR5%2520agonists%2520towards%2520orally%2520available%2520agents%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D205%26epage%3D210%26doi%3D10.1039%2FC2MD20174G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Piotrowski, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futatsugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman-Cook, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Londregan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolford, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roush, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinchey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. A.</span><span> </span><span class="NLM_article-title">Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1021/ml300277t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300277t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=63-68&author=D.+W.+Piotrowskiauthor=K.+Futatsugiauthor=J.+S.+Warmusauthor=S.+T.+Orrauthor=K.+D.+Freeman-Cookauthor=A.+T.+Londreganauthor=L.+Weiauthor=S.+M.+Jenningsauthor=M.+Herrauthor=S.+B.+Coffeyauthor=W.+Jiaoauthor=G.+Storerauthor=D.+Hepworthauthor=J.+Wangauthor=S.+Y.+Lavergneauthor=J.+E.+Chinauthor=J.+R.+Hadcockauthor=M.+B.+Brennerauthor=A.+C.+Wolfordauthor=A.+M.+Janssenauthor=N.+S.+Roushauthor=J.+Buxtonauthor=T.+Hincheyauthor=A.+S.+Kalgutkarauthor=R.+Sharmaauthor=D.+A.+Flynn&title=Identification+of+tetrahydropyrido%5B4%2C3-d%5Dpyrimidine+amides+as+a+new+class+of+orally+bioavailable+TGR5+agonists&doi=10.1021%2Fml300277t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists</span></div><div class="casAuthors">Piotrowski, David W.; Futatsugi, Kentaro; Warmus, Joseph S.; Orr, Suvi T. M.; Freeman-Cook, Kevin D.; Londregan, Allyn T.; Wei, Liuqing; Jennings, Sandra M.; Herr, Michael; Coffey, Steven B.; Jiao, Wenhua; Storer, Gregory; Hepworth, David; Wang, Jian; Lavergne, Sophie Y.; Chin, Janice E.; Hadcock, John R.; Brenner, Martin B.; Wolford, Angela C.; Janssen, Ann M.; Roush, Nicole S.; Buxton, Joanne; Hinchey, Terri; Kalgutkar, Amit S.; Sharma, Raman; Flynn, Declan A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-68</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Takeda G-protein-coupled receptor 5 (TGR5) represents an exciting biol. target for the potential treatment of diabetes and metabolic syndrome.  A new class of high-throughput screening (HTS)-derived tetrahydropyrido[4,3-d]pyrimidine amide TGR5 agonists is disclosed.  We describe our effort to identify an orally available agonist suitable for assessment of systemic TGR5 agonism.  This effort resulted in identification of I, which had acceptable potency and pharmacokinetic properties to allow for in vivo assessment in dog.  A key aspect of this work was the calibration of human and dog in vitro assay systems that could be linked with data from a human ex vivo peripheral blood monocyte assay that expresses receptor at endogenous levels.  Potency from the human in vitro assay was also found to correlate with data from an ex vivo human whole blood assay.  This calibration exercise provided confidence that I could be used to drive plasma exposures sufficient to test the effects of systemic activation of TGR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQmElgFEINRbVg90H21EOLACvtfcHk0lginjEuTypLrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrfP&md5=7806a5272db5d3b6bc935f6df38a2b04</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml300277t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300277t%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DFutatsugi%26aufirst%3DK.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DLondregan%26aufirst%3DA.%2BT.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DJennings%26aufirst%3DS.%2BM.%26aulast%3DHerr%26aufirst%3DM.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DStorer%26aufirst%3DG.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLavergne%26aufirst%3DS.%2BY.%26aulast%3DChin%26aufirst%3DJ.%2BE.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DBrenner%26aufirst%3DM.%2BB.%26aulast%3DWolford%26aufirst%3DA.%2BC.%26aulast%3DJanssen%26aufirst%3DA.%2BM.%26aulast%3DRoush%26aufirst%3DN.%2BS.%26aulast%3DBuxton%26aufirst%3DJ.%26aulast%3DHinchey%26aufirst%3DT.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DFlynn%26aufirst%3DD.%2BA.%26atitle%3DIdentification%2520of%2520tetrahydropyrido%255B4%252C3-d%255Dpyrimidine%2520amides%2520as%2520a%2520new%2520class%2520of%2520orally%2520bioavailable%2520TGR5%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D63%26epage%3D68%26doi%3D10.1021%2Fml300277t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fryer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nodop Mazurek, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaude, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skow, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthukumarana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilpin, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinallo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanyal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harcken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modis, L. K.</span><span> </span><span class="NLM_article-title">G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K<sub>Ca</sub>1.1 (BK<sub>Ca</sub>)-dependent mechanism</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1124/jpet.113.210005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1124%2Fjpet.113.210005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=24399854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFajtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=421-431&author=R.+M.+Fryerauthor=K.+J.+Ngauthor=S.+G.+Nodop+Mazurekauthor=L.+Patnaudeauthor=D.+J.+Skowauthor=A.+Muthukumaranaauthor=K.+E.+Gilpinauthor=R.+M.+Dinalloauthor=D.+Kuzmichauthor=J.+Lordauthor=S.+Sanyalauthor=H.+Yuauthor=C.+Harckenauthor=M.+A.+Cernyauthor=M.+C.+Cernyauthor=E.+R.+Hickeyauthor=L.+K.+Modis&title=G+protein-coupled+bile+acid+receptor+1+stimulation+mediates+arterial+vasodilation+through+a+KCa1.1+%28BKCa%29-dependent+mechanism&doi=10.1124%2Fjpet.113.210005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a KCa1.1 (BKCa)-dependent mechanism</span></div><div class="casAuthors">Fryer, Ryan M.; Ng, Khing Jow; Mazurek, Suzanne G. Nodop; Patnaude, Lori; Skow, Donna J.; Muthukumarana, Akalushi; Gilpin, Kyle E.; Dinallo, Roger M.; Kuzmich, Daniel; Lord, John; Sanyal, Sulagna; Yu, Hui; Harcken, Christian; Cerny, Matthew C.; Hickey, Eugene R.; Modis, Louise K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-431, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bile acids (BAs) and BA receptors, including G protein-coupled bile acid receptor 1 (GPBAR1), represent novel targets for the treatment of metabolic and inflammatory disorders.  However, BAs elicit myriad effects on cardiovascular function, although this has not been specifically ascribed to GPBAR1.  This study was designed to test whether stimulation of GPBAR1 elicits effects on cardiovascular function that are mechanism based that can be identified in acute ex vivo and in vivo cardiovascular models, to delineate whether effects were due to pathways known to be modulated by BAs, and to establish whether a therapeutic window between in vivo cardiovascular liabilities and on-target efficacy could be defined.  The results demonstrated that the infusion of three structurally diverse and selective GPBAR1 agonists produced marked redns. in vascular tone and blood pressure in dog, but not in rat, as well as reflex tachycardia and a pos. inotropic response, effects that manifested in an enhanced cardiac output.  Changes in cardiovascular function were unrelated to modulation of the levothyroxine/thyroxine axis and were nitric oxide independent.  A direct effect on vascular tone was confirmed in dog isolated vascular rings, whereby concn.-dependent decreases in tension that were tightly correlated with redns. in vascular tone obsd. in vivo and were blocked by iberiotoxin.  Compd. concns. in which cardiovascular effects occurred, both ex vivo and in vivo, could not be sepd. from those necessary for modulation of GPBAR1-mediated efficacy, resulting in project termination.  These results are the first to clearly demonstrate direct and potent peripheral arterial vasodilation due to GPBAR1 stimulation in vivo through activation of large conductance Ca2+ activated potassium channel KCa1.1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbGVwYRqt84LVg90H21EOLACvtfcHk0liZ8SnurR1whQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFajtL0%253D&md5=fe48570c7b439077da6787b5a292d369</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210005%26sid%3Dliteratum%253Aachs%26aulast%3DFryer%26aufirst%3DR.%2BM.%26aulast%3DNg%26aufirst%3DK.%2BJ.%26aulast%3DNodop%2BMazurek%26aufirst%3DS.%2BG.%26aulast%3DPatnaude%26aufirst%3DL.%26aulast%3DSkow%26aufirst%3DD.%2BJ.%26aulast%3DMuthukumarana%26aufirst%3DA.%26aulast%3DGilpin%26aufirst%3DK.%2BE.%26aulast%3DDinallo%26aufirst%3DR.%2BM.%26aulast%3DKuzmich%26aufirst%3DD.%26aulast%3DLord%26aufirst%3DJ.%26aulast%3DSanyal%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DHarcken%26aufirst%3DC.%26aulast%3DCerny%26aufirst%3DM.%2BA.%26aulast%3DCerny%26aufirst%3DM.%2BC.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DModis%26aufirst%3DL.%2BK.%26atitle%3DG%2520protein-coupled%2520bile%2520acid%2520receptor%25201%2520stimulation%2520mediates%2520arterial%2520vasodilation%2520through%2520a%2520KCa1.1%2520%2528BKCa%2529-dependent%2520mechanism%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D421%26epage%3D431%26doi%3D10.1124%2Fjpet.113.210005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Charmot, D.</span><span> </span><span class="NLM_article-title">Non-systemic drugs: a critical review</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1434</span><span class="NLM_x">–</span> <span class="NLM_lpage">1445</span><span class="refDoi"> DOI: 10.2174/138161212799504858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.2174%2F138161212799504858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=22300258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1434-1445&author=D.+Charmot&title=Non-systemic+drugs%3A+a+critical+review&doi=10.2174%2F138161212799504858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Non-systemic drugs: a critical review</span></div><div class="casAuthors">Charmot, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1434-1445</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation.  The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia.  The field has evolved towards non-absorbable small mols. or peptides targeting luminal enzymes or transporters for the treatment of mineral metab. disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections.  From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation.  The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia.  We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations.  The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdEQRhLF7irVg90H21EOLACvtfcHk0liZ8SnurR1whQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D&md5=7a391aa741bb1a4bba9516b0f39acee1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F138161212799504858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212799504858%26sid%3Dliteratum%253Aachs%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DNon-systemic%2520drugs%253A%2520a%2520critical%2520review%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D1434%26epage%3D1445%26doi%3D10.2174%2F138161212799504858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Duan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span> </span><span class="NLM_article-title">Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3315</span><span class="NLM_x">–</span> <span class="NLM_lpage">3328</span><span class="refDoi"> DOI: 10.1021/jm500829b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500829b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtF2ktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3315-3328&author=H.+Duanauthor=M.+Ningauthor=Q.+Zouauthor=Y.+Yeauthor=Y.+Fengauthor=L.+Zhangauthor=Y.+Lengauthor=J.+Shen&title=Discovery+of+intestinal+targeted+TGR5+agonists+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm500829b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Duan, Hongliang; Ning, Mengmeng; Zou, Qingan; Ye, Yangliang; Feng, Ying; Zhang, Lina; Leng, Ying; Shen, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3315-3328</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects.  A series of low-absorbed TGR5 agonists was prepd. by modifying compd. 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine.  Compd. 15c, with a mol. wt. of 1401, a PSA value of 223 Å2, and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo.  Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-mol. TGR5 agonist 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-HVYzFsOrfbVg90H21EOLACvtfcHk0liZ8SnurR1whQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtF2ktb0%253D&md5=527ba4d3e48e8f01f76bb7e88127d080</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm500829b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500829b%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DNing%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520intestinal%2520targeted%2520TGR5%2520agonists%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3315%26epage%3D3328%26doi%3D10.1021%2Fjm500829b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Cao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, M.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Q.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.-H.</span><span> </span><span class="NLM_article-title">Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">28676</span><span class="refDoi"> DOI: 10.1038/srep28676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1038%2Fsrep28676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=27339735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=28676&author=H.+Caoauthor=Z.-X.+Chenauthor=K.+Wangauthor=M.-M.+Ningauthor=Q.-A.+Zouauthor=Y.+Fengauthor=Y.-L.+Yeauthor=Y.+Lengauthor=J.-H.+Shen&title=Intestinally-targeted+TGR5+agonists+equipped+with+quaternary+ammonium+have+an+improved+hypoglycemic+effect+and+reduced+gallbladder+filling+effect&doi=10.1038%2Fsrep28676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect</span></div><div class="casAuthors">Cao, Hua; Chen, Zhi-Xiang; Wang, Kai; Ning, Meng-Meng; Zou, Qing-An; Feng, Ying; Ye, Yang-Liang; Leng, Ying; Shen, Jian-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">28676</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TGR5 activation of enteroendocrine cells increases glucagon-like peptide 1 (GLP-1) release, which maintains glycemic homeostasis.  However, TGR5 activation in the gallbladder and heart is assocd. with severe side effects.  Therefore, intestinally-targeted TGR5 agonists were suggested as potential hypoglycemic agents with minimal side effects.  However, until now no such compds. with robust glucose-lowering effects were reported, esp. in diabetic animal models.  Herein, we identify a TGR5 agonist, 26a, which was proven to be intestinally-targeted through pharmacokinetic studies.  26A was used as a tool drug to verify the intestinally-targeted strategy. 26a displayed a robust and long-lasting hypoglycemic effect in ob/ob mice (once a day dosing (QD) and 18-day treatment) owing to sustained stimulation of GLP-1 secretion, which suggested that robust hypoglycemic effect could be achieved with activation of TGR5 in intestine alone.  However, the gallbladder filling effect of 26a was rather complicated.  Although the gallbladder filling effect of 26a was decreased in mice after once a day dosing, this side effect was still not eliminated.  To solve the problem above, several research strategies were raised for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOH1FDqJK-brVg90H21EOLACvtfcHk0ljJilySh95Bxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKiurrM&md5=9d82249704d95dde0ecf5bc76e67eaab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fsrep28676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep28676%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.-X.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DNing%26aufirst%3DM.-M.%26aulast%3DZou%26aufirst%3DQ.-A.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.-L.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.-H.%26atitle%3DIntestinally-targeted%2520TGR5%2520agonists%2520equipped%2520with%2520quaternary%2520ammonium%2520have%2520an%2520improved%2520hypoglycemic%2520effect%2520and%2520reduced%2520gallbladder%2520filling%2520effect%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D28676%26doi%3D10.1038%2Fsrep28676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kramer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glombik, H.</span><span> </span><span class="NLM_article-title">Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1016</span><span class="refDoi"> DOI: 10.2174/092986706776361003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.2174%2F092986706776361003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=16611081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslKqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=997-1016&author=W.+Kramerauthor=H.+Glombik&title=Bile+acid+reabsorption+inhibitors+%28BARI%29%3A+novel+hypolipidemic+drugs&doi=10.2174%2F092986706776361003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs</span></div><div class="casAuthors">Kramer, Werner; Glombik, Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">997-1016</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The enterohepatic circulation of bile acids is a major regulator of serum cholesterol homeostasis.  After biosynthesis from cholesterol in the liver, bile acids are secreted with bile into the lumen of the small intestine to aid in the digestion and absorption of fat and fat-sol. vitamins.  The bile acids are nearly quant. reabsorbed in the terminal ileum by a Na+-dependent transport system (IBAT) and are transported with portal blood to the liver and taken up by a second Na+-/bile acid cotransporter (LBAT) to be resecreted into bile.  In the liver bile acids inhibit the rate-limiting enzyme for the conversion of cholesterol into bile acid: cholesterol-7α-hydroxylase; interruption of the enterohepatic circulation of bile acids withdraws this feedback inhibition and leads to an upregulation of hepatic LDL-receptors with a concomitant decrease of serum LDL-levels.  Specific inhibitors of the ileal bile acid transporter belonging to different chemotypes have been developed in recent years for this purpose, some now entering clin. stage.  To exert a profound systemic effect these compds. do not need to be available systemically but can act from the luminal side of the small intestine, which offers the advantage to avoid the well-known adverse side effects of other hypolipidemic drugs like statins due to metab. and drug-drug interactions in the liver.  This implies several aspects in compd. optimization and drug development quite different from std. procedures, for example the concept of low absorption drugs was established to avoid systemic side effects.  This review article covers the mechanistic and therapeutic principles of the approach and presents an overview on the mol. target, the discovery of specific inhibitors and resp. optimization strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXNSDtAqiZbVg90H21EOLACvtfcHk0ljJilySh95Bxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslKqtLs%253D&md5=8411f5d6f3e3218ad5ba6cb8fe2075c4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F092986706776361003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706776361003%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DW.%26aulast%3DGlombik%26aufirst%3DH.%26atitle%3DBile%2520acid%2520reabsorption%2520inhibitors%2520%2528BARI%2529%253A%2520novel%2520hypolipidemic%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D997%26epage%3D1016%26doi%3D10.2174%2F092986706776361003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Bollu, V.; Boren, B. C.; Dalgard, J. E.; Flatt, B. T.; HAQ, N.; Hudson, S.; Mohan, R.; Morrissey, M.; Pratt, B.; Wang, T.-L.</span> Triazole and Imidazole Derivatives for Use as TGR5 Agonists in the Treatment of Diabetes and Obesity. World Patent WO2010/093845,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bollu%2C+V.%3B+Boren%2C+B.+C.%3B+Dalgard%2C+J.+E.%3B+Flatt%2C+B.+T.%3B+HAQ%2C+N.%3B+Hudson%2C+S.%3B+Mohan%2C+R.%3B+Morrissey%2C+M.%3B+Pratt%2C+B.%3B+Wang%2C+T.-L.+Triazole+and+Imidazole+Derivatives+for+Use+as+TGR5+Agonists+in+the+Treatment+of+Diabetes+and+Obesity.+World+Patent+WO2010%2F093845%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBollu%26aufirst%3DV.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zamansky, I.; Galvin, G.; Girardet, J.-L.</span> Polymorphic, Crystalline and Mesophase Forms of Sodium 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and Uses Thereof. World Patent WO/2011/085009,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Zamansky%2C+I.%3B+Galvin%2C+G.%3B+Girardet%2C+J.-L.+Polymorphic%2C+Crystalline+and+Mesophase+Forms+of+Sodium+2-%285-Bromo-4-%284-cyclopropylnaphthalen-1-yl%29-4H-1%2C2%2C4-triazol-3-ylthio%29acetate%2C+and+Uses+Thereof.+World+Patent+WO%2F2011%2F085009%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZamansky%26aufirst%3DI.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lasalle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajaa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoguet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Obbergen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roussel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charton, J.</span><span> </span><span class="NLM_article-title">Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P)</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2015.01.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.tetlet.2015.01.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=1011-1014&author=M.+Lasalleauthor=S.+Piconauthor=B.+Rajaaauthor=V.+Hoguetauthor=J.+Van+Obbergenauthor=P.+Rousselauthor=B.+Deprezauthor=J.+Charton&title=Access+to+newly+functionalized+imidazole+derivatives%3A+efficient+synthesis+of+novel+5-amino-2-thioimidazoles+using+propylphosphonic+anhydride+%28%C2%AET3P%29&doi=10.1016%2Fj.tetlet.2015.01.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P)</span></div><div class="casAuthors">Lasalle, Manuel; Picon, Sylvain; Boulahjar, Rajaa; Hoguet, Vanessa; Van Obbergen, Jolien; Roussel, Pascal; Deprez, Benoit; Charton, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1011-1014</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We describe here an efficient method to synthesize 5-amino-2-thioimidazole compds. by T3P-mediated cyclization of N-acetamidoisothiourea intermediates.  E.g., in presence of T3P, cyclization/cyclodehydration of N-acetamidoisothiourea intermediate (I) gave 58% imidazole deriv. (II).  The newly functionalized 5-amino-2-thioimidazole compds. are finally obtained in 5 steps from an amine as starting block.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDvXr2kChRcLVg90H21EOLACvtfcHk0lgm3BKThOryZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFerug%253D%253D&md5=9bbd1dc423a88c19aea1808c85f3472b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2015.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2015.01.046%26sid%3Dliteratum%253Aachs%26aulast%3DLasalle%26aufirst%3DM.%26aulast%3DPicon%26aufirst%3DS.%26aulast%3DRajaa%26aufirst%3DB.%26aulast%3DHoguet%26aufirst%3DV.%26aulast%3DVan%2BObbergen%26aufirst%3DJ.%26aulast%3DRoussel%26aufirst%3DP.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DCharton%26aufirst%3DJ.%26atitle%3DAccess%2520to%2520newly%2520functionalized%2520imidazole%2520derivatives%253A%2520efficient%2520synthesis%2520of%2520novel%25205-amino-2-thioimidazoles%2520using%2520propylphosphonic%2520anhydride%2520%2528%25C2%25AET3P%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2015%26volume%3D56%26spage%3D1011%26epage%3D1014%26doi%3D10.1016%2Fj.tetlet.2015.01.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Fournie-Zaluski, M.-C.; Llorens-Cortes, C.; Roques, B. P.; Corvol, P.</span><span> </span><span class="NLM_article-title">Novel derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same</span>. US 2006/0135602,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.-C.+Fournie-Zaluski&author=C.+Llorens-Cortes&author=B.+P.+Roques&author=P.+Corvol&title=Novel+derivatives+of+4%2C4%E2%80%B2-dithiobis-%283-aminobutane-1-sulfphonates%29+and+compositions+containing+same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFournie-Zaluski%26aufirst%3DM.-C.%26atitle%3DNovel%2520derivatives%2520of%25204%252C4%25E2%2580%25B2-dithiobis-%25283-aminobutane-1-sulfphonates%2529%2520and%2520compositions%2520containing%2520same%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Egan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span> </span><span class="NLM_article-title">Prediction of drug absorption using multivariate statistics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3877</span><span class="refDoi"> DOI: 10.1021/jm000292e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&author=W.+J.+Eganauthor=K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+drug+absorption+using+multivariate+statistics&doi=10.1021%2Fjm000292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lgm3BKThOryZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520drug%2520absorption%2520using%2520multivariate%2520statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3867%26epage%3D3877%26doi%3D10.1021%2Fjm000292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span><span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0ljuEfckNYDvCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Palm, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artursson, P.</span><span> </span><span class="NLM_article-title">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1023/A:1012188625088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1023%2FA%3A1012188625088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=9165525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=568-571&author=K.+Palmauthor=P.+Stenbergauthor=K.+Luthmanauthor=P.+Artursson&title=Polar+molecular+surface+properties+predict+the+intestinal+absorption+of+drugs+in+humans&doi=10.1023%2FA%3A1012188625088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span></div><div class="casAuthors">Palm, Katrin; Stenberg, Patric; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum</span>)
        </div><div class="casAbstract">A theor. method was devised for prediction of drug absorption after oral administration to humans.  Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated.  The compds. also displayed diversity in physicochem. properties such as lipophilicity, hydrogen bonding potential and mol. size.  The dynamic mol. surface properties of the compds. were calcd., taking into account their 3-dimensional shape and flexibility.  An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar mol. surface area (PSAd) (r2 = 0.94).  The relationship was stronger than those obtained for more established predictors of drug absorption.  Drugs that are completely absorbed (FA > 90%) had a PSAd ≤ 60 Å2 while drugs that are < 10% absorbed had a PSAd ≥ 140 Å2.  PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW66hupHIyLVg90H21EOLACvtfcHk0ljuEfckNYDvCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D&md5=1394f0d1059e7d99ee02be977b92da8b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012188625088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012188625088%26sid%3Dliteratum%253Aachs%26aulast%3DPalm%26aufirst%3DK.%26aulast%3DStenberg%26aufirst%3DP.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DPolar%2520molecular%2520surface%2520properties%2520predict%2520the%2520intestinal%2520absorption%2520of%2520drugs%2520in%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D568%26epage%3D571%26doi%3D10.1023%2FA%3A1012188625088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmstrom, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umetani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangelsdorf, D. J.</span><span> </span><span class="NLM_article-title">The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling</span> <span class="citation_source-journal">Mol. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1066</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.1210/me.2010-0460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1210%2Fme.2010-0460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=21454404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsl2msLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1066-1071&author=T.+Liauthor=S.+R.+Holmstromauthor=S.+Kirauthor=M.+Umetaniauthor=D.+R.+Schmidtauthor=S.+A.+Kliewerauthor=D.+J.+Mangelsdorf&title=The+G+protein-coupled+bile+acid+receptor%2C+TGR5%2C+stimulates+gallbladder+filling&doi=10.1210%2Fme.2010-0460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling</span></div><div class="casAuthors">Li, Tingting; Holmstrom, Sam R.; Kir, Serkan; Umetani, Michihisa; Schmidt, Daniel R.; Kliewer, Steven A.; Mangelsdorf, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1066-1071</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">TGR5 is a G protein-coupled bile acid receptor present in brown adipose tissue and intestine, where its agonism increases energy expenditure and lowers blood glucose.  Thus, it is an attractive drug target for treating human metabolic disease.  However, TGR5 is also highly expressed in gallbladder, where its functions are less well characterized.  Here, we demonstrate that TGR5 stimulates the filling of the gallbladder with bile.  Gallbladder vol. was increased in wild-type but not Tgr5-/- mice by administration of either the naturally occurring TGR5 agonist, lithocholic acid, or the synthetic TGR5 agonist, INT-777.  These effects were independent of fibroblast growth factor 15, an enteric hormone previously shown to stimulate gallbladder filling.  Ex vivo analyses using gallbladder tissue showed that TGR5 activation increased cAMP concns. and caused smooth muscle relaxation in a TGR5-dependent manner.  These data reveal a novel, gallbladder-intrinsic mechanism for regulating gallbladder contractility.  They further suggest that TGR5 agonists should be assessed for effects on human gallbladder as they are developed for treating metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfl9_dLsVML7Vg90H21EOLACvtfcHk0ljuEfckNYDvCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsl2msLs%253D&md5=90d4a0754fe69f55b6a9b207351cd1a9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1210%2Fme.2010-0460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2010-0460%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DHolmstrom%26aufirst%3DS.%2BR.%26aulast%3DKir%26aufirst%3DS.%26aulast%3DUmetani%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMangelsdorf%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520G%2520protein-coupled%2520bile%2520acid%2520receptor%252C%2520TGR5%252C%2520stimulates%2520gallbladder%2520filling%26jtitle%3DMol.%2520Endocrinol.%26date%3D2011%26volume%3D25%26spage%3D1066%26epage%3D1071%26doi%3D10.1210%2Fme.2010-0460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Briere, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siesky, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez Sanfeliciano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suen, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coskun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M. D.</span><span> </span><span class="NLM_article-title">Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0136873</span><span class="refDoi"> DOI: 10.1371/journal.pone.0136873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1371%2Fjournal.pone.0136873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=26312995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0136873&author=D.+A.+Briereauthor=X.+Ruanauthor=C.+C.+Chengauthor=A.+M.+Sieskyauthor=T.+E.+Fitchauthor=C.+Dominguezauthor=S.+Gutierrez+Sanfelicianoauthor=C.+Monteroauthor=C.+S.+Suenauthor=Y.+Xuauthor=T.+Coskunauthor=M.+D.+Michael&title=Novel+small+molecule+agonist+of+TGR5+possesses+anti-diabetic+effects+but+causes+gallbladder+filling+in+mice&doi=10.1371%2Fjournal.pone.0136873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice</span></div><div class="casAuthors">Briere, Daniel A.; Ruan, Xiaoping; Cheng, Christine C.; Siesky, Angela M.; Fitch, Thomas E.; Dominguez, Carmen; Sanfeliciano, Sonia Gutierrez; Montero, Carlos; Suen, Chen S.; Xu, Yanping; Coskun, Tamer; Michael, M. Dodson</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0136873/1-e0136873/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Activation of TGR5 via bile acids or bile acid analogs leads to the release of glucagon-like peptide-1 (GLP-1) from intestine, increases energy expenditure in brown adipose tissue, and increases gallbladder filling with bile.  Here, we present compd. 18, a non-bile acid agonist of TGR5 that demonstrates robust GLP-1 secretion in a mouse enteroendocrine cell line yet weak GLP-1 secretion in a human enteroendocrine cell line.  Acute administration of compd. 18 to mice increased GLP-1 and peptide YY (PYY) secretion, leading to a lowering of the glucose excursion in an oral glucose tolerance test (OGTT), while chronic administration led to wt. loss.  In addn., compd. 18 showed a dose-dependent increase in gallbladder filling.  Lastly, compd. 18 failed to show similar pharmacol. effects on GLP-1, PYY, and gallbladder filling in Tgr5 knockout mice.  Together, these results demonstrate that compd. 18 is a mouse-selective TGR5 agonist that induces GLP-1 and PYY secretion, and lowers the glucose excursion in an OGTT, but only at doses that simultaneously induce gallbladder filling.  Overall, these data highlight the benefits and potential risks of using TGR5 agonists to treat diabetes and metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq_f7Nk17eNbVg90H21EOLACvtfcHk0lg3ulSamdgF4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFertw%253D%253D&md5=b3d4fe48455a9652c0f284ae62934e0f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0136873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0136873%26sid%3Dliteratum%253Aachs%26aulast%3DBriere%26aufirst%3DD.%2BA.%26aulast%3DRuan%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DC.%2BC.%26aulast%3DSiesky%26aufirst%3DA.%2BM.%26aulast%3DFitch%26aufirst%3DT.%2BE.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DGutierrez%2BSanfeliciano%26aufirst%3DS.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DSuen%26aufirst%3DC.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCoskun%26aufirst%3DT.%26aulast%3DMichael%26aufirst%3DM.%2BD.%26atitle%3DNovel%2520small%2520molecule%2520agonist%2520of%2520TGR5%2520possesses%2520anti-diabetic%2520effects%2520but%2520causes%2520gallbladder%2520filling%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0136873%26doi%3D10.1371%2Fjournal.pone.0136873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Brighton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rievaj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhre, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, F.</span><span> </span><span class="NLM_article-title">Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">3961</span><span class="NLM_x">–</span> <span class="NLM_lpage">3970</span><span class="refDoi"> DOI: 10.1210/en.2015-1321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1210%2Fen.2015-1321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=26280129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC28Xis1Ojur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=3961-3970&author=C.+A.+Brightonauthor=J.+Rievajauthor=R.+E.+Kuhreauthor=L.+L.+Glassauthor=K.+Schoonjansauthor=J.+J.+Holstauthor=F.+M.+Gribbleauthor=F.+Reimann&title=Bile+acids+trigger+GLP-1+release+predominantly+by+accessing+basolaterally+located+G+protein-coupled+bile+acid+receptors&doi=10.1210%2Fen.2015-1321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors</span></div><div class="casAuthors">Brighton, Cheryl A.; Rievaj, Juraj; Kuhre, Rune E.; Glass, Leslie L.; Schoonjans, Kristina; Holst, Jens J.; Gribble, Fiona M.; Reimann, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3961-3970</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Bile acids are well-recognized stimuli of glucagon-like peptide-1 (GLP-1) secretion.  This action has been attributed to activation of the G protein-coupled bile acid receptor GPBAR1(TGR5), although other potential bile acid sensors include the nuclear farnesoid receptor and the apical sodium coupled bile acid transporter ASBT.  The aim of this study was to identify pathways important for GLP-1 release and to det. whether bile acids target their receptors on GLP-1-secreting L-cells from the apical or basolateral compartment.  Using transgenic mice expressing fluorescent sensors specifically in L-cells, we obsd. that taurodeoxycholate (TDCA) and taurolithocholate (TLCA) increased intracellular cAMP and Ca2+.  In primary intestinal cultures, TDCA was a more potent GLP-1 secretagogue than taurocholate (TCA) and TLCA, correlating with a stronger Ca2+ response to TDCA.  Using small-vol. Ussing chambers optimized for measuring GLP-1 secretion, we found that both a GPBAR1 agonist and TDCA stimulated GLP-1 release better when applied from the basolateral than from the luminal direction and that luminal TDCA was ineffective when intestinal tissue was pretreated with an ASBT inhibitor.  ASBT inhibition had no significant effect in nonpolarized primary cultures.  Studies in the perfused rat gut confirmed that vascularly administered TDCA was more effective than luminal TDCA.  Intestinal primary cultures and Ussing chamber- mounted tissues from GPBAR1-knockout mice did not secrete GLP-1 in response to either TLCA or TDCA.  We conclude that the action of bile acids on GLP-1 secretion is predominantly mediated by GPBAR1 located on the basolateral L-cell membrane, suggesting that stimulation of gut hormone secretion may include postabsorptive mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopfu7ri_IsarVg90H21EOLACvtfcHk0lg3ulSamdgF4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xis1Ojur8%253D&md5=84e055a3542eaafd10875b3890e0eccc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1210%2Fen.2015-1321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2015-1321%26sid%3Dliteratum%253Aachs%26aulast%3DBrighton%26aufirst%3DC.%2BA.%26aulast%3DRievaj%26aufirst%3DJ.%26aulast%3DKuhre%26aufirst%3DR.%2BE.%26aulast%3DGlass%26aufirst%3DL.%2BL.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DGribble%26aufirst%3DF.%2BM.%26aulast%3DReimann%26aufirst%3DF.%26atitle%3DBile%2520acids%2520trigger%2520GLP-1%2520release%2520predominantly%2520by%2520accessing%2520basolaterally%2520located%2520G%2520protein-coupled%2520bile%2520acid%2520receptors%26jtitle%3DEndocrinology%26date%3D2015%26volume%3D156%26spage%3D3961%26epage%3D3970%26doi%3D10.1210%2Fen.2015-1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Charton, J.; Deprez, B.; Leroux, F.; Staels, B.; Muhr-Tailleux, A.; Hennuyer, N.; Lestavel, S.; Lasalle, M.; Dubanchet, B.</span><span> </span><span class="NLM_article-title">Imidazol- or 1,2,4-Triazol-Derivatives and Their Use</span>. World Patent WO2015/189330 A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Charton&author=B.+Deprez&author=F.+Leroux&author=B.+Staels&author=A.+Muhr-Tailleux&author=N.+Hennuyer&author=S.+Lestavel&author=M.+Lasalle&author=B.+Dubanchet&title=Imidazol-+or+1%2C2%2C4-Triazol-Derivatives+and+Their+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharton%26aufirst%3DJ.%26atitle%3DImidazol-%2520or%25201%252C2%252C4-Triazol-Derivatives%2520and%2520Their%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Sevin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehouck, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabulas-da Costa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecchelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehouck, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundquist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culot, M.</span><span> </span><span class="NLM_article-title">Accelerated Caco-2 cell permeability model for drug discovery</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1016/j.vascn.2013.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.vascn.2013.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=23916595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs12ltrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=334-339&author=E.+Sevinauthor=L.+Dehouckauthor=A.+Fabulas-da+Costaauthor=R.+Cecchelliauthor=M.+P.+Dehouckauthor=S.+Lundquistauthor=M.+Culot&title=Accelerated+Caco-2+cell+permeability+model+for+drug+discovery&doi=10.1016%2Fj.vascn.2013.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerated Caco-2 cell permeability model for drug discovery</span></div><div class="casAuthors">Sevin, E.; Dehouck, L.; Fabulas-da Costa, A.; Cecchelli, R.; Dehouck, M. P.; Lundquist, S.; Culot, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">By culturing Caco-2 cells according to a new and optimized protocol, it has been possible to accelerate the cell culture process in such a way that the cells can be used for expts. after only 6 days.  The accelerated Caco-2 model has been compared to the traditional model (requiring 21-25 days of culture) in terms of tightness of the junctions, ability to rank chem. compds. for apparent permeability, active efflux and to discriminate P-gp substrates.  In the new protocol, Caco-2 cells were cultured with the classical Caco-2 medium supplemented with puromycin.  The initial cell seeding d. was increased two times compared to the traditional procedure and the presence of a low concn. of puromycin in the culture medium reduced the Caco-2 permeability of mannitol.  Bi-directional studies were performed with known P-gp substrates (rhodamine 123, digoxin and saquinavir) and with a total of 20 marketed drugs covering a wide range of physicochem. characteristics and therapeutic indications.  Strong correlations were obtained between the apparent permeability in absorptive (Papp A → B) or secretory (Papp B → A) of the drugs in the accelerated model and in the traditional models and comparable efflux ratios were obsd. in the two studied models.  The new protocol reduces costs for screening and leads to higher throughput compared to traditional Caco-2 cell models.  This accelerated model provides short time-feedback to the drug design during the early stage of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbJT4UgykzJrVg90H21EOLACvtfcHk0lg3ulSamdgF4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs12ltrnL&md5=eac6ef3d9c948d54c85a13e42154e367</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2013.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2013.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DSevin%26aufirst%3DE.%26aulast%3DDehouck%26aufirst%3DL.%26aulast%3DFabulas-da%2BCosta%26aufirst%3DA.%26aulast%3DCecchelli%26aufirst%3DR.%26aulast%3DDehouck%26aufirst%3DM.%2BP.%26aulast%3DLundquist%26aufirst%3DS.%26aulast%3DCulot%26aufirst%3DM.%26atitle%3DAccelerated%2520Caco-2%2520cell%2520permeability%2520model%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2013%26volume%3D68%26spage%3D334%26epage%3D339%26doi%3D10.1016%2Fj.vascn.2013.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Vanessa Hoguet, Manuel Lasalle, Mathieu Maingot, Geoffroy Dequirez, Rajaa Boulahjar, Florence Leroux, Catherine Piveteau, Adrien Herledan, Alexandre Biela, Julie Dumont, Oscar Chávez-Talavera, Loïc Belloy, Isabelle Duplan, Nathalie Hennuyer, Laura Butruille, Sophie Lestavel, Emmanuel Sevin, Maxime Culot, Fabien Gosselet, Bart Staels, Benoit Deprez, Anne Tailleux, <span class="NLM_string-name hlFld-ContribAuthor">Julie Charton</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure–Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1593-1610. <a href="https://doi.org/10.1021/acs.jmedchem.0c01774" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01774</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01774%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBeyond%252Bthe%252BRule%252Bof%252B5%25253A%252BImpact%252Bof%252BPEGylation%252Bwith%252BVarious%252BPolymer%252BSizes%252Bon%252BPharmacokinetic%252BProperties%25252C%252BStructure%2525E2%252580%252593Properties%252BRelationships%252Bof%252BmPEGylated%252BSmall%252BAgonists%252Bof%252BTGR5%252BReceptor%26aulast%3DHoguet%26aufirst%3DVanessa%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09102020%26date%3D20012021%26volume%3D64%26issue%3D3%26spage%3D1593%26epage%3D1610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fanghong Wang, Xiaoyu Huang, Yueyang Chen, Danli Zhang, Danyi Chen, Lingxin Chen, <span class="NLM_string-name hlFld-ContribAuthor">Jun Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Study on the Effect of Capsaicin on the Intestinal Flora through High-Throughput Sequencing. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (2)
                                     , 1246-1253. <a href="https://doi.org/10.1021/acsomega.9b03798" title="DOI URL">https://doi.org/10.1021/acsomega.9b03798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03798%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DStudy%252Bon%252Bthe%252BEffect%252Bof%252BCapsaicin%252Bon%252Bthe%252BIntestinal%252BFlora%252Bthrough%252BHigh-Throughput%252BSequencing%26aulast%3DWang%26aufirst%3DFanghong%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D07112019%26date%3D23122019%26date%3D06012020%26volume%3D5%26issue%3D2%26spage%3D1246%26epage%3D1253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew J. West, James W. B. Fyfe, Julien C. Vantourout, <span class="NLM_string-name hlFld-ContribAuthor">Allan J. B. Watson</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Development and Recent Applications of the Chan–Lam Amination. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (24)
                                     , 12491-12523. <a href="https://doi.org/10.1021/acs.chemrev.9b00491" title="DOI URL">https://doi.org/10.1021/acs.chemrev.9b00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.9b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.9b00491%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DMechanistic%252BDevelopment%252Band%252BRecent%252BApplications%252Bof%252Bthe%252BChan%2525E2%252580%252593Lam%252BAmination%26aulast%3DWest%26aufirst%3DMatthew%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D05082019%26date%3D22112019%26volume%3D119%26issue%3D24%26spage%3D12491%26epage%3D12523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shaoyong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Jian Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (1)
                                     , 24-45. <a href="https://doi.org/10.1021/acs.jmedchem.7b01844" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01844%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BAllosteric%252BModulators%252Bof%252BG-Protein-Coupled%252BReceptors%25253A%252BDrug%2525E2%252580%252593Target%252BInteractions%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2019%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D26022018%26date%3D19022018%26volume%3D62%26issue%3D1%26spage%3D24%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley  Castellanos-Jankiewicz</span>, <span class="hlFld-ContribAuthor ">Omar  Guzmán-Quevedo</span>, <span class="hlFld-ContribAuthor ">Valérie S.  Fénelon</span>, <span class="hlFld-ContribAuthor ">Philippe  Zizzari</span>, <span class="hlFld-ContribAuthor ">Carmelo  Quarta</span>, <span class="hlFld-ContribAuthor ">Luigi  Bellocchio</span>, <span class="hlFld-ContribAuthor ">Anne  Tailleux</span>, <span class="hlFld-ContribAuthor ">Julie  Charton</span>, <span class="hlFld-ContribAuthor ">Daniela  Fernandois</span>, <span class="hlFld-ContribAuthor ">Marcus  Henricsson</span>, <span class="hlFld-ContribAuthor ">Catherine  Piveteau</span>, <span class="hlFld-ContribAuthor ">Vincent  Simon</span>, <span class="hlFld-ContribAuthor ">Camille  Allard</span>, <span class="hlFld-ContribAuthor ">Sandrine  Quemener</span>, <span class="hlFld-ContribAuthor ">Valentine  Guinot</span>, <span class="hlFld-ContribAuthor ">Nathalie  Hennuyer</span>, <span class="hlFld-ContribAuthor ">Alessia  Perino</span>, <span class="hlFld-ContribAuthor ">Alexia  Duveau</span>, <span class="hlFld-ContribAuthor ">Marlène  Maitre</span>, <span class="hlFld-ContribAuthor ">Thierry  Leste-Lasserre</span>, <span class="hlFld-ContribAuthor ">Samantha  Clark</span>, <span class="hlFld-ContribAuthor ">Nathalie  Dupuy</span>, <span class="hlFld-ContribAuthor ">Astrid  Cannich</span>, <span class="hlFld-ContribAuthor ">Delphine  Gonzales</span>, <span class="hlFld-ContribAuthor ">Benoit  Deprez</span>, <span class="hlFld-ContribAuthor ">Gilles  Mithieux</span>, <span class="hlFld-ContribAuthor ">David  Dombrowicz</span>, <span class="hlFld-ContribAuthor ">Fredrik  Bäckhed</span>, <span class="hlFld-ContribAuthor ">Vincent  Prevot</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marsicano</span>, <span class="hlFld-ContribAuthor ">Bart  Staels</span>, <span class="hlFld-ContribAuthor ">Kristina  Schoonjans</span>, <span class="hlFld-ContribAuthor ">Daniela  Cota</span>. </span><span class="cited-content_cbyCitation_article-title">Hypothalamic bile acid-TGR5 signaling protects from obesity. </span><span class="cited-content_cbyCitation_journal-name">Cell Metabolism</span><span> <strong>2021,</strong> <em>33 </em>
                                    (7)
                                     , 1483-1492.e10. <a href="https://doi.org/10.1016/j.cmet.2021.04.009" title="DOI URL">https://doi.org/10.1016/j.cmet.2021.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cmet.2021.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cmet.2021.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Metabolism%26atitle%3DHypothalamic%252Bbile%252Bacid-TGR5%252Bsignaling%252Bprotects%252Bfrom%252Bobesity%26aulast%3DCastellanos-Jankiewicz%26aufirst%3DAshley%26date%3D2021%26volume%3D33%26issue%3D7%26spage%3D1483%26epage%3D1492.e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Fiorucci</span>, <span class="hlFld-ContribAuthor ">Eleonora  Distrutti</span>, <span class="hlFld-ContribAuthor ">Adriana  Carino</span>, <span class="hlFld-ContribAuthor ">Angela  Zampella</span>, <span class="hlFld-ContribAuthor ">Michele  Biagioli</span>. </span><span class="cited-content_cbyCitation_article-title">Bile acids and their receptors in metabolic disorders. </span><span class="cited-content_cbyCitation_journal-name">Progress in Lipid Research</span><span> <strong>2021,</strong> <em>82 </em>, 101094. <a href="https://doi.org/10.1016/j.plipres.2021.101094" title="DOI URL">https://doi.org/10.1016/j.plipres.2021.101094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.plipres.2021.101094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.plipres.2021.101094%26sid%3Dliteratum%253Aachs%26jtitle%3DProgress%2520in%2520Lipid%2520Research%26atitle%3DBile%252Bacids%252Band%252Btheir%252Breceptors%252Bin%252Bmetabolic%252Bdisorders%26aulast%3DFiorucci%26aufirst%3DStefano%26date%3D2021%26volume%3D82%26spage%3D101094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessia  Perino</span>, <span class="hlFld-ContribAuthor ">Hadrien  Demagny</span>, <span class="hlFld-ContribAuthor ">Laura  Velazquez-Villegas</span>, <span class="hlFld-ContribAuthor ">Kristina  Schoonjans</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular physiology of bile acid signaling in health, disease, and aging. </span><span class="cited-content_cbyCitation_journal-name">Physiological Reviews</span><span> <strong>2021,</strong> <em>101 </em>
                                    (2)
                                     , 683-731. <a href="https://doi.org/10.1152/physrev.00049.2019" title="DOI URL">https://doi.org/10.1152/physrev.00049.2019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/physrev.00049.2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fphysrev.00049.2019%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysiological%2520Reviews%26atitle%3DMolecular%252Bphysiology%252Bof%252Bbile%252Bacid%252Bsignaling%252Bin%252Bhealth%25252C%252Bdisease%25252C%252Band%252Baging%26aulast%3DPerino%26aufirst%3DAlessia%26date%3D2021%26volume%3D101%26issue%3D2%26spage%3D683%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charlotte  Lefort</span>, <span class="hlFld-ContribAuthor ">Patrice D.  Cani</span>. </span><span class="cited-content_cbyCitation_article-title">The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 400. <a href="https://doi.org/10.3390/cells10020400" title="DOI URL">https://doi.org/10.3390/cells10020400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10020400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10020400%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DThe%252BLiver%252Bunder%252Bthe%252BSpotlight%25253A%252BBile%252BAcids%252Band%252BOxysterols%252Bas%252BPivotal%252BActors%252BControlling%252BMetabolism%26aulast%3DLefort%26aufirst%3DCharlotte%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D2%26spage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Yong  Chu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule GLP-1 secretagogs: challenges and recent advances. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (11)
                                     , 2023-2029. <a href="https://doi.org/10.1016/j.drudis.2020.08.003" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DSmall-molecule%252BGLP-1%252Bsecretagogs%25253A%252Bchallenges%252Band%252Brecent%252Badvances%26aulast%3DHe%26aufirst%3DJie%26date%3D2020%26volume%3D25%26issue%3D11%26spage%3D2023%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fanghui  Han</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Ning</span>, <span class="hlFld-ContribAuthor ">Hua  Cao</span>, <span class="hlFld-ContribAuthor ">Yangliang  Ye</span>, <span class="hlFld-ContribAuthor ">Ying  Feng</span>, <span class="hlFld-ContribAuthor ">Ying  Leng</span>, <span class="hlFld-ContribAuthor ">Jianhua  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112619. <a href="https://doi.org/10.1016/j.ejmech.2020.112619" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112619</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112619%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252BG-protein-coupled%252Bbile%252Bacid%252Breceptor%252B1%252B%252528GPBAR1%25252C%252BTGR5%252529%252Bsoft%252Bdrugs%252Bwith%252Breduced%252Bgallbladder-filling%252Beffects%26aulast%3DHan%26aufirst%3DFanghui%26date%3D2020%26volume%3D203%26spage%3D112619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sei  Higuchi</span>. </span><span class="cited-content_cbyCitation_article-title">The Physiological Importance of Bile Acid Structure and Composition on Glucose Homeostasis. </span><span class="cited-content_cbyCitation_journal-name">Current Diabetes Reports</span><span> <strong>2020,</strong> <em>20 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s11892-020-01329-5" title="DOI URL">https://doi.org/10.1007/s11892-020-01329-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11892-020-01329-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11892-020-01329-5%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Diabetes%2520Reports%26atitle%3DThe%252BPhysiological%252BImportance%252Bof%252BBile%252BAcid%252BStructure%252Band%252BComposition%252Bon%252BGlucose%252BHomeostasis%26aulast%3DHiguchi%26aufirst%3DSei%26date%3D2020%26date%3D2020%26volume%3D20%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yantao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Synthesis of Methylated Products through Indirect Approaches. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (5)
                                     , 998-1014. <a href="https://doi.org/10.1002/adsc.201901240" title="DOI URL">https://doi.org/10.1002/adsc.201901240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201901240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201901240%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DAdvances%252Bin%252Bthe%252BSynthesis%252Bof%252BMethylated%252BProducts%252Bthrough%252BIndirect%252BApproaches%26aulast%3DChen%26aufirst%3DYantao%26date%3D2020%26date%3D2019%26volume%3D362%26issue%3D5%26spage%3D998%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Maurizio  Ciofalo</span>. </span><span class="cited-content_cbyCitation_article-title">Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (19)
                                     , 2016-2101. <a href="https://doi.org/10.2174/1385272823666191014154129" title="DOI URL">https://doi.org/10.2174/1385272823666191014154129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666191014154129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666191014154129%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DCurrent%252BAdvances%252Bin%252Bthe%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPharmacologically%252BRelevant%252B1%25252C2%25252C4%25252C5-Tetrasubstituted-1H-Imidazole%252BDerivatives%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2019%26volume%3D23%26issue%3D19%26spage%3D2016%26epage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tiara R.  Ahmad</span>, <span class="hlFld-ContribAuthor ">Rebecca A.  Haeusler</span>. </span><span class="cited-content_cbyCitation_article-title">Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Endocrinology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (12)
                                     , 701-712. <a href="https://doi.org/10.1038/s41574-019-0266-7" title="DOI URL">https://doi.org/10.1038/s41574-019-0266-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41574-019-0266-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41574-019-0266-7%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Endocrinology%26atitle%3DBile%252Bacids%252Bin%252Bglucose%252Bmetabolism%252Band%252Binsulin%252Bsignalling%252B%2525E2%252580%252594%252Bmechanisms%252Band%252Bresearch%252Bneeds%26aulast%3DAhmad%26aufirst%3DTiara%2BR.%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D12%26spage%3D701%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco Saverio  Di Leva</span>, <span class="hlFld-ContribAuthor ">Carmen  Festa</span>, <span class="hlFld-ContribAuthor ">Adriana  Carino</span>, <span class="hlFld-ContribAuthor ">Simona  De Marino</span>, <span class="hlFld-ContribAuthor ">Silvia  Marchianò</span>, <span class="hlFld-ContribAuthor ">Daniele  Di Marino</span>, <span class="hlFld-ContribAuthor ">Claudia  Finamore</span>, <span class="hlFld-ContribAuthor ">Maria Chiara  Monti</span>, <span class="hlFld-ContribAuthor ">Angela  Zampella</span>, <span class="hlFld-ContribAuthor ">Stefano  Fiorucci</span>, <span class="hlFld-ContribAuthor ">Vittorio  Limongelli</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-38840-z" title="DOI URL">https://doi.org/10.1038/s41598-019-38840-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-38840-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-38840-z%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDiscovery%252Bof%252B%252528%2525281%25252C2%25252C4-oxadiazol-5-yl%252529pyrrolidin-3-yl%252529ureidyl%252Bderivatives%252Bas%252Bselective%252Bnon-steroidal%252Bagonists%252Bof%252Bthe%252BG-protein%252Bcoupled%252Bbile%252Bacid%252Breceptor-1%26aulast%3DDi%2BLeva%26aufirst%3DFrancesco%2BSaverio%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xian  Wu</span>, <span class="hlFld-ContribAuthor ">Caihong  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Chen</span>, <span class="hlFld-ContribAuthor ">Yi-Feng  Du</span>, <span class="hlFld-ContribAuthor ">Mei  Hu</span>, <span class="hlFld-ContribAuthor ">Miranda N.  Reed</span>, <span class="hlFld-ContribAuthor ">Yan  Long</span>, <span class="hlFld-ContribAuthor ">Vishnu  Suppiramaniam</span>, <span class="hlFld-ContribAuthor ">Hao  Hong</span>, <span class="hlFld-ContribAuthor ">Su-Su  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Protective effects of tauroursodeoxycholic acid on lipopolysaccharide-induced cognitive impairment and neurotoxicity in mice. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2019,</strong> <em>72 </em>, 166-175. <a href="https://doi.org/10.1016/j.intimp.2019.03.065" title="DOI URL">https://doi.org/10.1016/j.intimp.2019.03.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2019.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2019.03.065%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DProtective%252Beffects%252Bof%252Btauroursodeoxycholic%252Bacid%252Bon%252Blipopolysaccharide-induced%252Bcognitive%252Bimpairment%252Band%252Bneurotoxicity%252Bin%252Bmice%26aulast%3DWu%26aufirst%3DXian%26date%3D2019%26volume%3D72%26spage%3D166%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Bonacina</span>, <span class="hlFld-ContribAuthor ">D.  Albano</span>, <span class="hlFld-ContribAuthor ">M.  Gazzilli</span>, <span class="hlFld-ContribAuthor ">R.  Durmo</span>, <span class="hlFld-ContribAuthor ">E.  Cerudelli</span>, <span class="hlFld-ContribAuthor ">G.  Bosio</span>, <span class="hlFld-ContribAuthor ">F.  Bertagna</span>, <span class="hlFld-ContribAuthor ">R.  Giubbini</span>. </span><span class="cited-content_cbyCitation_article-title">Detección de grasa parda en la PET/TC con 18F-FDG: diferencias entre la población adulta y pediátrica en una experiencia de 12 años. </span><span class="cited-content_cbyCitation_journal-name">Revista Española de Medicina Nuclear e Imagen Molecular</span><span> <strong>2019,</strong> <em>38 </em>
                                    (4)
                                     , 224-228. <a href="https://doi.org/10.1016/j.remn.2019.01.006" title="DOI URL">https://doi.org/10.1016/j.remn.2019.01.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.remn.2019.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.remn.2019.01.006%26sid%3Dliteratum%253Aachs%26jtitle%3DRevista%2520Espa%25C3%25B1ola%2520de%2520Medicina%2520Nuclear%2520e%2520Imagen%2520Molecular%26atitle%3DDetecci%2525C3%2525B3n%252Bde%252Bgrasa%252Bparda%252Ben%252Bla%252BPET%25252FTC%252Bcon%252B18F-FDG%25253A%252Bdiferencias%252Bentre%252Bla%252Bpoblaci%2525C3%2525B3n%252Badulta%252By%252Bpedi%2525C3%2525A1trica%252Ben%252Buna%252Bexperiencia%252Bde%252B12%252Ba%2525C3%2525B1os%26aulast%3DBonacina%26aufirst%3DM.%26date%3D2019%26volume%3D38%26issue%3D4%26spage%3D224%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mattia  Bonacina</span>, <span class="hlFld-ContribAuthor ">Domenico  Albano</span>, <span class="hlFld-ContribAuthor ">Maria  Gazzilli</span>, <span class="hlFld-ContribAuthor ">Rexhep  Durmo</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Cerudelli</span>, <span class="hlFld-ContribAuthor ">Giovanni  Bosio</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertagna</span>, <span class="hlFld-ContribAuthor ">Raffaele  Giubbini</span>. </span><span class="cited-content_cbyCitation_article-title">18F-FDG PET/CT brown fat detection: Differences between adult and pediatric population in a 12 year experience. </span><span class="cited-content_cbyCitation_journal-name">Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)</span><span> <strong>2019,</strong> <em>38 </em>
                                    (4)
                                     , 224-228. <a href="https://doi.org/10.1016/j.remnie.2019.02.004" title="DOI URL">https://doi.org/10.1016/j.remnie.2019.02.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.remnie.2019.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.remnie.2019.02.004%26sid%3Dliteratum%253Aachs%26jtitle%3DRevista%2520Espa%25C3%25B1ola%2520de%2520Medicina%2520Nuclear%2520e%2520Imagen%2520Molecular%2520%2528English%2520Edition%2529%26atitle%3D18F-FDG%252BPET%25252FCT%252Bbrown%252Bfat%252Bdetection%25253A%252BDifferences%252Bbetween%252Badult%252Band%252Bpediatric%252Bpopulation%252Bin%252Ba%252B12%252Byear%252Bexperience%26aulast%3DBonacina%26aufirst%3DMattia%26date%3D2019%26volume%3D38%26issue%3D4%26spage%3D224%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ida M  Gether</span>, <span class="hlFld-ContribAuthor ">Christina  Nexøe-Larsen</span>, <span class="hlFld-ContribAuthor ">Filip K  Knop</span>. </span><span class="cited-content_cbyCitation_article-title">New Avenues in the Regulation of Gallbladder Motility—Implications for the Use of Glucagon-Like Peptide–Derived Drugs. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Endocrinology & Metabolism</span><span> <strong>2019,</strong> <em>104 </em>
                                    (7)
                                     , 2463-2472. <a href="https://doi.org/10.1210/jc.2018-01008" title="DOI URL">https://doi.org/10.1210/jc.2018-01008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/jc.2018-01008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fjc.2018-01008%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Endocrinology%2520%2526%2520Metabolism%26atitle%3DNew%252BAvenues%252Bin%252Bthe%252BRegulation%252Bof%252BGallbladder%252BMotility%2525E2%252580%252594Implications%252Bfor%252Bthe%252BUse%252Bof%252BGlucagon-Like%252BPeptide%2525E2%252580%252593Derived%252BDrugs%26aulast%3DGether%26aufirst%3DIda%2BM%26date%3D2019%26date%3D2018%26volume%3D104%26issue%3D7%26spage%3D2463%26epage%3D2472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin R.  Joris</span>, <span class="hlFld-ContribAuthor ">Gregory B.  Gloor</span>. </span><span class="cited-content_cbyCitation_article-title">Unaccounted risk of cardiovascular disease. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Lipidology</span><span> <strong>2019,</strong> <em>30 </em>
                                    (2)
                                     , 125-133. <a href="https://doi.org/10.1097/MOL.0000000000000582" title="DOI URL">https://doi.org/10.1097/MOL.0000000000000582</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MOL.0000000000000582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMOL.0000000000000582%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Lipidology%26atitle%3DUnaccounted%252Brisk%252Bof%252Bcardiovascular%252Bdisease%26aulast%3DJoris%26aufirst%3DBenjamin%2BR.%26date%3D2019%26volume%3D30%26issue%3D2%26spage%3D125%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yantao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Methylation: A Guide for Selecting Methylation Reagents. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (14)
                                     , 3405-3439. <a href="https://doi.org/10.1002/chem.201803642" title="DOI URL">https://doi.org/10.1002/chem.201803642</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201803642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201803642%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DRecent%252BAdvances%252Bin%252BMethylation%25253A%252BA%252BGuide%252Bfor%252BSelecting%252BMethylation%252BReagents%26aulast%3DChen%26aufirst%3DYantao%26date%3D2019%26date%3D2018%26volume%3D25%26issue%3D14%26spage%3D3405%26epage%3D3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanne M.  Donkers</span>, <span class="hlFld-ContribAuthor ">Reinout L.P.  Roscam Abbing</span>, <span class="hlFld-ContribAuthor ">Stan F.J.  van de Graaf</span>. </span><span class="cited-content_cbyCitation_article-title">Developments in bile salt based therapies: A critical overview. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>161 </em>, 1-13. <a href="https://doi.org/10.1016/j.bcp.2018.12.018" title="DOI URL">https://doi.org/10.1016/j.bcp.2018.12.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2018.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2018.12.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDevelopments%252Bin%252Bbile%252Bsalt%252Bbased%252Btherapies%25253A%252BA%252Bcritical%252Boverview%26aulast%3DDonkers%26aufirst%3DJoanne%2BM.%26date%3D2019%26volume%3D161%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Finamore</span>, <span class="hlFld-ContribAuthor ">Giuliana  Baronissi</span>, <span class="hlFld-ContribAuthor ">Silvia  Marchianò</span>, <span class="hlFld-ContribAuthor ">Francesco  Di Leva</span>, <span class="hlFld-ContribAuthor ">Adriana  Carino</span>, <span class="hlFld-ContribAuthor ">Maria  Monti</span>, <span class="hlFld-ContribAuthor ">Vittorio  Limongelli</span>, <span class="hlFld-ContribAuthor ">Angela  Zampella</span>, <span class="hlFld-ContribAuthor ">Stefano  Fiorucci</span>, <span class="hlFld-ContribAuthor ">Valentina  Sepe</span>. </span><span class="cited-content_cbyCitation_article-title">Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (6)
                                     , 1043. <a href="https://doi.org/10.3390/molecules24061043" title="DOI URL">https://doi.org/10.3390/molecules24061043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24061043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24061043%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIntroduction%252Bof%252BNonacidic%252BSide%252BChains%252Bon%252B6-Ethylcholane%252BScaffolds%252Bin%252Bthe%252BIdentification%252Bof%252BPotent%252BBile%252BAcid%252BReceptor%252BAgonists%252Bwith%252BImproved%252BPharmacokinetic%252BProperties%26aulast%3DFinamore%26aufirst%3DClaudia%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D6%26spage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simona  De Marino</span>, <span class="hlFld-ContribAuthor ">Carmen  Festa</span>, <span class="hlFld-ContribAuthor ">Valentina  Sepe</span>, <span class="hlFld-ContribAuthor ">Angela  Zampella</span>. </span><span class="cited-content_cbyCitation_article-title">Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 137-165. <a href="https://doi.org/10.1007/164_2019_237" title="DOI URL">https://doi.org/10.1007/164_2019_237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2019_237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2019_237%26sid%3Dliteratum%253Aachs%26atitle%3DChemistry%252Band%252BPharmacology%252Bof%252BGPBAR1%252Band%252BFXR%252BSelective%252BAgonists%25252C%252BDual%252BAgonists%25252C%252Band%252BAntagonists%26aulast%3DDe%2BMarino%26aufirst%3DSimona%26date%3D2019%26date%3D2019%26spage%3D137%26epage%3D165%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DBile%252BAcids%252Band%252BTheir%252BReceptors%26aulast%3DFiorucci%26aufirst%3DStefano%26date%3D2019%26volume%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvano  Paternoster</span>, <span class="hlFld-ContribAuthor ">Marco  Falasca</span>. </span><span class="cited-content_cbyCitation_article-title">Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fendo.2018.00584" title="DOI URL">https://doi.org/10.3389/fendo.2018.00584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2018.00584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2018.00584%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DDissecting%252Bthe%252BPhysiology%252Band%252BPathophysiology%252Bof%252BGlucagon-Like%252BPeptide-1%26aulast%3DPaternoster%26aufirst%3DSilvano%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hagit  Shapiro</span>, <span class="hlFld-ContribAuthor ">Aleksandra A.  Kolodziejczyk</span>, <span class="hlFld-ContribAuthor ">Daniel  Halstuch</span>, <span class="hlFld-ContribAuthor ">Eran  Elinav</span>. </span><span class="cited-content_cbyCitation_article-title">Bile acids in glucose metabolism in health and disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental Medicine</span><span> <strong>2018,</strong> <em>215 </em>
                                    (2)
                                     , 383-396. <a href="https://doi.org/10.1084/jem.20171965" title="DOI URL">https://doi.org/10.1084/jem.20171965</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1084/jem.20171965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1084%2Fjem.20171965%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520Medicine%26atitle%3DBile%252Bacids%252Bin%252Bglucose%252Bmetabolism%252Bin%252Bhealth%252Band%252Bdisease%26aulast%3DShapiro%26aufirst%3DHagit%26date%3D2018%26date%3D2018%26volume%3D215%26issue%3D2%26spage%3D383%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Herman-Edelstein</span>, <span class="hlFld-ContribAuthor ">Talia  Weinstein</span>, <span class="hlFld-ContribAuthor ">Moshe  Levi</span>. </span><span class="cited-content_cbyCitation_article-title">Bile acid receptors and the kidney. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Nephrology and Hypertension</span><span> <strong>2018,</strong> <em>27 </em>
                                    (1)
                                     , 56-62. <a href="https://doi.org/10.1097/MNH.0000000000000374" title="DOI URL">https://doi.org/10.1097/MNH.0000000000000374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MNH.0000000000000374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMNH.0000000000000374%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Nephrology%2520and%2520Hypertension%26atitle%3DBile%252Bacid%252Breceptors%252Band%252Bthe%252Bkidney%26aulast%3DHerman-Edelstein%26aufirst%3DMichal%26date%3D2018%26volume%3D27%26issue%3D1%26spage%3D56%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Isosteric Replacement Strategy and Scaffold Switching</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route to <b>1</b>–<b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) 4-fluorophenylisothiocyanate, DIEA, DMF, 50 °C, 15 h; (ii) NaOH 2 M, 50 °C, 60 h, 87%; (b) 2-bromomethyl-1,3-difluoro-benzene, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 3 h, 98%; (c) (i) MeONa, paraformaldehyde, MeOH, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 30 min, 76%; (d) Chan-Lam coupling, 3,4-dimethoxyphenylboronic acid, pyridine, Cu(OAc)<sub>2</sub>, MS 4 Å, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 24–48 h, 11–50%; (e) Ac<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 30 min, 66%; (f) AcCl, EtOH, reflux, 30 min, 57%.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route to <b>3</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) paraformaldehyde, MeONa, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 1–3 h, 77%; (b) chloroacetyl chloride, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (c) aq. NH<sub>3</sub>, EtOH, 65 °C, 1 h, 75% (over two steps); (d) 4-fluorophenylisothiocyanate, NEt<sub>3</sub>, EtOH, room temp., 15 min, 76%; (e) R -Cl, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temperature, 16 h, 90–98%; (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150 °C (μW), 10–40 min, or reflux (classical heating), 24 h, 32–61%.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route to <b>7</b>–<b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) paraformaldehyde, MeONa, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 1–3 h, 77%; (b) chloroacetyl chloride, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (c) aq. NH<sub>3</sub>, EtOH, 65 °C, 1 h, 75% (over two steps); (b′) Boc-Gly-OH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min–48 h, 100%; (c′) TFA (30%) /DCM, room temp., 30 min, 100%; (d) R-N = C═S, NEt<sub>3</sub>, EtOH, room temp. or 60 °C, 15 min to overnight, 30–53%; (d′) aniline, TCDI, NEt<sub>3</sub>, dioxane, room temp.–60 °C, overnight, 49%; (e) 2-bromomethyl-1,3-difluoro-benzene, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temperature, 16 h, 82–99%; (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAC, 150 °C (μW), 10–40 min, or reflux (classical heating), 24 h, 11–63%.</p></p></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route to <b>13</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) paraformaldehyde, MeONa, room temp., 16 h; (ii) NaBH<sub>4</sub>, MeOH, reflux, 1–3 h, 51–96%; (a′) allyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 16 h; (b) chloroacetyl chloride, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (c) aq. NH<sub>3</sub>, EtOH, 65 °C, 1 h, 75%; (b′) Boc-Gly-OH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min–48 h, 79–100%; (c′) TFA (30%)/CH<sub>2</sub>Cl<sub>2</sub>, room temp., 30 min; (d) 4-fluorophenylisothiocyanate, NEt<sub>3</sub>, EtOH, room temp., 15–60 min, 90–100%; (e) 2-bromomethyl-1,3-difluoro-benzene, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temperature, overnight, 58–100%; (f) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, 150 °C (μW), 10–40 min, or reflux (classical heating), 24 h, 10–59%.</p></p></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route to <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-aminoacetonitrile hydrochloride, NEt<sub>3</sub>, DMF, room temp. to 0 °C, 30 min, 80%; (b) 2-bromomethyl-1,3-difluorobenzene, DIEA, CH<sub>3</sub>CN, room temp., 10 min; (c) 3,4-dimethoxybenzoic acid, thionyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, THF, pyridine, room temp., 4 h, 31%.</p></p></figure><figure data-id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0014.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthetic Route to <b>20</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R-Cl, NaI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 16 h, room temp. 95%; (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 24 h, 74%; (c) <i>N</i>,<i>N</i>-dimethylpropargylamine, pyrrolidine, CuI, PdCl<sub>2</sub>(dppf), DMF, 80 °C, 16 h, 47%; (d) MeI, THF/Et<sub>2</sub>O, room temp., 2–6 h, 17–19%.</p></p></figure><figure data-id="sch8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0015.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthetic Route to Intermediate <b>23ii</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) NaOH, H<sub>2</sub>O, reflux, 24 h, 94%; (ii) H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux, 18 h, 90%; (iii) DIBAlH, THF, 0 °C, 1.5 h then NaK-tartrate aq (1 M), room temp., 0.5 h, 80%; (b) (i) Cl(CH<sub>2</sub>)<sub>3</sub>Br, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 3 h, 96%; (ii) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp., 16 h, 100%.</p></p></figure><figure data-id="sch9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0016.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthetic Route to Intermediate <b>23</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>23ii</b>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, room temp., 16 h, 73%; (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 28 h, 96%; (c) NaI, Na<sub>2</sub>SO<sub>3</sub>, dioxane/H<sub>2</sub>O (1/1), μW, 130 °C, 100 min, 36%; (d) DABCO, CH<sub>3</sub>CN, μW, 100 °C, 30 min, 23%.</p></p></figure><figure data-id="sch10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0017.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthetic Route to Intermediate <b>25iii</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1,3-dibromopropane, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 3 h, 76%; (b) <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonylcarbamate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 30 min, 95%; (c) NEt<sub>3</sub>, MsCl, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp., overnight, 87%.</p></p></figure><figure data-id="sch11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0018.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthetic Route to <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>25iii</b>, DIEA, CH<sub>3</sub>CN, room temp., overnight, 35%; (b) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux, 48 h, 62%; (c) TFA (10%), CH<sub>2</sub>Cl<sub>2</sub>, room temp., 5 h, 98%; (d) sodium 2-chloroethanesulfonate, NaI, DIEA, DMF, μW, 100 °C, 2 h, 16%.</p></p></figure><figure data-id="sch12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0019.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthetic Route to <b>26</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BocHN–CH(R)-COOH, 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, room temp., 30 min–1 h, 66–97%; (b) TFA (30%)/ CH<sub>2</sub>Cl<sub>2</sub>, 30 min, 100%; (c) 4-fluorophenylisothiocyanate, TEA, EtOH, 5 min, 70–79%; (d) 2-bromoethyl-1,3-difluoro-benzene, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, room temp., overnight, 84–89%; (e) 1-propylphosphonic acid cyclic anhydride, DIEA, EtOAc, reflux (classical heating), 48 h, 6–32%; (f) NaOH 1N, MeOH, room temp., overnight, 93%; (g) piperidine, EtOAc, room temp., 60%; (h) MeI, DIEA, Et<sub>2</sub>O/THF (1/1), room temp., overnight, 20%.</p></p></figure><figure data-id="fig1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0001.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound <b>22</b> (gray bars) were administered to mice at 3 consecutive time-points (T-6h, T-4h, and T-2h, 3 × 20 mg/kg) before challenge with a bolus of water or glucose (T0). All groups received sitagliptin (25 mg/kg) 45 min prior to blood sample collection (T+15 min). Mean ± SEM (<i>n</i> = 6/group). * <i>p</i> < 0.05, ** <i>p</i> < 0.01 (ANOVA and Holm-Sidak test). Veh = vehicle (Tween 0.1%). Glc = glucose (2g/kg). <b>22</b> = compound <b>22</b> in Tween 0.1% (3 × 20 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0002.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound <b>24</b> (gray bars) were administered to mice at 3 time-points (T-6h, T-4h, and T-2h, 3 × 20 mg/kg) before blood collection (T0) to measure active GLP-1 plasma concentrations. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 8/group). *** <i>p</i> < 0.001 (Student’s <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0003.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Time-course of compound <b>24</b> concentrations in the duodenum, jejunum, ileum, and colon of C57Bl6 mice, after a single oral administration (20 mg/kg). Mean ± SEM (<i>n</i> = 3 mice/time).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0004.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice. Vehicle (white bars) or compound <b>24</b> (gray bars) were administrated to mice 4 h (<i>t</i> + 4 h) or 7 h (<i>t</i> + 7 h) before blood collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 6/group). ** <i>p</i> < 0.01 (Student’s <i>t</i> test). Vehicle = Tween 0.1%. <b>24</b> = compound <b>24</b> in Tween 0.1% (20 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0005.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> dose–response effect of compound <b>24</b> in C57Bl6 mice. (A) GLP-1 secretion after oral administration of the vehicle (white bar) or <b>24</b> (gray bars) 8 h prior to blood sample collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 6/group). **** <i>p</i> < 0.0001 (ANOVA-Dunnet test). (B) Gallbladder volume in fasted mice 8 h after oral administration of compound <b>24</b>. Mean ± SEM (<i>n</i> = 6/group). ** <i>p</i> < 0.01 (ANOVA-Dunnet test). (C) Gallbladder volume in fasted (6 h) and refed (fasted 4 h then refed for 2 h) mice after oral administration of compound <b>24</b> (20 mg/kg) or vehicle. Mean ± SEM (<i>n</i> = 6/group). ANOVA-Tukey test. Veh = vehicle (Tween 0.1%). <b>24</b> = compound <b>24</b> in Tween 0.1%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0006.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>In vivo</i> GLP-1 secretion in C57Bl6 mice fed a HFD. Vehicle (white bars) or compound <b>24</b> (gray bars) were administrated to mice 8 h prior to blood sample collection for active GLP-1 plasma concentration measurement. All groups received sitagliptin (25 mg/kg) 45 min prior to blood sampling. Mean ± SEM (<i>n</i> = 10/group). **** <i>p</i> < 0.0001 (Student’s <i>t</i> test). Veh = vehicle (Tween 0.1%). <b>24</b> = compound <b>24</b> in Tween 0.1% (20 mg/kg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/medium/jm-2016-018738_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0007.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>24</b> administration on oral glucose tolerance test in HFD fed C57BL6 mice. Obese, insulin-resistant mice were treated with vehicle or <b>24</b>. (Veh = vehicle (Tween 0.1%). <b>24</b> = compound <b>24</b> (20 mg/kg) in Tween 0.1%). Seven hours later, mice were challenged with an oral bolus of glucose (4g/kg) and glucose measured at the indicated time-points. (A) Glycemia excursion curve. (B) Incremental area under the curve (AUC), expressed as arbitrary units (A.U.). Mean ± SEM (<i>n</i> = 8/group). * <i>p</i> < 0.05, ** <i>p</i> < 0.01 (Student’s <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.6b01873/20170519/images/large/jm-2016-018738_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01873&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i167">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lefebvre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cariou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staels, B.</span><span> </span><span class="NLM_article-title">Role of bile acids and bile acid receptors in metabolic regulation</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1152/physrev.00010.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1152%2Fphysrev.00010.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=19126757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Cqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=147-191&author=P.+Lefebvreauthor=B.+Cariouauthor=F.+Lienauthor=F.+Kuipersauthor=B.+Staels&title=Role+of+bile+acids+and+bile+acid+receptors+in+metabolic+regulation&doi=10.1152%2Fphysrev.00010.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Role of bile acids and bile acid receptors in metabolic regulation</span></div><div class="casAuthors">Lefebvre, Philippe; Cariou, Bertrand; Lien, Fleur; Kuipers, Folkert; Staels, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-191</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  The incidence of the metabolic syndrome has taken epidemic proportions in the past decades, contributing to an increased risk of cardiovascular disease and diabetes.  The metabolic syndrome can be defined as a cluster of cardiovascular disease risk factors including visceral obesity, insulin resistance, dyslipidemia, increased blood pressure, and hypercoagulability.  The farnesoid X receptor (FXR) belongs to the superfamily of ligand-activated nuclear receptor transcription factors.  FXR is activated by bile acids, and FXR-deficient (FXR-/-) mice display elevated serum levels of triglycerides and high-d. lipoprotein cholesterol, demonstrating a crit. role of FXR in lipid metab.  In an opposite manner, activation of FXR by bile acids (BAs) or nonsteroidal synthetic FXR agonists lowers plasma triglycerides by a mechanism that may involve the repression of hepatic SREBP-1c expression and/or the modulation of glucose-induced lipogenic genes.  A cross-talk between BA and glucose metab. was recently identified, implicating both FXR-dependent and FXR-independent pathways.  The first indication for a potential role of FXR in diabetes came from the observation that hepatic FXR expression is reduced in animal models of diabetes.  While FXR-/- mice display both impaired glucose tolerance and decreased insulin sensitivity, activation of FXR improves hyperglycemia and dyslipidemia in vivo in diabetic mice.  Finally, a recent report also indicates that BA may regulate energy expenditure in a FXR-independent manner in mice, via activation of the G protein-coupled receptor TGR5.  Taken together, these findings suggest that modulation of FXR activity and BA metab. may open new attractive pharmacol. approaches for the treatment of the metabolic syndrome and type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc0VIzJznf17Vg90H21EOLACvtfcHk0lie7h19hcd0bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Cqtro%253D&md5=b540fb270c957511e5511730f31f6181</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00010.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00010.2008%26sid%3Dliteratum%253Aachs%26aulast%3DLefebvre%26aufirst%3DP.%26aulast%3DCariou%26aufirst%3DB.%26aulast%3DLien%26aufirst%3DF.%26aulast%3DKuipers%26aufirst%3DF.%26aulast%3DStaels%26aufirst%3DB.%26atitle%3DRole%2520of%2520bile%2520acids%2520and%2520bile%2520acid%2520receptors%2520in%2520metabolic%2520regulation%26jtitle%3DPhysiol.%2520Rev.%26date%3D2009%26volume%3D89%26spage%3D147%26epage%3D191%26doi%3D10.1152%2Fphysrev.00010.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollister, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, B. M.</span><span> </span><span class="NLM_article-title">Endogenous bile acids are ligands for the nuclear receptor FXR/BAR</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1016/S1097-2765(00)80348-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2FS1097-2765%2800%2980348-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10360171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADyaK1MXjslCqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1999&pages=543-553&author=H.+Wangauthor=J.+Chenauthor=K.+Hollisterauthor=L.+C.+Sowersauthor=B.+M.+Forman&title=Endogenous+bile+acids+are+ligands+for+the+nuclear+receptor+FXR%2FBAR&doi=10.1016%2FS1097-2765%2800%2980348-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous bile acids are ligands for the nuclear receptor FXR/BAR</span></div><div class="casAuthors">Wang, Haibo; Chen, Jasmine; Hollister, Kevin; Sowers, Lawrence C.; Forman, Barry M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-553</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The major metabolic pathway for elimination of cholesterol is via conversion to bile acids.  In addn. to this metabolic function, bile acids also act as signaling mols. that neg. regulate their own biosynthesis.  However, the precise nature of this signaling pathway has been elusive.  We have isolated an endogenous biliary component (chenodeoxycholic acid) that selectively activates the orphan nuclear receptor, FXR.  Structure-activity anal. defined a subset of related bile acid ligands that activate FXR and promote coactivator recruitment.  Finally, we show that ligand-occupied FXR inhibits transactivation from the oxysterol receptor LXRα, a pos. regulator of cholesterol degrdn.  We suggest that FXR (BAR) is the endogenous bile acid sensor and thus an important regulator of cholesterol homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoauTFRc0isNLVg90H21EOLACvtfcHk0lgbQ4VoJubltw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslCqurg%253D&md5=3665b97ff39dd986916101f5834e5ae5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2800%2980348-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252800%252980348-2%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHollister%26aufirst%3DK.%26aulast%3DSowers%26aufirst%3DL.%2BC.%26aulast%3DForman%26aufirst%3DB.%2BM.%26atitle%3DEndogenous%2520bile%2520acids%2520are%2520ligands%2520for%2520the%2520nuclear%2520receptor%2520FXR%252FBAR%26jtitle%3DMol.%2520Cell%26date%3D1999%26volume%3D3%26spage%3D543%26epage%3D553%26doi%3D10.1016%2FS1097-2765%2800%2980348-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itadani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span> </span><span class="NLM_article-title">Identification of membrane-type receptor for bile acids (M-BAR)</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span><span class="refDoi"> DOI: 10.1016/S0006-291X(02)02550-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2FS0006-291X%2802%2902550-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=12419312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot12kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=714-719&author=T.+Maruyamaauthor=Y.+Miyamotoauthor=T.+Nakamuraauthor=Y.+Tamaiauthor=H.+Okadaauthor=E.+Sugiyamaauthor=T.+Nakamuraauthor=H.+Itadaniauthor=K.+Tanaka&title=Identification+of+membrane-type+receptor+for+bile+acids+%28M-BAR%29&doi=10.1016%2FS0006-291X%2802%2902550-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of membrane-type receptor for bile acids (M-BAR)</span></div><div class="casAuthors">Maruyama, Takaharu; Miyamoto, Yasuhisa; Nakamura, Takao; Tamai, Yoshitaka; Okada, Hiromasa; Sugiyama, Eiji; Nakamura, Tatsuji; Itadani, Hiraku; Tanaka, Kenichi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">714-719</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Bile acids play an essential role in the solubilization and absorption of dietary fat and lipid-sol. vitamins.  Bile acids also modulate the transcription of various genes for enzymes and transport proteins for their own and cholesterol homeostasis through binding to nuclear receptors.  Here we report a novel category of bile acid receptor, a membrane-type G protein-coupled receptor (GPCR), BG37.  Bile acids induced rapid and dose-dependent elevation of intracellular cAMP levels in BG37-expressing cells, but not in mock-transfected cells, independently of nuclear receptor expression.  The rank order of potency of various bile acids for BG37-expressing cells was different from that for the nuclear receptor-mediated response.  These observations demonstrate the presence of two independent signaling pathways for bile acids; membrane-type GPCR for rapid signaling and nuclear receptors for delayed signaling.  Expression of BG37 was detected in various specific tissues, suggesting its physiol. role, although it remains to be further characterized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFW81vc2oQfLVg90H21EOLACvtfcHk0lgtJTaW2HZ8hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot12kt78%253D&md5=6d3133ccf80e6222d7beb52ae31f3324</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2802%2902550-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252802%252902550-0%26sid%3Dliteratum%253Aachs%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DTamai%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DE.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DItadani%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520membrane-type%2520receptor%2520for%2520bile%2520acids%2520%2528M-BAR%2529%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2002%26volume%3D298%26spage%3D714%26epage%3D719%26doi%3D10.1016%2FS0006-291X%2802%2902550-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kawamata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukusumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shintani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">A G protein-coupled receptor responsive to bile acids</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">9435</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span><span class="refDoi"> DOI: 10.1074/jbc.M209706200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1074%2Fjbc.M209706200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=12524422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvV2isrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=9435-9440&author=Y.+Kawamataauthor=R.+Fujiiauthor=M.+Hosoyaauthor=M.+Haradaauthor=H.+Yoshidaauthor=M.+Miwaauthor=S.+Fukusumiauthor=Y.+Habataauthor=T.+Itohauthor=Y.+Shintaniauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=A+G+protein-coupled+receptor+responsive+to+bile+acids&doi=10.1074%2Fjbc.M209706200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A G Protein-coupled Receptor Responsive to Bile Acids</span></div><div class="casAuthors">Kawamata, Yuji; Fujii, Ryo; Hosoya, Masaki; Harada, Masataka; Yoshida, Hiromi; Miwa, Masanori; Fukusumi, Shoji; Habata, Yugo; Itoh, Takashi; Shintani, Yasushi; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9435-9440</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We have identified a G protein-coupled receptor, TGR5, that is responsive to bile acids as a cell-surface receptor.  Bile acids specifically induced receptor internalization, the activation of extracellular signal-regulated kinase mitogen-activated protein kinase, the increase of guanosine 5'-O-3-thio-triphosphate binding in membrane fractions, and intracellular cAMP prodn. in Chinese hamster ovary cells expressing TGR5.  Our quant. analyses for TGR5 mRNA showed that it was abundantly expressed in monocytes/macrophages in human and rabbit.  Treatment with bile acids was found to suppress the functions of rabbit alveolar macrophages including phagocytosis and lipopolysaccharide-stimulated cytokine productions.  We prepd. a monocytic cell line expressing TGR5 by transfecting a TGR5 cDNA into THP-1 cells that did not express TGR5 originally.  Treatment with bile acids suppressed the cytokine productions in the THP-1 cells expressing TGR5, whereas it did not influence those in the original THP-1 cells, suggesting that TGR5 is implicated in the suppression of macrophage functions by bile acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb5GfTzFYNbrVg90H21EOLACvtfcHk0lgtJTaW2HZ8hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvV2isrY%253D&md5=1add10cd2720795a8c1c2fa3a40e6638</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M209706200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M209706200%26sid%3Dliteratum%253Aachs%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DMiwa%26aufirst%3DM.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DHabata%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DShintani%26aufirst%3DY.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DA%2520G%2520protein-coupled%2520receptor%2520responsive%2520to%2520bile%2520acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D9435%26epage%3D9440%26doi%3D10.1074%2Fjbc.M209706200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Porez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prawitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staels, B.</span><span> </span><span class="NLM_article-title">Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1723</span><span class="NLM_x">–</span> <span class="NLM_lpage">1737</span><span class="refDoi"> DOI: 10.1194/jlr.R024794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1194%2Fjlr.R024794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=22550135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ghs7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=1723-1737&author=G.+Porezauthor=J.+Prawittauthor=B.+Grossauthor=B.+Staels&title=Bile+acid+receptors+as+targets+for+the+treatment+of+dyslipidemia+and+cardiovascular+disease&doi=10.1194%2Fjlr.R024794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease</span></div><div class="casAuthors">Porez, Geoffrey; Prawitt, Janne; Gross, Barbara; Staels, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1723-1737</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis.  When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD.  Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge.  Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis.  The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metab., rendering them potential pharmacol. targets for MS therapy.  This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAdJV6_suFibVg90H21EOLACvtfcHk0lilmdkyn1abDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ghs7bM&md5=6ead79e9c31616180658f7660ce0a5e3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R024794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R024794%26sid%3Dliteratum%253Aachs%26aulast%3DPorez%26aufirst%3DG.%26aulast%3DPrawitt%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DB.%26aulast%3DStaels%26aufirst%3DB.%26atitle%3DBile%2520acid%2520receptors%2520as%2520targets%2520for%2520the%2520treatment%2520of%2520dyslipidemia%2520and%2520cardiovascular%2520disease%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2012%26volume%3D53%26spage%3D1723%26epage%3D1737%26doi%3D10.1194%2Fjlr.R024794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Campbell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span> </span><span class="NLM_article-title">Pharmacology, physiology, and mechanisms of incretin hormone action</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span><span class="refDoi"> DOI: 10.1016/j.cmet.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.cmet.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=23684623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=819-837&author=J.+E.+Campbellauthor=D.+J.+Drucker&title=Pharmacology%2C+physiology%2C+and+mechanisms+of+incretin+hormone+action&doi=10.1016%2Fj.cmet.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action</span></div><div class="casAuthors">Campbell, Jonathan E.; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">819-837</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose concns., lipid metab., gut motility, appetite and body wt., and immune function, providing a scientific basis for utilizing incretin-based therapies in the treatment of type 2 diabetes.  Activation of GLP-1 and GIP receptors also leads to nonglycemic effects in multiple tissues, through direct actions on tissues expressing incretin receptors and indirect mechanisms mediated through neuronal and endocrine pathways.  Here we contrast the pharmacol. and physiol. of incretin hormones and review recent advances in mechanisms coupling incretin receptor signaling to pleiotropic metabolic actions in preclin. studies.  We discuss whether mechanisms identified in preclin. studies have potential translational relevance for the treatment of human disease and highlight controversies and uncertainties in incretin biol. that require resoln. in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRNiGuKdmu97Vg90H21EOLACvtfcHk0lilmdkyn1abDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGktbs%253D&md5=8a82721ed5d7542784f27ca95c62a694</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DPharmacology%252C%2520physiology%252C%2520and%2520mechanisms%2520of%2520incretin%2520hormone%2520action%26jtitle%3DCell%2520Metab.%26date%3D2013%26volume%3D17%26spage%3D819%26epage%3D837%26doi%3D10.1016%2Fj.cmet.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Watanabe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houten, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mataki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christoffolete, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messaddeq, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harney, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ezaki, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auwerx, J.</span><span> </span><span class="NLM_article-title">Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">484</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.1038/nature04330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1038%2Fnature04330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=16400329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFWmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=484-489&author=M.+Watanabeauthor=S.+M.+Houtenauthor=C.+Matakiauthor=M.+A.+Christoffoleteauthor=B.+W.+Kimauthor=H.+Satoauthor=N.+Messaddeqauthor=J.+W.+Harneyauthor=O.+Ezakiauthor=T.+Kodamaauthor=K.+Schoonjansauthor=A.+C.+Biancoauthor=J.+Auwerx&title=Bile+acids+induce+energy+expenditure+by+promoting+intracellular+thyroid+hormone+activation&doi=10.1038%2Fnature04330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation</span></div><div class="casAuthors">Watanabe, Mitsuhiro; Houten, Sander M.; Mataki, Chikage; Christoffolete, Marcelo A.; Kim, Brian W.; Sato, Hiroyuki; Messaddeq, Nadia; Harney, John W.; Ezaki, Osamu; Kodama, Tatsuhiko; Schoonjans, Kristina; Bianco, Antonio C.; Auwerx, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7075</span>),
    <span class="NLM_cas:pages">484-489</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">While bile acids (BAs) have long been known to be essential in dietary lipid absorption and cholesterol catabolism, in recent years an important role for BAs as signaling mols. has emerged.  BAs activate mitogen-activated protein kinase pathways, are ligands for the G-protein-coupled receptor (GPCR) TGR5 and activate nuclear hormone receptors such as farnesoid X receptor α (FXR-α; NR1H4).  FXR-α regulates the enterohepatic recycling and biosynthesis of BAs by controlling the expression of genes such as the short heterodimer partner (SHP; NR0B2) that inhibits the activity of other nuclear receptors.  The FXR-α-mediated SHP induction also underlies the downregulation of the hepatic fatty acid and triglyceride biosynthesis and very-low-d. lipoprotein prodn. mediated by sterol-regulatory-element-binding protein 1c.  This indicates that BAs might be able to function beyond the control of BA homeostasis as general metabolic integrators.  The administration of BAs to mice increases energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin.  This novel metabolic effect of BAs is critically dependent on induction of the cyclic-AMP-dependent thyroid hormone activating enzyme type 2 iodothyronine deiodinase (D2) because it is lost in D2-/- mice.  Treatment of brown adipocytes and human skeletal myocytes with BA increases D2 activity and oxygen consumption.  These effects are independent of FXR-α, and instead are mediated by increased cAMP prodn. that stems from the binding of BAs with the G-protein-coupled receptor TGR5.  In both rodents and humans, the most thermogenically important tissues are specifically targeted by this mechanism because they coexpress D2 and TGR5.  The BA-TGR5-cAMP-D2 signaling pathway is therefore a crucial mechanism for fine-tuning energy homeostasis that can be targeted to improve metabolic control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvq784CAfKkrVg90H21EOLACvtfcHk0lhA3Nt3R4ksWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFWmuw%253D%253D&md5=13c8bfe241fac294ba3fb1de99577d67</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature04330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04330%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DHouten%26aufirst%3DS.%2BM.%26aulast%3DMataki%26aufirst%3DC.%26aulast%3DChristoffolete%26aufirst%3DM.%2BA.%26aulast%3DKim%26aufirst%3DB.%2BW.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMessaddeq%26aufirst%3DN.%26aulast%3DHarney%26aufirst%3DJ.%2BW.%26aulast%3DEzaki%26aufirst%3DO.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DBianco%26aufirst%3DA.%2BC.%26aulast%3DAuwerx%26aufirst%3DJ.%26atitle%3DBile%2520acids%2520induce%2520energy%2520expenditure%2520by%2520promoting%2520intracellular%2520thyroid%2520hormone%2520activation%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D484%26epage%3D489%26doi%3D10.1038%2Fnature04330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Broeders, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nascimento, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havekes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roumans, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tailleux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvy, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mottaghy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Marken Lichtenbelt, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrauwen, P.</span><span> </span><span class="NLM_article-title">The bile acid chenodeoxycholic acid increases human brown adipose tissue activity</span> <span class="citation_source-journal">Cell Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">418</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1016/j.cmet.2015.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.cmet.2015.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=26235421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=418-426&author=E.+P.+Broedersauthor=E.+B.+Nascimentoauthor=B.+Havekesauthor=B.+Bransauthor=K.+H.+Roumansauthor=A.+Tailleuxauthor=G.+Schaartauthor=M.+Kouachauthor=J.+Chartonauthor=B.+Deprezauthor=N.+D.+Bouvyauthor=F.+Mottaghyauthor=B.+Staelsauthor=W.+D.+van+Marken+Lichtenbeltauthor=P.+Schrauwen&title=The+bile+acid+chenodeoxycholic+acid+increases+human+brown+adipose+tissue+activity&doi=10.1016%2Fj.cmet.2015.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity</span></div><div class="casAuthors">Broeders, Evie P. M.; Nascimento, Emmani B. M.; Havekes, Bas; Brans, Boudewijn; Roumans, Kay H. M.; Tailleux, Anne; Schaart, Gert; Kouach, Mostafa; Charton, Julie; Deprez, Benoit; Bouvy, Nicole D.; Mottaghy, Felix; Staels, Bart; van Marken Lichtenbelt, Wouter D.; Schrauwen, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">418-426</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The interest in brown adipose tissue (BAT) as a target to combat metabolic disease has recently been renewed with the discovery of functional BAT in humans.  In rodents, BAT can be activated by bile acids, which activate type 2 iodothyronine deiodinase (D2) in BAT via the G-coupled protein receptor TGR5, resulting in increased oxygen consumption and energy expenditure.  Here we examd. the effects of oral supplementation of the bile acid chenodeoxycholic acid (CDCA) on human BAT activity.  Treatment of 12 healthy female subjects with CDCA for 2 days resulted in increased BAT activity.  Whole-body energy expenditure was also increased upon CDCA treatment.  In vitro treatment of primary human brown adipocytes derived with CDCA or specific TGR5 agonists increased mitochondrial uncoupling and D2 expression, an effect that was absent in human primary white adipocytes.  These findings identify bile acids as a target to activate BAT in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIqcIdgYe7ArVg90H21EOLACvtfcHk0lg85wcBLDI-kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KmtbfM&md5=29e30c2fae177db869be0fe7fde441f6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DBroeders%26aufirst%3DE.%2BP.%26aulast%3DNascimento%26aufirst%3DE.%2BB.%26aulast%3DHavekes%26aufirst%3DB.%26aulast%3DBrans%26aufirst%3DB.%26aulast%3DRoumans%26aufirst%3DK.%2BH.%26aulast%3DTailleux%26aufirst%3DA.%26aulast%3DSchaart%26aufirst%3DG.%26aulast%3DKouach%26aufirst%3DM.%26aulast%3DCharton%26aufirst%3DJ.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DBouvy%26aufirst%3DN.%2BD.%26aulast%3DMottaghy%26aufirst%3DF.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3Dvan%2BMarken%2BLichtenbelt%26aufirst%3DW.%2BD.%26aulast%3DSchrauwen%26aufirst%3DP.%26atitle%3DThe%2520bile%2520acid%2520chenodeoxycholic%2520acid%2520increases%2520human%2520brown%2520adipose%2520tissue%2520activity%26jtitle%3DCell%2520Metab.%26date%3D2015%26volume%3D22%26spage%3D418%26epage%3D426%26doi%3D10.1016%2Fj.cmet.2015.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lavoie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balemba, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassileva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mawe, G. M.</span><span> </span><span class="NLM_article-title">Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels</span> <span class="citation_source-journal">J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">588</span><span class="NLM_x">, </span> <span class="NLM_fpage">3295</span><span class="NLM_x">–</span> <span class="NLM_lpage">3305</span><span class="refDoi"> DOI: 10.1113/jphysiol.2010.192146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1113%2Fjphysiol.2010.192146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=20624794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2rur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=588&publication_year=2010&pages=3295-3305&author=B.+Lavoieauthor=O.+B.+Balembaauthor=C.+Godfreyauthor=C.+A.+Watsonauthor=G.+Vassilevaauthor=C.+U.+Corveraauthor=M.+T.+Nelsonauthor=G.+M.+Mawe&title=Hydrophobic+bile+salts+inhibit+gallbladder+smooth+muscle+function+via+stimulation+of+GPBAR1+receptors+and+activation+of+KATP+channels&doi=10.1113%2Fjphysiol.2010.192146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels</span></div><div class="casAuthors">Lavoie, Brigitte; Balemba, Onesmo B.; Godfrey, Cody; Watson, Conall A.; Vassileva, Galya; Corvera, Carlos U.; Nelson, Mark T.; Mawe, Gary M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">588</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3295-3305</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Hydrophobic bile salts are thought to contribute to the disruption of gallbladder smooth muscle (GBSM) function that occurs in gallstone disease, but their mechanism of action is unknown.  The current study was undertaken to det. how hydrophobic bile salts interact with GBSM, and how they reduce GBSM activity.  The effect of hydrophobic bile salts on the activity of GBSM was measured by intracellular recording and calcium imaging using wholemount prepns. from guinea pig and mouse gallbladder.  RT-PCR and immunohistochem. were used to evaluate expression of the G protein-coupled bile acid receptor, GPBAR1.  Application of tauro-chenodeoxycholate (CDC, 50-100 μM) to in situ GBSM rapidly reduced spontaneous Ca2+ flashes and action potentials, and caused a membrane hyperpolarization.  Immunoreactivity and transcript for GPBAR1 were detected in gallbladder muscularis.  The GPBAR1 agonist, tauro-lithocholic acid (LCA, 10 μM) mimicked the effect of CDC on GBSM.  The actions of LCA were blocked by the protein kinase A (PKA) inhibitor, KT5720 (0.5-1.0 μM) and the KATP channel blocker, glibenclamide (10 μM).  Furthermore, LCA failed to disrupt GBSM activity in Gpbar1-/- mice.  The findings of this study indicate that hydrophobic bile salts activate GPBAR1 on GBSM, and this leads to activation of the cAMP-PKA pathway, and ultimately the opening of KATP channels, thus hyperpolarizing the membrane and decreasing GBSM activity.  This inhibitory effect of hydrophobic bile salt activation of GPBAR1 could be a contributing factor in the manifestation of gallstone disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFGGa0RZVV67Vg90H21EOLACvtfcHk0lg85wcBLDI-kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2rur%252FP&md5=d9f817f60f8ba9f97b20958af25c875e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2010.192146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2010.192146%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DB.%26aulast%3DBalemba%26aufirst%3DO.%2BB.%26aulast%3DGodfrey%26aufirst%3DC.%26aulast%3DWatson%26aufirst%3DC.%2BA.%26aulast%3DVassileva%26aufirst%3DG.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26aulast%3DNelson%26aufirst%3DM.%2BT.%26aulast%3DMawe%26aufirst%3DG.%2BM.%26atitle%3DHydrophobic%2520bile%2520salts%2520inhibit%2520gallbladder%2520smooth%2520muscle%2520function%2520via%2520stimulation%2520of%2520GPBAR1%2520receptors%2520and%2520activation%2520of%2520KATP%2520channels%26jtitle%3DJ.%2520Physiol.%26date%3D2010%26volume%3D588%26spage%3D3295%26epage%3D3305%26doi%3D10.1113%2Fjphysiol.2010.192146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Keitel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cupisti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullmer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoefel, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubitz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Häussinger, D.</span><span> </span><span class="NLM_article-title">The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">870</span><span class="refDoi"> DOI: 10.1002/hep.23032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1002%2Fhep.23032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=861-870&author=V.+Keitelauthor=K.+Cupistiauthor=C.+Ullmerauthor=W.+T.+Knoefelauthor=R.+Kubitzauthor=D.+H%C3%A4ussinger&title=The+membrane-bound+bile+acid+receptor+TGR5+is+localized+in+the+epithelium+of+human+gallbladders&doi=10.1002%2Fhep.23032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.23032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23032%26sid%3Dliteratum%253Aachs%26aulast%3DKeitel%26aufirst%3DV.%26aulast%3DCupisti%26aufirst%3DK.%26aulast%3DUllmer%26aufirst%3DC.%26aulast%3DKnoefel%26aufirst%3DW.%2BT.%26aulast%3DKubitz%26aufirst%3DR.%26aulast%3DH%25C3%25A4ussinger%26aufirst%3DD.%26atitle%3DThe%2520membrane-bound%2520bile%2520acid%2520receptor%2520TGR5%2520is%2520localized%2520in%2520the%2520epithelium%2520of%2520human%2520gallbladders%26jtitle%3DHepatology%26date%3D2009%26volume%3D50%26spage%3D861%26epage%3D870%26doi%3D10.1002%2Fhep.23032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Alemi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poole, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattaruzza, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cevikbas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Materazzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero-Alba, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valdez-Morales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottrell, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geppetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunnett, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvera, C. U.</span><span> </span><span class="NLM_article-title">The TGR5 receptor mediates bile acid-induced itch and analgesia</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">1513</span><span class="NLM_x">–</span> <span class="NLM_lpage">1530</span><span class="refDoi"> DOI: 10.1172/JCI64551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1172%2FJCI64551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=23524965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVKhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=1513-1530&author=F.+Alemiauthor=E.+Kwonauthor=D.+P.+Pooleauthor=T.+Lieuauthor=V.+Lyoauthor=F.+Cattaruzzaauthor=F.+Cevikbasauthor=M.+Steinhoffauthor=R.+Nassiniauthor=S.+Materazziauthor=R.+Guerrero-Albaauthor=E.+Valdez-Moralesauthor=G.+S.+Cottrellauthor=K.+Schoonjansauthor=P.+Geppettiauthor=S.+J.+Vannerauthor=N.+W.+Bunnettauthor=C.+U.+Corvera&title=The+TGR5+receptor+mediates+bile+acid-induced+itch+and+analgesia&doi=10.1172%2FJCI64551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The TGR5 receptor mediates bile acid-induced itch and analgesia</span></div><div class="casAuthors">Alemi, Farzad; Kwon, Edwin; Poole, Daniel P.; Lieu, TinaMarie; Lyo, Victoria; Cattaruzza, Fiore; Cevikbas, Ferda; Steinhoff, Martin; Nassini, Romina; Materazzi, Serena; Guerrero-Alba, Raquel; Valdez-Morales, Eduardo; Cottrell, Graeme S.; Schoonjans, Kristina; Geppetti, Pierangelo; Vanner, Stephen J.; Bunnett, Nigel W.; Corvera, Carlos U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1513-1530</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Patients with cholestatic disease exhibit pruritus and analgesia, but the mechanisms underlying these symptoms are unknown.  We report that bile acids, which are elevated in the circulation and tissues during cholestasis, cause itch and analgesia by activating the GPCR TGR5.  TGR5 was detected in peptidergic neurons of mouse dorsal root ganglia and spinal cord that transmit itch and pain, and in dermal macrophages that contain opioids.  Bile acids and a TGR5-selective agonist induced hyperexcitability of dorsal root ganglia neurons and stimulated the release of the itch and analgesia transmitters gastrin-releasing peptide and leucine-enkephalin.  Intradermal injection of bile acids and a TGR5-selective agonist stimulated scratching behavior by gastrin-releasing peptide- and opioid-dependent mechanisms in mice.  Scratching was attenuated in Tgr5-KO mice but exacerbated in Tgr5-Tg mice (overexpressing mouse TGR5), which exhibited spontaneous pruritus.  Intraplantar and intrathecal injection of bile acids caused analgesia to mech. stimulation of the paw by an opioid-dependent mechanism.  Both peripheral and central mechanisms of analgesia were absent from Tgr5-KO mice.  Thus, bile acids activate TGR5 on sensory nerves, stimulating the release of neuropeptides in the spinal cord that transmit itch and analgesia.  These mechanisms could contribute to pruritus and painless jaundice that occur during cholestatic liver diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo96EIvqKSC4rVg90H21EOLACvtfcHk0lhlVU3q-InnAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVKhsL8%253D&md5=cd059ff96952743f065d002d7eb2d1cd</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1172%2FJCI64551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64551%26sid%3Dliteratum%253Aachs%26aulast%3DAlemi%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DE.%26aulast%3DPoole%26aufirst%3DD.%2BP.%26aulast%3DLieu%26aufirst%3DT.%26aulast%3DLyo%26aufirst%3DV.%26aulast%3DCattaruzza%26aufirst%3DF.%26aulast%3DCevikbas%26aufirst%3DF.%26aulast%3DSteinhoff%26aufirst%3DM.%26aulast%3DNassini%26aufirst%3DR.%26aulast%3DMaterazzi%26aufirst%3DS.%26aulast%3DGuerrero-Alba%26aufirst%3DR.%26aulast%3DValdez-Morales%26aufirst%3DE.%26aulast%3DCottrell%26aufirst%3DG.%2BS.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DGeppetti%26aufirst%3DP.%26aulast%3DVanner%26aufirst%3DS.%2BJ.%26aulast%3DBunnett%26aufirst%3DN.%2BW.%26aulast%3DCorvera%26aufirst%3DC.%2BU.%26atitle%3DThe%2520TGR5%2520receptor%2520mediates%2520bile%2520acid-induced%2520itch%2520and%2520analgesia%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D1513%26epage%3D1530%26doi%3D10.1172%2FJCI64551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Futatsugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahnck, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautreau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman-Perez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinchey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowski, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roush, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolford, A. C.</span><span> </span><span class="NLM_article-title">Optimization of triazole-based TGR5 agonists towards orally available agents</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1039/C2MD20174G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1039%2FC2MD20174G" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=205-210&author=K.+Futatsugiauthor=K.+B.+Bahnckauthor=M.+B.+Brennerauthor=J.+Buxtonauthor=J.+E.+Chinauthor=S.+B.+Coffeyauthor=J.+Dubinsauthor=D.+Flynnauthor=D.+Gautreauauthor=A.+Guzman-Perezauthor=J.+R.+Hadcockauthor=D.+Hepworthauthor=M.+Herrauthor=T.+Hincheyauthor=A.+M.+Janssenauthor=S.+M.+Jenningsauthor=W.+Jiaoauthor=S.+Y.+Lavergneauthor=B.+Liauthor=M.+Liauthor=M.+J.+Munchhofauthor=S.+T.+M.+Orrauthor=D.+W.+Piotrowskiauthor=N.+S.+Roushauthor=M.+Sammonsauthor=B.+D.+Stevensauthor=G.+Storerauthor=J.+Wangauthor=J.+S.+Warmusauthor=L.+Weiauthor=A.+C.+Wolford&title=Optimization+of+triazole-based+TGR5+agonists+towards+orally+available+agents&doi=10.1039%2FC2MD20174G"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1039%2FC2MD20174G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20174G%26sid%3Dliteratum%253Aachs%26aulast%3DFutatsugi%26aufirst%3DK.%26aulast%3DBahnck%26aufirst%3DK.%2BB.%26aulast%3DBrenner%26aufirst%3DM.%2BB.%26aulast%3DBuxton%26aufirst%3DJ.%26aulast%3DChin%26aufirst%3DJ.%2BE.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DDubins%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DD.%26aulast%3DGautreau%26aufirst%3DD.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHerr%26aufirst%3DM.%26aulast%3DHinchey%26aufirst%3DT.%26aulast%3DJanssen%26aufirst%3DA.%2BM.%26aulast%3DJennings%26aufirst%3DS.%2BM.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DLavergne%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DRoush%26aufirst%3DN.%2BS.%26aulast%3DSammons%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DStorer%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWolford%26aufirst%3DA.%2BC.%26atitle%3DOptimization%2520of%2520triazole-based%2520TGR5%2520agonists%2520towards%2520orally%2520available%2520agents%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D205%26epage%3D210%26doi%3D10.1039%2FC2MD20174G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Piotrowski, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futatsugi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmus, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman-Cook, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Londregan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hepworth, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavergne, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolford, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roush, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinchey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. A.</span><span> </span><span class="NLM_article-title">Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1021/ml300277t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300277t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=63-68&author=D.+W.+Piotrowskiauthor=K.+Futatsugiauthor=J.+S.+Warmusauthor=S.+T.+Orrauthor=K.+D.+Freeman-Cookauthor=A.+T.+Londreganauthor=L.+Weiauthor=S.+M.+Jenningsauthor=M.+Herrauthor=S.+B.+Coffeyauthor=W.+Jiaoauthor=G.+Storerauthor=D.+Hepworthauthor=J.+Wangauthor=S.+Y.+Lavergneauthor=J.+E.+Chinauthor=J.+R.+Hadcockauthor=M.+B.+Brennerauthor=A.+C.+Wolfordauthor=A.+M.+Janssenauthor=N.+S.+Roushauthor=J.+Buxtonauthor=T.+Hincheyauthor=A.+S.+Kalgutkarauthor=R.+Sharmaauthor=D.+A.+Flynn&title=Identification+of+tetrahydropyrido%5B4%2C3-d%5Dpyrimidine+amides+as+a+new+class+of+orally+bioavailable+TGR5+agonists&doi=10.1021%2Fml300277t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists</span></div><div class="casAuthors">Piotrowski, David W.; Futatsugi, Kentaro; Warmus, Joseph S.; Orr, Suvi T. M.; Freeman-Cook, Kevin D.; Londregan, Allyn T.; Wei, Liuqing; Jennings, Sandra M.; Herr, Michael; Coffey, Steven B.; Jiao, Wenhua; Storer, Gregory; Hepworth, David; Wang, Jian; Lavergne, Sophie Y.; Chin, Janice E.; Hadcock, John R.; Brenner, Martin B.; Wolford, Angela C.; Janssen, Ann M.; Roush, Nicole S.; Buxton, Joanne; Hinchey, Terri; Kalgutkar, Amit S.; Sharma, Raman; Flynn, Declan A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-68</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Takeda G-protein-coupled receptor 5 (TGR5) represents an exciting biol. target for the potential treatment of diabetes and metabolic syndrome.  A new class of high-throughput screening (HTS)-derived tetrahydropyrido[4,3-d]pyrimidine amide TGR5 agonists is disclosed.  We describe our effort to identify an orally available agonist suitable for assessment of systemic TGR5 agonism.  This effort resulted in identification of I, which had acceptable potency and pharmacokinetic properties to allow for in vivo assessment in dog.  A key aspect of this work was the calibration of human and dog in vitro assay systems that could be linked with data from a human ex vivo peripheral blood monocyte assay that expresses receptor at endogenous levels.  Potency from the human in vitro assay was also found to correlate with data from an ex vivo human whole blood assay.  This calibration exercise provided confidence that I could be used to drive plasma exposures sufficient to test the effects of systemic activation of TGR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQmElgFEINRbVg90H21EOLACvtfcHk0ljTF3myp0nO9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrfP&md5=7806a5272db5d3b6bc935f6df38a2b04</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fml300277t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300277t%26sid%3Dliteratum%253Aachs%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DFutatsugi%26aufirst%3DK.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DFreeman-Cook%26aufirst%3DK.%2BD.%26aulast%3DLondregan%26aufirst%3DA.%2BT.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DJennings%26aufirst%3DS.%2BM.%26aulast%3DHerr%26aufirst%3DM.%26aulast%3DCoffey%26aufirst%3DS.%2BB.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DStorer%26aufirst%3DG.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLavergne%26aufirst%3DS.%2BY.%26aulast%3DChin%26aufirst%3DJ.%2BE.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DBrenner%26aufirst%3DM.%2BB.%26aulast%3DWolford%26aufirst%3DA.%2BC.%26aulast%3DJanssen%26aufirst%3DA.%2BM.%26aulast%3DRoush%26aufirst%3DN.%2BS.%26aulast%3DBuxton%26aufirst%3DJ.%26aulast%3DHinchey%26aufirst%3DT.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DFlynn%26aufirst%3DD.%2BA.%26atitle%3DIdentification%2520of%2520tetrahydropyrido%255B4%252C3-d%255Dpyrimidine%2520amides%2520as%2520a%2520new%2520class%2520of%2520orally%2520bioavailable%2520TGR5%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D63%26epage%3D68%26doi%3D10.1021%2Fml300277t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fryer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nodop Mazurek, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaude, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skow, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthukumarana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilpin, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinallo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanyal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harcken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modis, L. K.</span><span> </span><span class="NLM_article-title">G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K<sub>Ca</sub>1.1 (BK<sub>Ca</sub>)-dependent mechanism</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1124/jpet.113.210005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1124%2Fjpet.113.210005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=24399854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvFajtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=421-431&author=R.+M.+Fryerauthor=K.+J.+Ngauthor=S.+G.+Nodop+Mazurekauthor=L.+Patnaudeauthor=D.+J.+Skowauthor=A.+Muthukumaranaauthor=K.+E.+Gilpinauthor=R.+M.+Dinalloauthor=D.+Kuzmichauthor=J.+Lordauthor=S.+Sanyalauthor=H.+Yuauthor=C.+Harckenauthor=M.+A.+Cernyauthor=M.+C.+Cernyauthor=E.+R.+Hickeyauthor=L.+K.+Modis&title=G+protein-coupled+bile+acid+receptor+1+stimulation+mediates+arterial+vasodilation+through+a+KCa1.1+%28BKCa%29-dependent+mechanism&doi=10.1124%2Fjpet.113.210005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a KCa1.1 (BKCa)-dependent mechanism</span></div><div class="casAuthors">Fryer, Ryan M.; Ng, Khing Jow; Mazurek, Suzanne G. Nodop; Patnaude, Lori; Skow, Donna J.; Muthukumarana, Akalushi; Gilpin, Kyle E.; Dinallo, Roger M.; Kuzmich, Daniel; Lord, John; Sanyal, Sulagna; Yu, Hui; Harcken, Christian; Cerny, Matthew C.; Hickey, Eugene R.; Modis, Louise K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">421-431, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bile acids (BAs) and BA receptors, including G protein-coupled bile acid receptor 1 (GPBAR1), represent novel targets for the treatment of metabolic and inflammatory disorders.  However, BAs elicit myriad effects on cardiovascular function, although this has not been specifically ascribed to GPBAR1.  This study was designed to test whether stimulation of GPBAR1 elicits effects on cardiovascular function that are mechanism based that can be identified in acute ex vivo and in vivo cardiovascular models, to delineate whether effects were due to pathways known to be modulated by BAs, and to establish whether a therapeutic window between in vivo cardiovascular liabilities and on-target efficacy could be defined.  The results demonstrated that the infusion of three structurally diverse and selective GPBAR1 agonists produced marked redns. in vascular tone and blood pressure in dog, but not in rat, as well as reflex tachycardia and a pos. inotropic response, effects that manifested in an enhanced cardiac output.  Changes in cardiovascular function were unrelated to modulation of the levothyroxine/thyroxine axis and were nitric oxide independent.  A direct effect on vascular tone was confirmed in dog isolated vascular rings, whereby concn.-dependent decreases in tension that were tightly correlated with redns. in vascular tone obsd. in vivo and were blocked by iberiotoxin.  Compd. concns. in which cardiovascular effects occurred, both ex vivo and in vivo, could not be sepd. from those necessary for modulation of GPBAR1-mediated efficacy, resulting in project termination.  These results are the first to clearly demonstrate direct and potent peripheral arterial vasodilation due to GPBAR1 stimulation in vivo through activation of large conductance Ca2+ activated potassium channel KCa1.1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbGVwYRqt84LVg90H21EOLACvtfcHk0ljTF3myp0nO9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvFajtL0%253D&md5=fe48570c7b439077da6787b5a292d369</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210005%26sid%3Dliteratum%253Aachs%26aulast%3DFryer%26aufirst%3DR.%2BM.%26aulast%3DNg%26aufirst%3DK.%2BJ.%26aulast%3DNodop%2BMazurek%26aufirst%3DS.%2BG.%26aulast%3DPatnaude%26aufirst%3DL.%26aulast%3DSkow%26aufirst%3DD.%2BJ.%26aulast%3DMuthukumarana%26aufirst%3DA.%26aulast%3DGilpin%26aufirst%3DK.%2BE.%26aulast%3DDinallo%26aufirst%3DR.%2BM.%26aulast%3DKuzmich%26aufirst%3DD.%26aulast%3DLord%26aufirst%3DJ.%26aulast%3DSanyal%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DHarcken%26aufirst%3DC.%26aulast%3DCerny%26aufirst%3DM.%2BA.%26aulast%3DCerny%26aufirst%3DM.%2BC.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DModis%26aufirst%3DL.%2BK.%26atitle%3DG%2520protein-coupled%2520bile%2520acid%2520receptor%25201%2520stimulation%2520mediates%2520arterial%2520vasodilation%2520through%2520a%2520KCa1.1%2520%2528BKCa%2529-dependent%2520mechanism%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D421%26epage%3D431%26doi%3D10.1124%2Fjpet.113.210005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Charmot, D.</span><span> </span><span class="NLM_article-title">Non-systemic drugs: a critical review</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1434</span><span class="NLM_x">–</span> <span class="NLM_lpage">1445</span><span class="refDoi"> DOI: 10.2174/138161212799504858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.2174%2F138161212799504858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=22300258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1434-1445&author=D.+Charmot&title=Non-systemic+drugs%3A+a+critical+review&doi=10.2174%2F138161212799504858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Non-systemic drugs: a critical review</span></div><div class="casAuthors">Charmot, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1434-1445</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation.  The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia.  The field has evolved towards non-absorbable small mols. or peptides targeting luminal enzymes or transporters for the treatment of mineral metab. disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections.  From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation.  The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia.  We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations.  The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdEQRhLF7irVg90H21EOLACvtfcHk0lhzsatyaBZ7Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D&md5=7a391aa741bb1a4bba9516b0f39acee1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F138161212799504858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212799504858%26sid%3Dliteratum%253Aachs%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DNon-systemic%2520drugs%253A%2520a%2520critical%2520review%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D1434%26epage%3D1445%26doi%3D10.2174%2F138161212799504858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Duan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span> </span><span class="NLM_article-title">Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3315</span><span class="NLM_x">–</span> <span class="NLM_lpage">3328</span><span class="refDoi"> DOI: 10.1021/jm500829b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500829b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtF2ktb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3315-3328&author=H.+Duanauthor=M.+Ningauthor=Q.+Zouauthor=Y.+Yeauthor=Y.+Fengauthor=L.+Zhangauthor=Y.+Lengauthor=J.+Shen&title=Discovery+of+intestinal+targeted+TGR5+agonists+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm500829b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Duan, Hongliang; Ning, Mengmeng; Zou, Qingan; Ye, Yangliang; Feng, Ying; Zhang, Lina; Leng, Ying; Shen, Jianhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3315-3328</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects.  A series of low-absorbed TGR5 agonists was prepd. by modifying compd. 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine.  Compd. 15c, with a mol. wt. of 1401, a PSA value of 223 Å2, and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo.  Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-mol. TGR5 agonist 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-HVYzFsOrfbVg90H21EOLACvtfcHk0lhzsatyaBZ7Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtF2ktb0%253D&md5=527ba4d3e48e8f01f76bb7e88127d080</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm500829b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500829b%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DNing%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520intestinal%2520targeted%2520TGR5%2520agonists%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3315%26epage%3D3328%26doi%3D10.1021%2Fjm500829b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Cao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, M.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Q.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.-H.</span><span> </span><span class="NLM_article-title">Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">28676</span><span class="refDoi"> DOI: 10.1038/srep28676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1038%2Fsrep28676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=27339735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=28676&author=H.+Caoauthor=Z.-X.+Chenauthor=K.+Wangauthor=M.-M.+Ningauthor=Q.-A.+Zouauthor=Y.+Fengauthor=Y.-L.+Yeauthor=Y.+Lengauthor=J.-H.+Shen&title=Intestinally-targeted+TGR5+agonists+equipped+with+quaternary+ammonium+have+an+improved+hypoglycemic+effect+and+reduced+gallbladder+filling+effect&doi=10.1038%2Fsrep28676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect</span></div><div class="casAuthors">Cao, Hua; Chen, Zhi-Xiang; Wang, Kai; Ning, Meng-Meng; Zou, Qing-An; Feng, Ying; Ye, Yang-Liang; Leng, Ying; Shen, Jian-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">28676</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TGR5 activation of enteroendocrine cells increases glucagon-like peptide 1 (GLP-1) release, which maintains glycemic homeostasis.  However, TGR5 activation in the gallbladder and heart is assocd. with severe side effects.  Therefore, intestinally-targeted TGR5 agonists were suggested as potential hypoglycemic agents with minimal side effects.  However, until now no such compds. with robust glucose-lowering effects were reported, esp. in diabetic animal models.  Herein, we identify a TGR5 agonist, 26a, which was proven to be intestinally-targeted through pharmacokinetic studies.  26A was used as a tool drug to verify the intestinally-targeted strategy. 26a displayed a robust and long-lasting hypoglycemic effect in ob/ob mice (once a day dosing (QD) and 18-day treatment) owing to sustained stimulation of GLP-1 secretion, which suggested that robust hypoglycemic effect could be achieved with activation of TGR5 in intestine alone.  However, the gallbladder filling effect of 26a was rather complicated.  Although the gallbladder filling effect of 26a was decreased in mice after once a day dosing, this side effect was still not eliminated.  To solve the problem above, several research strategies were raised for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOH1FDqJK-brVg90H21EOLACvtfcHk0lhzsatyaBZ7Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKiurrM&md5=9d82249704d95dde0ecf5bc76e67eaab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fsrep28676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep28676%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.-X.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DNing%26aufirst%3DM.-M.%26aulast%3DZou%26aufirst%3DQ.-A.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.-L.%26aulast%3DLeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.-H.%26atitle%3DIntestinally-targeted%2520TGR5%2520agonists%2520equipped%2520with%2520quaternary%2520ammonium%2520have%2520an%2520improved%2520hypoglycemic%2520effect%2520and%2520reduced%2520gallbladder%2520filling%2520effect%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D28676%26doi%3D10.1038%2Fsrep28676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kramer, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glombik, H.</span><span> </span><span class="NLM_article-title">Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1016</span><span class="refDoi"> DOI: 10.2174/092986706776361003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.2174%2F092986706776361003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=16611081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslKqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=997-1016&author=W.+Kramerauthor=H.+Glombik&title=Bile+acid+reabsorption+inhibitors+%28BARI%29%3A+novel+hypolipidemic+drugs&doi=10.2174%2F092986706776361003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs</span></div><div class="casAuthors">Kramer, Werner; Glombik, Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">997-1016</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The enterohepatic circulation of bile acids is a major regulator of serum cholesterol homeostasis.  After biosynthesis from cholesterol in the liver, bile acids are secreted with bile into the lumen of the small intestine to aid in the digestion and absorption of fat and fat-sol. vitamins.  The bile acids are nearly quant. reabsorbed in the terminal ileum by a Na+-dependent transport system (IBAT) and are transported with portal blood to the liver and taken up by a second Na+-/bile acid cotransporter (LBAT) to be resecreted into bile.  In the liver bile acids inhibit the rate-limiting enzyme for the conversion of cholesterol into bile acid: cholesterol-7α-hydroxylase; interruption of the enterohepatic circulation of bile acids withdraws this feedback inhibition and leads to an upregulation of hepatic LDL-receptors with a concomitant decrease of serum LDL-levels.  Specific inhibitors of the ileal bile acid transporter belonging to different chemotypes have been developed in recent years for this purpose, some now entering clin. stage.  To exert a profound systemic effect these compds. do not need to be available systemically but can act from the luminal side of the small intestine, which offers the advantage to avoid the well-known adverse side effects of other hypolipidemic drugs like statins due to metab. and drug-drug interactions in the liver.  This implies several aspects in compd. optimization and drug development quite different from std. procedures, for example the concept of low absorption drugs was established to avoid systemic side effects.  This review article covers the mechanistic and therapeutic principles of the approach and presents an overview on the mol. target, the discovery of specific inhibitors and resp. optimization strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXNSDtAqiZbVg90H21EOLACvtfcHk0li7DGEkxeryfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslKqtLs%253D&md5=8411f5d6f3e3218ad5ba6cb8fe2075c4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F092986706776361003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706776361003%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DW.%26aulast%3DGlombik%26aufirst%3DH.%26atitle%3DBile%2520acid%2520reabsorption%2520inhibitors%2520%2528BARI%2529%253A%2520novel%2520hypolipidemic%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D997%26epage%3D1016%26doi%3D10.2174%2F092986706776361003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Bollu, V.; Boren, B. C.; Dalgard, J. E.; Flatt, B. T.; HAQ, N.; Hudson, S.; Mohan, R.; Morrissey, M.; Pratt, B.; Wang, T.-L.</span> Triazole and Imidazole Derivatives for Use as TGR5 Agonists in the Treatment of Diabetes and Obesity. World Patent WO2010/093845,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bollu%2C+V.%3B+Boren%2C+B.+C.%3B+Dalgard%2C+J.+E.%3B+Flatt%2C+B.+T.%3B+HAQ%2C+N.%3B+Hudson%2C+S.%3B+Mohan%2C+R.%3B+Morrissey%2C+M.%3B+Pratt%2C+B.%3B+Wang%2C+T.-L.+Triazole+and+Imidazole+Derivatives+for+Use+as+TGR5+Agonists+in+the+Treatment+of+Diabetes+and+Obesity.+World+Patent+WO2010%2F093845%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBollu%26aufirst%3DV.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zamansky, I.; Galvin, G.; Girardet, J.-L.</span> Polymorphic, Crystalline and Mesophase Forms of Sodium 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and Uses Thereof. World Patent WO/2011/085009,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Zamansky%2C+I.%3B+Galvin%2C+G.%3B+Girardet%2C+J.-L.+Polymorphic%2C+Crystalline+and+Mesophase+Forms+of+Sodium+2-%285-Bromo-4-%284-cyclopropylnaphthalen-1-yl%29-4H-1%2C2%2C4-triazol-3-ylthio%29acetate%2C+and+Uses+Thereof.+World+Patent+WO%2F2011%2F085009%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZamansky%26aufirst%3DI.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lasalle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajaa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoguet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Obbergen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roussel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charton, J.</span><span> </span><span class="NLM_article-title">Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P)</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2015.01.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.tetlet.2015.01.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=1011-1014&author=M.+Lasalleauthor=S.+Piconauthor=B.+Rajaaauthor=V.+Hoguetauthor=J.+Van+Obbergenauthor=P.+Rousselauthor=B.+Deprezauthor=J.+Charton&title=Access+to+newly+functionalized+imidazole+derivatives%3A+efficient+synthesis+of+novel+5-amino-2-thioimidazoles+using+propylphosphonic+anhydride+%28%C2%AET3P%29&doi=10.1016%2Fj.tetlet.2015.01.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P)</span></div><div class="casAuthors">Lasalle, Manuel; Picon, Sylvain; Boulahjar, Rajaa; Hoguet, Vanessa; Van Obbergen, Jolien; Roussel, Pascal; Deprez, Benoit; Charton, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1011-1014</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We describe here an efficient method to synthesize 5-amino-2-thioimidazole compds. by T3P-mediated cyclization of N-acetamidoisothiourea intermediates.  E.g., in presence of T3P, cyclization/cyclodehydration of N-acetamidoisothiourea intermediate (I) gave 58% imidazole deriv. (II).  The newly functionalized 5-amino-2-thioimidazole compds. are finally obtained in 5 steps from an amine as starting block.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDvXr2kChRcLVg90H21EOLACvtfcHk0li7DGEkxeryfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFerug%253D%253D&md5=9bbd1dc423a88c19aea1808c85f3472b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2015.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2015.01.046%26sid%3Dliteratum%253Aachs%26aulast%3DLasalle%26aufirst%3DM.%26aulast%3DPicon%26aufirst%3DS.%26aulast%3DRajaa%26aufirst%3DB.%26aulast%3DHoguet%26aufirst%3DV.%26aulast%3DVan%2BObbergen%26aufirst%3DJ.%26aulast%3DRoussel%26aufirst%3DP.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DCharton%26aufirst%3DJ.%26atitle%3DAccess%2520to%2520newly%2520functionalized%2520imidazole%2520derivatives%253A%2520efficient%2520synthesis%2520of%2520novel%25205-amino-2-thioimidazoles%2520using%2520propylphosphonic%2520anhydride%2520%2528%25C2%25AET3P%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D2015%26volume%3D56%26spage%3D1011%26epage%3D1014%26doi%3D10.1016%2Fj.tetlet.2015.01.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Fournie-Zaluski, M.-C.; Llorens-Cortes, C.; Roques, B. P.; Corvol, P.</span><span> </span><span class="NLM_article-title">Novel derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same</span>. US 2006/0135602,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.-C.+Fournie-Zaluski&author=C.+Llorens-Cortes&author=B.+P.+Roques&author=P.+Corvol&title=Novel+derivatives+of+4%2C4%E2%80%B2-dithiobis-%283-aminobutane-1-sulfphonates%29+and+compositions+containing+same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFournie-Zaluski%26aufirst%3DM.-C.%26atitle%3DNovel%2520derivatives%2520of%25204%252C4%25E2%2580%25B2-dithiobis-%25283-aminobutane-1-sulfphonates%2529%2520and%2520compositions%2520containing%2520same%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Egan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span> </span><span class="NLM_article-title">Prediction of drug absorption using multivariate statistics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3877</span><span class="refDoi"> DOI: 10.1021/jm000292e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&author=W.+J.+Eganauthor=K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+drug+absorption+using+multivariate+statistics&doi=10.1021%2Fjm000292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0ljWBJYlpuxpiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520drug%2520absorption%2520using%2520multivariate%2520statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3867%26epage%3D3877%26doi%3D10.1021%2Fjm000292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span><span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0ljWBJYlpuxpiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Palm, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artursson, P.</span><span> </span><span class="NLM_article-title">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1023/A:1012188625088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1023%2FA%3A1012188625088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=9165525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=568-571&author=K.+Palmauthor=P.+Stenbergauthor=K.+Luthmanauthor=P.+Artursson&title=Polar+molecular+surface+properties+predict+the+intestinal+absorption+of+drugs+in+humans&doi=10.1023%2FA%3A1012188625088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span></div><div class="casAuthors">Palm, Katrin; Stenberg, Patric; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum</span>)
        </div><div class="casAbstract">A theor. method was devised for prediction of drug absorption after oral administration to humans.  Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated.  The compds. also displayed diversity in physicochem. properties such as lipophilicity, hydrogen bonding potential and mol. size.  The dynamic mol. surface properties of the compds. were calcd., taking into account their 3-dimensional shape and flexibility.  An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar mol. surface area (PSAd) (r2 = 0.94).  The relationship was stronger than those obtained for more established predictors of drug absorption.  Drugs that are completely absorbed (FA > 90%) had a PSAd ≤ 60 Å2 while drugs that are < 10% absorbed had a PSAd ≥ 140 Å2.  PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW66hupHIyLVg90H21EOLACvtfcHk0lht2AM0MxyLCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D&md5=1394f0d1059e7d99ee02be977b92da8b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012188625088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012188625088%26sid%3Dliteratum%253Aachs%26aulast%3DPalm%26aufirst%3DK.%26aulast%3DStenberg%26aufirst%3DP.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DPolar%2520molecular%2520surface%2520properties%2520predict%2520the%2520intestinal%2520absorption%2520of%2520drugs%2520in%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D568%26epage%3D571%26doi%3D10.1023%2FA%3A1012188625088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmstrom, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umetani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliewer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangelsdorf, D. J.</span><span> </span><span class="NLM_article-title">The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling</span> <span class="citation_source-journal">Mol. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1066</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.1210/me.2010-0460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1210%2Fme.2010-0460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=21454404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsl2msLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1066-1071&author=T.+Liauthor=S.+R.+Holmstromauthor=S.+Kirauthor=M.+Umetaniauthor=D.+R.+Schmidtauthor=S.+A.+Kliewerauthor=D.+J.+Mangelsdorf&title=The+G+protein-coupled+bile+acid+receptor%2C+TGR5%2C+stimulates+gallbladder+filling&doi=10.1210%2Fme.2010-0460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling</span></div><div class="casAuthors">Li, Tingting; Holmstrom, Sam R.; Kir, Serkan; Umetani, Michihisa; Schmidt, Daniel R.; Kliewer, Steven A.; Mangelsdorf, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1066-1071</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">TGR5 is a G protein-coupled bile acid receptor present in brown adipose tissue and intestine, where its agonism increases energy expenditure and lowers blood glucose.  Thus, it is an attractive drug target for treating human metabolic disease.  However, TGR5 is also highly expressed in gallbladder, where its functions are less well characterized.  Here, we demonstrate that TGR5 stimulates the filling of the gallbladder with bile.  Gallbladder vol. was increased in wild-type but not Tgr5-/- mice by administration of either the naturally occurring TGR5 agonist, lithocholic acid, or the synthetic TGR5 agonist, INT-777.  These effects were independent of fibroblast growth factor 15, an enteric hormone previously shown to stimulate gallbladder filling.  Ex vivo analyses using gallbladder tissue showed that TGR5 activation increased cAMP concns. and caused smooth muscle relaxation in a TGR5-dependent manner.  These data reveal a novel, gallbladder-intrinsic mechanism for regulating gallbladder contractility.  They further suggest that TGR5 agonists should be assessed for effects on human gallbladder as they are developed for treating metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfl9_dLsVML7Vg90H21EOLACvtfcHk0lht2AM0MxyLCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsl2msLs%253D&md5=90d4a0754fe69f55b6a9b207351cd1a9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1210%2Fme.2010-0460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fme.2010-0460%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DHolmstrom%26aufirst%3DS.%2BR.%26aulast%3DKir%26aufirst%3DS.%26aulast%3DUmetani%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DKliewer%26aufirst%3DS.%2BA.%26aulast%3DMangelsdorf%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520G%2520protein-coupled%2520bile%2520acid%2520receptor%252C%2520TGR5%252C%2520stimulates%2520gallbladder%2520filling%26jtitle%3DMol.%2520Endocrinol.%26date%3D2011%26volume%3D25%26spage%3D1066%26epage%3D1071%26doi%3D10.1210%2Fme.2010-0460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Briere, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siesky, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez Sanfeliciano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suen, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coskun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, M. D.</span><span> </span><span class="NLM_article-title">Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0136873</span><span class="refDoi"> DOI: 10.1371/journal.pone.0136873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1371%2Fjournal.pone.0136873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=26312995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFertw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0136873&author=D.+A.+Briereauthor=X.+Ruanauthor=C.+C.+Chengauthor=A.+M.+Sieskyauthor=T.+E.+Fitchauthor=C.+Dominguezauthor=S.+Gutierrez+Sanfelicianoauthor=C.+Monteroauthor=C.+S.+Suenauthor=Y.+Xuauthor=T.+Coskunauthor=M.+D.+Michael&title=Novel+small+molecule+agonist+of+TGR5+possesses+anti-diabetic+effects+but+causes+gallbladder+filling+in+mice&doi=10.1371%2Fjournal.pone.0136873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice</span></div><div class="casAuthors">Briere, Daniel A.; Ruan, Xiaoping; Cheng, Christine C.; Siesky, Angela M.; Fitch, Thomas E.; Dominguez, Carmen; Sanfeliciano, Sonia Gutierrez; Montero, Carlos; Suen, Chen S.; Xu, Yanping; Coskun, Tamer; Michael, M. Dodson</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0136873/1-e0136873/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Activation of TGR5 via bile acids or bile acid analogs leads to the release of glucagon-like peptide-1 (GLP-1) from intestine, increases energy expenditure in brown adipose tissue, and increases gallbladder filling with bile.  Here, we present compd. 18, a non-bile acid agonist of TGR5 that demonstrates robust GLP-1 secretion in a mouse enteroendocrine cell line yet weak GLP-1 secretion in a human enteroendocrine cell line.  Acute administration of compd. 18 to mice increased GLP-1 and peptide YY (PYY) secretion, leading to a lowering of the glucose excursion in an oral glucose tolerance test (OGTT), while chronic administration led to wt. loss.  In addn., compd. 18 showed a dose-dependent increase in gallbladder filling.  Lastly, compd. 18 failed to show similar pharmacol. effects on GLP-1, PYY, and gallbladder filling in Tgr5 knockout mice.  Together, these results demonstrate that compd. 18 is a mouse-selective TGR5 agonist that induces GLP-1 and PYY secretion, and lowers the glucose excursion in an OGTT, but only at doses that simultaneously induce gallbladder filling.  Overall, these data highlight the benefits and potential risks of using TGR5 agonists to treat diabetes and metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq_f7Nk17eNbVg90H21EOLACvtfcHk0lht2AM0MxyLCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFertw%253D%253D&md5=b3d4fe48455a9652c0f284ae62934e0f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0136873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0136873%26sid%3Dliteratum%253Aachs%26aulast%3DBriere%26aufirst%3DD.%2BA.%26aulast%3DRuan%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DC.%2BC.%26aulast%3DSiesky%26aufirst%3DA.%2BM.%26aulast%3DFitch%26aufirst%3DT.%2BE.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DGutierrez%2BSanfeliciano%26aufirst%3DS.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DSuen%26aufirst%3DC.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCoskun%26aufirst%3DT.%26aulast%3DMichael%26aufirst%3DM.%2BD.%26atitle%3DNovel%2520small%2520molecule%2520agonist%2520of%2520TGR5%2520possesses%2520anti-diabetic%2520effects%2520but%2520causes%2520gallbladder%2520filling%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0136873%26doi%3D10.1371%2Fjournal.pone.0136873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Brighton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rievaj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhre, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoonjans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, F.</span><span> </span><span class="NLM_article-title">Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">3961</span><span class="NLM_x">–</span> <span class="NLM_lpage">3970</span><span class="refDoi"> DOI: 10.1210/en.2015-1321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1210%2Fen.2015-1321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=26280129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC28Xis1Ojur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=3961-3970&author=C.+A.+Brightonauthor=J.+Rievajauthor=R.+E.+Kuhreauthor=L.+L.+Glassauthor=K.+Schoonjansauthor=J.+J.+Holstauthor=F.+M.+Gribbleauthor=F.+Reimann&title=Bile+acids+trigger+GLP-1+release+predominantly+by+accessing+basolaterally+located+G+protein-coupled+bile+acid+receptors&doi=10.1210%2Fen.2015-1321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors</span></div><div class="casAuthors">Brighton, Cheryl A.; Rievaj, Juraj; Kuhre, Rune E.; Glass, Leslie L.; Schoonjans, Kristina; Holst, Jens J.; Gribble, Fiona M.; Reimann, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3961-3970</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Bile acids are well-recognized stimuli of glucagon-like peptide-1 (GLP-1) secretion.  This action has been attributed to activation of the G protein-coupled bile acid receptor GPBAR1(TGR5), although other potential bile acid sensors include the nuclear farnesoid receptor and the apical sodium coupled bile acid transporter ASBT.  The aim of this study was to identify pathways important for GLP-1 release and to det. whether bile acids target their receptors on GLP-1-secreting L-cells from the apical or basolateral compartment.  Using transgenic mice expressing fluorescent sensors specifically in L-cells, we obsd. that taurodeoxycholate (TDCA) and taurolithocholate (TLCA) increased intracellular cAMP and Ca2+.  In primary intestinal cultures, TDCA was a more potent GLP-1 secretagogue than taurocholate (TCA) and TLCA, correlating with a stronger Ca2+ response to TDCA.  Using small-vol. Ussing chambers optimized for measuring GLP-1 secretion, we found that both a GPBAR1 agonist and TDCA stimulated GLP-1 release better when applied from the basolateral than from the luminal direction and that luminal TDCA was ineffective when intestinal tissue was pretreated with an ASBT inhibitor.  ASBT inhibition had no significant effect in nonpolarized primary cultures.  Studies in the perfused rat gut confirmed that vascularly administered TDCA was more effective than luminal TDCA.  Intestinal primary cultures and Ussing chamber- mounted tissues from GPBAR1-knockout mice did not secrete GLP-1 in response to either TLCA or TDCA.  We conclude that the action of bile acids on GLP-1 secretion is predominantly mediated by GPBAR1 located on the basolateral L-cell membrane, suggesting that stimulation of gut hormone secretion may include postabsorptive mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopfu7ri_IsarVg90H21EOLACvtfcHk0liiQF2554NX3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xis1Ojur8%253D&md5=84e055a3542eaafd10875b3890e0eccc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1210%2Fen.2015-1321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2015-1321%26sid%3Dliteratum%253Aachs%26aulast%3DBrighton%26aufirst%3DC.%2BA.%26aulast%3DRievaj%26aufirst%3DJ.%26aulast%3DKuhre%26aufirst%3DR.%2BE.%26aulast%3DGlass%26aufirst%3DL.%2BL.%26aulast%3DSchoonjans%26aufirst%3DK.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DGribble%26aufirst%3DF.%2BM.%26aulast%3DReimann%26aufirst%3DF.%26atitle%3DBile%2520acids%2520trigger%2520GLP-1%2520release%2520predominantly%2520by%2520accessing%2520basolaterally%2520located%2520G%2520protein-coupled%2520bile%2520acid%2520receptors%26jtitle%3DEndocrinology%26date%3D2015%26volume%3D156%26spage%3D3961%26epage%3D3970%26doi%3D10.1210%2Fen.2015-1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Charton, J.; Deprez, B.; Leroux, F.; Staels, B.; Muhr-Tailleux, A.; Hennuyer, N.; Lestavel, S.; Lasalle, M.; Dubanchet, B.</span><span> </span><span class="NLM_article-title">Imidazol- or 1,2,4-Triazol-Derivatives and Their Use</span>. World Patent WO2015/189330 A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Charton&author=B.+Deprez&author=F.+Leroux&author=B.+Staels&author=A.+Muhr-Tailleux&author=N.+Hennuyer&author=S.+Lestavel&author=M.+Lasalle&author=B.+Dubanchet&title=Imidazol-+or+1%2C2%2C4-Triazol-Derivatives+and+Their+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharton%26aufirst%3DJ.%26atitle%3DImidazol-%2520or%25201%252C2%252C4-Triazol-Derivatives%2520and%2520Their%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Sevin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehouck, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabulas-da Costa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecchelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dehouck, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundquist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culot, M.</span><span> </span><span class="NLM_article-title">Accelerated Caco-2 cell permeability model for drug discovery</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1016/j.vascn.2013.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=10.1016%2Fj.vascn.2013.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=23916595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs12ltrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=334-339&author=E.+Sevinauthor=L.+Dehouckauthor=A.+Fabulas-da+Costaauthor=R.+Cecchelliauthor=M.+P.+Dehouckauthor=S.+Lundquistauthor=M.+Culot&title=Accelerated+Caco-2+cell+permeability+model+for+drug+discovery&doi=10.1016%2Fj.vascn.2013.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerated Caco-2 cell permeability model for drug discovery</span></div><div class="casAuthors">Sevin, E.; Dehouck, L.; Fabulas-da Costa, A.; Cecchelli, R.; Dehouck, M. P.; Lundquist, S.; Culot, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">By culturing Caco-2 cells according to a new and optimized protocol, it has been possible to accelerate the cell culture process in such a way that the cells can be used for expts. after only 6 days.  The accelerated Caco-2 model has been compared to the traditional model (requiring 21-25 days of culture) in terms of tightness of the junctions, ability to rank chem. compds. for apparent permeability, active efflux and to discriminate P-gp substrates.  In the new protocol, Caco-2 cells were cultured with the classical Caco-2 medium supplemented with puromycin.  The initial cell seeding d. was increased two times compared to the traditional procedure and the presence of a low concn. of puromycin in the culture medium reduced the Caco-2 permeability of mannitol.  Bi-directional studies were performed with known P-gp substrates (rhodamine 123, digoxin and saquinavir) and with a total of 20 marketed drugs covering a wide range of physicochem. characteristics and therapeutic indications.  Strong correlations were obtained between the apparent permeability in absorptive (Papp A → B) or secretory (Papp B → A) of the drugs in the accelerated model and in the traditional models and comparable efflux ratios were obsd. in the two studied models.  The new protocol reduces costs for screening and leads to higher throughput compared to traditional Caco-2 cell models.  This accelerated model provides short time-feedback to the drug design during the early stage of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbJT4UgykzJrVg90H21EOLACvtfcHk0liiQF2554NX3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs12ltrnL&md5=eac6ef3d9c948d54c85a13e42154e367</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2013.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2013.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DSevin%26aufirst%3DE.%26aulast%3DDehouck%26aufirst%3DL.%26aulast%3DFabulas-da%2BCosta%26aufirst%3DA.%26aulast%3DCecchelli%26aufirst%3DR.%26aulast%3DDehouck%26aufirst%3DM.%2BP.%26aulast%3DLundquist%26aufirst%3DS.%26aulast%3DCulot%26aufirst%3DM.%26atitle%3DAccelerated%2520Caco-2%2520cell%2520permeability%2520model%2520for%2520drug%2520discovery%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2013%26volume%3D68%26spage%3D334%26epage%3D339%26doi%3D10.1016%2Fj.vascn.2013.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d140e9848-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i161"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01873">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00787"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01873">10.1021/acs.jmedchem.6b01873</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01873/suppl_file/jm6b01873_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01873/suppl_file/jm6b01873_si_001.csv">jm6b01873_si_001.csv (1.87 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01873&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-10%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01873%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01873" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ce44582824f5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
